U.S. patent application number 15/973376 was filed with the patent office on 2018-10-04 for chimaeric surrogate light chains (slc) comprising human vpreb.
The applicant listed for this patent is Kymab Limited. Invention is credited to Allan BRADLEY, Nicholas ENGLAND, E-Chiang LEE, Qi LIANG, Dominik SPENSBERGER.
Application Number | 20180282761 15/973376 |
Document ID | / |
Family ID | 46963985 |
Filed Date | 2018-10-04 |
United States Patent
Application |
20180282761 |
Kind Code |
A1 |
BRADLEY; Allan ; et
al. |
October 4, 2018 |
Chimaeric Surrogate Light Chains (SLC) Comprising Human VpreB
Abstract
The present invention relates inter alia to improvements in the
production of chimaeric antibodies in non-human transgenic
vertebrates such as mice and rats bearing one or more chimaeric
antibody transgenes. In particular, the invention provides for
improved non-human vertebrates and cells in which VpreB has been
species-matched with the variable region of the chimaeric
antibodies. Also, embodiments also provide for species-matching of
the entire surrogate light chain for efficient pairing with
chimaeric heavy chains during B-cell development in vivo in a
non-human transgenic vertebrate setting.
Inventors: |
BRADLEY; Allan; (Cambridge,
GB) ; LEE; E-Chiang; (Cambridge, GB) ; LIANG;
Qi; (Cambridge, GB) ; SPENSBERGER; Dominik;
(Cambridge, GB) ; ENGLAND; Nicholas; (Cambridge,
GB) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Kymab Limited |
Cambridge |
|
GB |
|
|
Family ID: |
46963985 |
Appl. No.: |
15/973376 |
Filed: |
May 7, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14226698 |
Mar 26, 2014 |
9963716 |
|
|
15973376 |
|
|
|
|
PCT/GB2012/052380 |
Sep 26, 2012 |
|
|
|
14226698 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C12N 5/10 20130101; C12N
15/85 20130101; H05K 999/99 20130101; C12N 2015/8518 20130101; A01K
2217/077 20130101; A01K 67/0278 20130101; A01K 2227/105 20130101;
A01K 67/02 20130101; A01K 2227/10 20130101; C12N 15/8509 20130101;
A01K 2217/07 20130101; A01K 2267/01 20130101 |
International
Class: |
C12N 15/85 20060101
C12N015/85; A01K 67/027 20060101 A01K067/027; A01K 67/02 20060101
A01K067/02; C12N 5/10 20060101 C12N005/10 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 26, 2011 |
GB |
1116495.1 |
Nov 28, 2011 |
GB |
1120423.7 |
Claims
1. A method for producing an antibody specific for a selected
antigen, said antibody comprising an immunoglobulin heavy (IgH)
chain comprising a human IgH chain variable region, the method
comprising isolating from a cultured cell expressing said IgH chain
or fragment thereof comprising said human IgH chain variable
region, one or more of the group consisting of: (i) said IgH chain
or fragment thereof comprising said human IgH chain variable
region; and (ii) nucleic acid encoding said IgH chain or fragment
thereof comprising said human IgH chain variable region; wherein
said human IgH chain variable region is of a transgenic mouse
contacted with said selected antigen or epitope thereof, for a time
and under conditions which permit the antigen-contacted mouse to
produce antibody specific for said antigen; wherein said transgenic
mouse comprises an IgH chain transgene, the IgH transgene
comprising (a) one or more human VH gene segments, one or more
human D gene segments and one or more human JH gene segments
operably connected upstream of a constant region gene so that the
transgene is capable of undergoing VDJ recombination in vivo to
produce an antibody gene comprising a rearranged VDJC encoding an
antibody heavy chain having a human variable region and a constant
region; the genome further comprising (i) a human VpreB gene
capable of expressing a human VpreB, and (ii) a mouse or rat
.lamda.5 gene; wherein the transgenic mouse is capable of
expressing a chimaeric surrogate light chain comprising human VpreB
and mouse or rat .lamda.5 for pairing with the heavy chain.
2. The method of claim 1, wherein the constant region is a mouse
constant region.
3. The method of claim 1, wherein the constant region and the
.lamda.5 gene are mouse constant region and mouse .lamda.5 gene,
respectively.
4. The method of claim 2, wherein the transgenic mouse is a strain
selected from the group consisting of a 129-derived mouse strain, a
C57Bl/6 derived mouse strain and a JM8 derived mouse strain.
5. The method of claim 2, wherein the constant region is of a mouse
129 strain constant region or of a C57Bl/6 strain constant region,
and the .lamda.5 gene is a mouse 129 strain or a mouse C57Bl/6
strain.
6. The method of claim 1, wherein the constant region gene and the
.lamda.5 gene are endogenous genes of said transgenic mouse.
7. The method of claim 1, wherein the genome is homozygous for said
transgene, human VpreB gene and mouse or rat .lamda.5 gene.
8. The method of claim 1, wherein endogenous antibody heavy chain
expression in said mouse is inactive.
9. The method of claim 1, wherein endogenous antibody light chain
expression in said mouse is inactive.
10. The method of claim 1, wherein the heavy chain transgene is
devoid of a CHI gene segment and the genome comprises no functional
antibody light chain locus.
11. The method of claim 1, wherein the heavy chain transgene is
devoid of a gamma CHI gene segment and the genome comprises no
functional antibody light chain locus.
12. The method of claim 1, wherein the heavy chain transgene is
devoid of a mu CHI gene segment and the genome comprises no
functional antibody light chain locus.
13. The method of claim 1, wherein the constant region is a mu
constant region.
14. The method of claim 1, wherein the human VpreB gene has a
nucleotide sequence that is at least 85% identical to SEQ ID
NO:1.
15. The method of claim 1, wherein said genome does not comprise a
non-human vertebrate species VpreB1 and/or VpreB2 gene.
16. The method of claim 1, wherein said genome comprises an
insertion of human lambda V region or lambda VJ region comprising
all of the V regions and intervening sequences, wherein the lambda
V region or VJ region comprises a human VpreB gene.
17. The method of claim 16, wherein non-functional V and/or J gene
segments are omitted.
18. The method of claim 16, wherein the lambda V region or VJ
region comprises a human VpreB gene and its associated
promoter.
19. The method of claim 16, wherein the insertion is an insertion
into an antibody light chain locus.
20. The method of claim 16, wherein the insertion replaces
endogenous V.lamda. in whole or in part.
21. The method of claim 1, wherein the human VpreB gene is not
within the endogenous VpreB-.lamda.5 locus.
22. The method of claim 1, wherein the expression of the human
VpreB gene is under endogenous control.
23. The method of claim 1, wherein the human VpreB gene is operably
linked to one or more DNaseI hypersensitive sites.
24. The method of claim 1, wherein the human VpreB gene is present
in the genome in any one of 2, 3, 4, 5, 6, 7, 8, 9 or 10
copies.
25. The method of claim 1, wherein all .lamda.5 sequences in the
genome are mouse .lamda.5 sequences.
26. The method of claim 22, wherein the human VpreB gene is
operably linked to an endogenous promoter.
27. The method of claim 1, wherein said transgenic mouse expresses
a repertoire of Ig heavy chain variable regions that significantly
differs from the heavy chain variable region repertoire of a
control vertebrate in the proportion expressed as a percentage of
use of heavy chain variable gene segments, wherein the control and
said transgenic mouse genomes are of the same background strain and
both comprise said antibody heavy chain transgene, the transgenes
being identical in the control and said mouse, and wherein the
control does not express a human VpreB.
28. The method of claim 1, wherein said transgenic mouse expresses
a repertoire of Ig heavy chain variable regions that significantly
differs from the IgH heavy chain variable region repertoire of a
control vertebrate in the proportion expressed as a percentage of
use of heavy chain JH gene segments, wherein the control and said
transgenic mouse genomes are of the same background strain and both
comprise said antibody heavy chain transgene, the transgenes being
identical in the control and said mouse, and wherein the control
does not express a human VpreB.
29. The method of claim 1, wherein said transgenic mouse expresses
a repertoire of Ig heavy chain variable regions that significantly
differs from the IgH heavy chain variable region repertoire of a
control vertebrate in the proportion expressed as a percentage of
one or more or all heavy chain variable region gene segments
selected from the group consisting of VH6-1, VH1-3, VH3-7, VH1-8,
VH3-9, VH3-11, JH1 and JH6, wherein the control and said transgenic
mouse genomes are of the same background strain and both comprise
said antibody heavy chain transgene, the transgenes being identical
in the control and said mouse, and wherein the control does not
express a human VpreB.
30. The method of claim 27, wherein use of one or more or all of
VH6-1, VH1-3, VH3-9 and JH1 is higher in the repertoire of said
mouse than in the repertoire of the control.
31. The method of claim 27, wherein use of one or more or all of
VH3-7, VH1-8, VH3-11 and JH6 is lower in the repertoire of said
mouse than in the repertoire of the control.
32. The method of claim 4, wherein said transgenic mouse is a
C57Bl/6--129/Sv hybrid strain.
33. The method of claim 13, wherein said mu constant region is an
endogenous mu constant region.
34. The method of claim 16, wherein said genome comprises an
insertion of human lambda V region or lambda VJ region comprising
all of the V regions and all the J regions and intervening
sequences, wherein the lambda V region or VJ region comprises a
human VpreB gene.
35. The method of claim 19, where the insertion is an insertion
into an endogenous lambda locus upstream of the endogenous lambda
constant region.
36. The method of claim 26, wherein said endogenous promoter is an
endogenous VpreB promoter (e.g., a VpreB1 promoter).
37. The method of claim 28, wherein the transgenic mouse expresses
a repertoire of Ig heavy chain variable regions that differs by a
probability of less than 0.05 in a binomial distribution test, from
the IgH heavy chain variable region repertoire of a control
vertebrate in the proportion expressed as a percentage of use of
heavy chain JH gene segments, wherein the control and said
transgenic mouse genomes are of the same background mouse strain
and both comprise said antibody heavy chain transgene, the
transgenes being identical in the control and said mouse, and
wherein the control does not express a human VpreB.
38. The method of claim 1, wherein the genome of said transgenic
mouse comprises (a) said antibody heavy chain transgene; and (b) an
antibody kappa light chain transgene and/or an antibody lambda
chain transgene; wherein all of the V, D and J in said transgenes
are human V, D and J; wherein endogenous antibody heavy and light
chain expression is inactive.
39. The method of claim 38, wherein the genome of said transgenic
mouse is homozygous for said heavy and light chain transgenes.
40. A method of promoting B cell development in a non-human
vertebrate comprising an immunoglobulin heavy (IgH) chain
comprising a human IgH chain variable region, wherein said
non-human vertebrate is a mouse or a rat, wherein said non-human
vertebrate comprises an IgH chain transgene, the IgH transgene
comprising one or more human VH gene segments, one or more human D
gene segments and one or more human JH gene segments operably
connected upstream of a constant region gene so that the transgene
is capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding an antibody
heavy chain having a human variable region and a constant region,
optionally wherein the genome is homozygous for said IgH chain
transgene; the method comprising: (i) inactivating endogenous heavy
chain expression in said vertebrate; (ii) providing in the genome
of said vertebrate: (a) a human VpreB gene capable of expressing a
human VpreB, and (b) a mouse or rat .lamda.5 gene; wherein the
transgenic mouse is capable of expressing a chimaeric surrogate
light chain comprising human VpreB and mouse or rat .lamda.5,
wherein the transgenic mouse is capable of expressing a pre-B-cell
receptor comprising said chimaeric surrogate light chain and an IgH
mu chain comprising said human variable region, wherein said
pre-B-cell receptor promotes B cell development of cells bearing
said IgH mu chain in said vertebrate.
41. The method of claim 40, wherein said non-human vertebrate
comprising an IgH chain transgene is a mouse, and wherein the
constant region of said antibody heavy chain is a mouse constant
region.
42. The method of claim 40, wherein said non-human vertebrate
comprising an IgH chain transgene is a mouse, and wherein the
constant region of said antibody heavy chain and the .lamda.5 gene
are mouse constant region and mouse .lamda.5 gene,
respectively.
43. The method of claim 41, wherein said mouse is a strain selected
from the group consisting of a 129-derived mouse strain, a C57Bl/6
derived mouse strain and a JM8 derived mouse strain.
44. The method of claim 41, wherein the constant region of said
antibody heavy chain is of a mouse 129 strain constant region or of
a C57Bl/6 strain constant region, and the .lamda.5 gene is a mouse
129 strain or a mouse C57Bl/6 strain.
45. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein the
constant region gene and the .lamda.5 gene are endogenous genes of
said transgenic mouse.
46. The method of claim 40, wherein the genome is homozygous for
said transgene, human VpreB gene and mouse or rat .lamda.5
gene.
47. The method of claim 1, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein
endogenous antibody heavy chain expression in said mouse is
inactive.
48. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein
endogenous antibody light chain expression in said mouse is
inactive.
49. The method of claim 40, wherein the heavy chain transgene is
devoid of a CHI gene segment and the genome comprises no functional
antibody light chain locus.
50. The method of claim 40, wherein the heavy chain transgene is
devoid of a gamma CHI gene segment and the genome comprises no
functional antibody light chain locus.
51. The method of claim 40, wherein the heavy chain transgene is
devoid of a mu CHI gene segment and the genome comprises no
functional antibody light chain locus.
52. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein the
constant region of said antibody heavy chain is a mouse mu constant
region.
53. The method of claim 40, wherein the human VpreB gene has a
nucleotide sequence that is at least 85% identical to SEQ ID
NO:1.
54. The method of claim 40, wherein said genome does not comprise a
non-human vertebrate species VpreB1 and/or VpreB2 gene.
55. The method of claim 40, wherein said genome comprises an
insertion of human lambda V region or lambda VJ region comprising
all of the V regions and intervening sequences, wherein the lambda
V region or VJ region comprises a human VpreB gene.
56. The method of claim 55, wherein non-functional V and/or J gene
segments are omitted.
57. The method of claim 55, wherein the lambda V region or VJ
region comprises a human VpreB gene and its associated
promoter.
58. The method of claim 55, wherein the insertion is an insertion
into an antibody light chain locus.
59. The method of claim 55, wherein the insertion replaces
endogenous V.lamda. in whole or in part.
60. The method of claim 40, wherein the human VpreB gene is not
within the endogenous VpreB-.lamda.5 locus.
61. The method of claim 40, wherein the expression of the human
VpreB gene is under endogenous control.
62. The method of claim 40, wherein the human VpreB gene is
operably linked to one or more DNaseI hypersensitive sites.
63. The method of claim 40, wherein the human VpreB gene is present
in the genome in any one of 2, 3, 4, 5, 6, 7, 8 9 or 10 copies.
64. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein all
.lamda.5 sequences in the genome are mouse .lamda.5 sequences.
65. The method of claim 61, wherein the human VpreB gene is
operably linked to an endogenous promoter.
66. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, wherein said
transgenic mouse expresses a repertoire of Ig heavy chain variable
regions that significantly differs from the heavy chain variable
region repertoire of a control mouse in the proportion expressed as
a percentage of use of heavy chain variable gene segments, wherein
the control and said transgenic mouse genomes are of the same
background strain and both comprise said antibody heavy chain
transgene, the transgenes being identical in the control and said
mouse, and wherein the control does not express a human VpreB.
67. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, wherein said
transgenic mouse expresses a repertoire of Ig heavy chain variable
regions that significantly differs from the IgH heavy chain
variable region repertoire of a control vertebrate in the
proportion expressed as a percentage of use of heavy chain JH gene
segments, wherein the control and said transgenic mouse genomes are
of the same background strain and both comprise said antibody heavy
chain transgene, the transgenes being identical in the control and
said mouse, and wherein the control does not express a human
VpreB.
68. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, wherein said
transgenic mouse expresses a repertoire of Ig heavy chain variable
regions that significantly differs from the IgH heavy chain
variable region repertoire of a control vertebrate in the
proportion expressed as a percentage of one or more or all heavy
chain variable region gene segments selected from the group
consisting of VH6-1, VH1-3, VH3-7, VH1-8, VH3-9, VH3-11, JH1 and
JH6, wherein the control and said transgenic mouse genomes are of
the same background strain and both comprise said antibody heavy
chain transgene, the transgenes being identical in the control and
said mouse, and wherein the control does not express a human
VpreB.
69. The method of claim 66, wherein use of one or more or all of
VH6-1, VH1-3, VH3-9 and JH1 is higher in the repertoire of said
mouse than in the repertoire of the control.
70. The method of claim 66, wherein use of one or more or all of
VH3-7, VH1-8, VH3-11 and JH6 is lower in the repertoire of said
mouse than in the repertoire of the control.
71. The method of claim 43, wherein said transgenic mouse is a
C57Bl/6-129/Sv hybrid strain.
72. The method of claim 52, wherein said mu constant region is an
endogenous mu constant region.
73. The method of claim 55, wherein said genome comprises an
insertion of human lambda V region or lambda VJ region comprising
all of the V regions and all the J regions and intervening
sequences, wherein the lambda V region or VJ region comprises a
human VpreB gene.
74. The method of claim 58, where the insertion is an insertion
into an endogenous lambda locus upstream of the endogenous lambda
constant region.
75. The method of claim 65, wherein said endogenous promoter is an
endogenous VpreB promoter (e.g., a VpreB1 promoter).
76. The method of claim 67, wherein the transgenic mouse expresses
a repertoire of Ig heavy chain variable regions that differs by a
probability of less than 0.05 in a binomial distribution test, from
the IgH heavy chain variable region repertoire of a control
vertebrate in the proportion expressed as a percentage of use of
heavy chain JH gene segments, wherein the control and said
transgenic mouse genomes are of the same background mouse strain
and both comprise said antibody heavy chain transgene, the
transgenes being identical in the control and said mouse, and
wherein the control does not express a human VpreB.
77. The method of claim 40, wherein said non-human vertebrate
comprising said IgH chain transgene is a mouse, and wherein the
genome of said transgenic mouse comprises (a) said antibody heavy
chain transgene; and (b) an antibody kappa light chain transgene
and/or an antibody lambda chain transgene; wherein all of the V,
(D) and J in said transgenes are human V, (D) and J; wherein
endogenous antibody heavy and light chain expression is
inactive.
78. The method of claim 77, wherein the genome of said transgenic
mouse is homozygous for said heavy and light chain transgenes.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 14/226,698, filed Mar. 26, 2014, which is a continuation of
PCT/GB2012/052380, filed Sep. 26, 2012, which claims the benefit of
GB 1116495.1, filed Sep. 26, 2011, and GB 1120423.7, filed Nov. 28,
2011, the contents of each which are incorporated by reference
herein in their entirety. The attached sequence listing is hereby
incorporated by reference.
[0002] The present invention relates inter alia to improvements in
the production of chimaeric antibodies in non-human transgenic
vertebrates such as mice and rats bearing one or more chimaeric
antibody transgenes. In particular, the invention provides for
improved non-human vertebrates and cells in which VpreB has been
species-matched with the variable region of the chimaeric
antibodies. Also, embodiments provide for species-matching of the
entire surrogate light chain for efficient pairing with chimaeric
heavy chains during B-cell development in vivo in a non-human
transgenic vertebrate setting.
[0003] Furthermore, the invention relates to a method of using the
vertebrates to isolate antibodies or nucleotide sequences encoding
antibodies. Antibodies, nucleotide sequences, pharmaceutical
compositions and uses are also provided by the invention.
BACKGROUND
[0004] Advancements in the construction of transgenic mice bearing
human antibody gene loci have led researchers to move away from the
provision of entirely human transgenic antibody loci (bearing human
variable and constant region gene segments) to chimaeric transgenic
antibody loci. The transgenic loci comprise human V(D)J segments
operably connected upstream of non-human constant regions. The use
of constant regions that are endogenous to the transgenic non-human
vertebrate (eg, endogenous mouse or rat constant regions) are
desirable to harness the endogenous control of antibody generation
and maturation following immunisation of the vertebrate with
antigen.
[0005] B-cell development is characterized by the ordered
rearrangement of immunoglobulin variable region genes. After the
VDJ rearrangement of the H chain gene segments, a precursor
(pre)-B-cell is generated. After the functional rearrangement of a
light chain gene, the cells develop into surface IgM-bearing mature
B-cells. Fully assembled IgH and L chains are transported onto the
surface of B-cells, while free H chains are retained in the
endoplasmic reticulum (ER) in association with BiP.
[0006] A critical step in B-cell differentiation is the selective
expansion of cells with a functional .mu. heavy chain resulting
from productive IgH rearrangement. This is achieved by the
association of the .mu. heavy chain with the surrogate light chain
(SLC) proteins .lamda.5 and VpreB and the signal transducing
heterodimer Ig.alpha. and .beta. to form the pre-B-cell receptor
(pre-BCR). The expression and formation of a pre-BCR dramatically
improves the efficiency of pre-B and B-cell production, by
signalling proliferative expansion of pre-B-cells. The major
function of the pre-BCR is the selection and expansion of cells
that have undergone a productive VDJ rearrangement. The expression
of membrane-bound .mu. chains is essential for the clonal
expansion, and initiation of L chain gene rearrangement.
[0007] The association of SLC with .mu. chain works as a checkpoint
to determine whether the cell has successfully completed VDJ
combination and expresses a functional .mu.H chain. More than half
of all .mu. chains cannot assemble with the SLC, accounting for
most of the changes in the V heavy repertoire during B-cell
development.
[0008] VpreB is homologous to variable regions, .lamda.5 is
homologous to light chain constant region. The protein encoded by
the two genes can form a tightly, but noncovalently bound
heterodimer with the general structure of an L chain. .lamda.5
protein can be covalently disulphide-bonded to .mu. H chains in
pre-B-cells. Whereas VpreB alone can associate with Ig.mu.,
.lamda.5 alone cannot. Only when it is non-covalently associated
with VpreB does .lamda.5 form a disulphide bridge with the first
constant region (CH1) of an Ig.mu. chain to form the pre-BCR.
[0009] The .lamda.5 and VpreB, which together form the SLC, are
early markers of B-cell commitment. They are expressed at the pro-
and pre-B-cell stages and silenced in immature and mature B-cells.
In pre-B-cells, following rearrangement of the heavy chain locus,
the surrogate light chain (SLC) acts as a chaperone, mediating
transport of the newly synthesised heavy chain mu to the cell
surface and together with C mu forms part of the pre-BCR (Immunol
Today. 1993 February; 14(2):60-8; The surrogate light chain in
B-cell development; Melchers F, Karasuyama H, Haasner D, Bauer S,
Kudo A, Sakaguchi N, Jameson B, Rolink A). The pre-BCR mediates
signalling, leading to proliferation of pre-B-cells that have a
productive heavy chain rearrangement. Mice that lack a functional
.lamda.5 show a drastic reduction in the number of B-cells. Using
VpreB knock-out mice, it has been shown that VpreB is also required
for efficient B-cell development, particularly for the transition
to pre-BCR bearing cells (pre-611 stage) (see, Int Immunol. 1999
March; 11(3):453-60; Partial block in B lymphocyte development at
the transition into the pre-B cell receptor stage in
Vpre-B1-deficient mice; Martensson A, Argon Y, Melchers F, Dul J L,
Martensson IL; and Sabbattini & Dillon 2005 infra). As the
degree of proliferation has been proposed to be dependent upon the
stability of the association of the mu heavy chain with the
components of the SLC, the pre-BCR is thought to influence the
choice, and thus the extent and diversity of, the heavy chain
variable region repertoire.
[0010] Besides its role in signalling proliferation, the pre-BCR is
also thought to mediate down regulation of the RAG genes, thereby
preventing the rearrangement of other IgH loci (allelic exclusion)
and the occurrence of double-strand breaks in dividing pre-B-cells.
The pre-BCR has also been proposed to exert a negative feedback on
.lamda.5 and VpreB expression so that, after a phase of clonal
expansion, the large pre-BII cells become depleted of pre-BCR, exit
the cell cycle and differentiate into resting small pre-BII cells.
At this stage, the SLC is repressed while the IgL loci start to be
rearranged. The product of a successfully rearranged IgL gene will
then pair with the mu heavy chain to form a BCR with
antigen-binding capability on the surface of immature B-cells.
These cells migrate to the peripheral blood and secondary lymphoid
organs, and develop into mature B-cells ready for subsequent
encounter with antigen (Sabbattini & Dillon 2005 infra).
SUMMARY OF THE INVENTION
[0011] The inventors were aware of the desirability to use
endogenous non-human (eg, mouse or rat) constant regions to harness
the endogenous control of antibody generation and maturation
following immunisation. They have realised, however, that these
considerations do not address earlier B-cell stages in vivo (prior
to antigen stimulation) when the animal's B-cell repertoire is
maturing. Such maturation includes transition from immature
pro-B-cells to pre-B-cells, including the pre-BII stage when
B-cells bear surface B-cell receptors (BCR) in which the heavy
chain variable region is paired with the VpreB. CH1 regions of
heavy chains are paired with .lamda.5 in the pre-BCRs. The
inventors realised that the provision of genes encoding chimaeric
antibodies is not tailored to the pre-BII stage, and they realised
that it is important to address this since this stage features huge
clonal expansion required to provide a pool of B-cells for
functional heavy chain selection during subsequent B-cell
development.
[0012] To this end, the present invention provides for
species-matching of human V regions in chimaeric heavy chains with
human VpreB. In embodiments, the invention also provides for
species-matching of the mu constant region with .lamda.5, so that
heavy chains in pre-BCRs are completely species-matched with
chimaeric surrogate light chain (SLC).
[0013] Thus, a first configuration of the present invention
provides,
[0014] A non-human vertebrate (eg, a mouse or rat) or cell (eg, a
mouse cell or rat cell) whose genome comprises an antibody heavy
chain transgene,
[0015] the transgene comprising
[0016] (a) one or more human VH gene segments, one or more human D
gene segments and one or more human JH gene segments operably
connected upstream of a constant region gene so that the transgene
is capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding an antibody
heavy chain having a human variable region and a constant region;
or
[0017] (b) a rearranged VDJ encoding a human variable region
operably connected upstream of a constant region gene so that the
transgene encodes (optionally following VDJ combination with the
constant region) a chimaeric antibody heavy chain having a human
variable region and a constant region;
[0018] the genome further comprising a human VpreB gene capable of
expressing a human VpreB.
[0019] The present invention is applicable to the production of
4-chain antibodies in transgenic animals, where the antibodies each
contain 2 heavy chains and 2 light chains. Alternatively, the
invention can be applied to the production of H2 antibodies (heavy
chain antibodies) which are devoid of CH1 and light chains.
[0020] In a second embodiment, the invention provides
[0021] A method of constructing a transgenic non-human vertebrate
cell (eg, an ES cell, eg, a mouse or rat ES cell), the method
comprising
[0022] (i) introducing into the genome of a non-human vertebrate
cell (or an ancestor thereof) one or more human VH gene segments,
one or more human D gene segments and one or more human JH gene
segments so that said gene segments are operably connected upstream
of a constant region gene (optionally an endogenous non-human
vertebrate constant region gene) to form a heavy chain transgene,
wherein in said cell or a progeny thereof the transgene is capable
of undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding an antibody heavy chain
having a human variable region and a constant region; or
[0023] (ii) introducing into the genome of a non-human vertebrate
cell (or an ancestor thereof) a rearranged VDJ encoding a human
variable region so that said VDJ is operably connected upstream of
a constant region gene (optionally an endogenous non-human
vertebrate constant region gene) to form a heavy chain transgene,
wherein in said cell or a progeny thereof the transgene encodes
(optionally following VDJ combination with the constant region) an
antibody heavy chain having a human variable region and a constant
region;
[0024] and wherein the method further comprises introducing into
the cell a human VpreB gene capable of expressing a human
VpreB.
[0025] In a third embodiment, the invention provides
[0026] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0027] (a) providing in a non-human vertebrate embryonic stem (ES)
cell genome an immunoglobulin transgene capable of expressing an
antibody mu heavy chain, wherein the antibody heavy chain comprises
a human variable region and a mu constant region (optionally an
endogenous non-human vertebrate mu constant region); and creating a
first non-human vertebrate from said ES cell or a progeny
thereof;
[0028] (b) providing in a second ES cell genome a second transgene
comprising a human VpreB gene capable of expressing a human VpreB;
and creating a second non-human vertebrate from said ES cell or a
progeny thereof; and
[0029] (c) creating by breeding a third non-human vertebrate
capable of co-expressing the mu antibody heavy chain and human
vpreB wherein a pre-B-cell receptor can form to promote B-cell
development of cells bearing a mu heavy chain in said third
vertebrate; the third vertebrate being made by crossing said first
and second vertebrates or progeny thereof by breeding to create
said third vertebrate, the third vertebrate comprising the first
and second transgenes, and wherein endogenous heavy chain
expression has been inactivated in said third vertebrate.
[0030] In a fourth embodiment, the invention provides
[0031] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0032] (i) inactivating endogenous heavy chain expression in said
vertebrate;
[0033] (ii) providing in the genome of said vertebrate an
immunoglobulin transgene capable of expressing an antibody mu heavy
chain, wherein the antibody heavy chain comprises a human variable
region and a non-human vertebrate mu constant region (optionally an
endogenous non-human vertebrate mu constant region); and
[0034] (ii) providing in the genome of said vertebrate a second
transgene capable of expressing a human VpreB wherein a pre-B-cell
receptor can form to promote B-cell development of cells bearing a
mu heavy chain in said vertebrate;
[0035] Optionally wherein the genome is homozygous for said first
transgene.
[0036] An aspect of the invention further provides for the
possibility of species-matching in vivo the variable and constant
regions of the antibody heavy chain with a chimaeric SLC. This is
useful for promoting B-cell development in the transgenic non-human
vertebrate (eg, a mouse or rat).
[0037] To this end, the invention provides a fifth
embodiment:--
[0038] A non-human vertebrate (eg, a mouse or rat) or cell (eg, a
mouse cell or rat cell) whose genome comprises an antibody heavy
chain transgene,
[0039] the transgene comprising
[0040] (a) one or more human VH gene segments, one or more human D
gene segments and one or more human JH gene segments operably
connected upstream of a constant region gene of a non-human
vertebrate (eg, mouse or rat) species so that the transgene is
capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding a chimaeric
antibody heavy chain having a human variable region and a non-human
vertebrate constant region; or
[0041] (b) a rearranged VDJ encoding a human variable region
operably connected upstream of a constant region gene of a
non-human vertebrate (eg, mouse or rat) species so that the
transgene encodes (optionally following VDJ combination with the
constant region) a chimaeric antibody heavy chain having a human
variable region and a non-human vertebrate constant region;
[0042] the genome further comprising one or more genes together
encoding a chimaeric surrogate light chain, the surrogate light
chain comprising a human VpreB and .lamda.5 of said non-human
vertebrate (eg, mouse or rat) species.
[0043] A sixth embodiment of the invention provides
[0044] A method of constructing a transgenic non-human vertebrate
cell (eg, an ES cell, eg, a mouse or rat ES cell), the method
comprising
[0045] (i) introducing into a non-human vertebrate cell (or an
ancestor thereof) one or more human VH gene segments, one or more
human D gene segments and one or more human JH gene segments so
that said gene segments are operably connected upstream of an
endogenous non-human vertebrate constant region gene, wherein in
said cell or a progeny thereof the transgene is capable of
undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding a chimaeric antibody heavy
chain having a human variable region and a non-human vertebrate
constant region; or
[0046] (ii) introducing into a non-human vertebrate cell (or an
ancestor thereof) a rearranged VDJ encoding a human variable region
so that said VDJ is operably connected upstream of an endogenous
non-human vertebrate constant region gene, wherein in said cell or
a progeny thereof the transgene encodes (optionally following VDJ
combination with the constant region) a chimaeric antibody heavy
chain having a human variable region and a non-human vertebrate
constant region;
[0047] and wherein the method further comprises introducing into
the cell a human VpreB gene such that the cell or a progeny thereof
is capable of expressing a chimaeric surrogate light chain as well
as said chimaeric antibody heavy chain, wherein the surrogate light
chain comprises a human VpreB and an endogenous non-human
vertebrate .lamda.5.
[0048] A seventh embodiment of the invention further provides
[0049] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0050] (a) providing in a non-human vertebrate embryonic stem (ES)
cell an immunoglobulin transgene capable of expressing a chimaeric
antibody mu heavy chain, wherein the chimaeric antibody heavy chain
comprises a human variable region and an endogenous non-human
vertebrate mu constant region; and creating a first non-human
vertebrate from said ES cell or a progeny thereof;
[0051] (b) providing in a second ES cell a second transgene capable
of expressing a human VpreB so that the human VpreB and an
endogenous .lamda.5 form a chimaeric surrogate light chain; and
creating a second non-human vertebrate from said ES cell or a
progeny thereof; and
[0052] (c) creating by breeding a third non-human vertebrate
capable of co-expressing the chimaeric mu antibody heavy chain and
chimaeric surrogate light chain wherein a pre-BCR can form to
promote B-cell development in said third vertebrate; the third
vertebrate being made by crossing said first and second vertebrates
or progeny thereof by breeding to create said third vertebrate, the
third vertebrate comprising the first and second transgenes, and
wherein endogenous heavy chain expression has been inactivated in
said third vertebrate.
[0053] A transgenic mouse according to the vertebrate of this
method, or a progeny thereof, is provided.
[0054] An eighth embodiment of the invention provides
[0055] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0056] (i) inactivating endogenous heavy chain expression in said
vertebrate;
[0057] (ii) providing in the genome of said vertebrate an
immunoglobulin transgene capable of expressing a chimaeric antibody
mu heavy chain, wherein the chimaeric antibody heavy chain
comprises a human variable region and an endogenous non-human
vertebrate mu constant region; and
[0058] (ii) providing in the genome of said vertebrate a second
transgene capable of expressing a human VpreB so that the human
VpreB and an endogenous .lamda.5 form a chimaeric surrogate light
chain; so that the vertebrate is capable of co-expressing the
chimaeric mu antibody heavy chain and chimaeric surrogate light
chain wherein a pre-BCR can form to promote B-cell development in
said vertebrate;
[0059] Optionally wherein the genome is homozygous for said first
transgene.
[0060] A transgenic mouse according to the vertebrate of this
method, or a progeny thereof, is provided.
BRIEF DESCRIPTION OF THE FIGURES
[0061] FIGS. 1A & B: Schematic representation of the steps
involved in replacement of the mouse VpreB1 with human VpreB1. The
most 5' gene is Topo3.beta..
[0062] FIG. 2: Upper Schematic: representation of vector for
retrieval of the 19 kb mouse DNA sequence containing the human
VpreB1 gene; Lower Schematic:representation of the vector
containing the retrieved 19 kb mouse DNA sequence containing the
human VpreB1 gene. Black rectangular boxes represent homology arms.
Black arrows represent the coding sequences of VpreB1 and mouse
.lamda.5.
[0063] FIGS. 3A & B: Schematic maps of insert (FIG. 3A) a human
BAC (FIG. 3B) containing correctly targeted human VpreB1, .lamda.5
and mouse regulatory elements.
[0064] FIG. 4: Schematic representation of the steps involved in
replacement of the mouse .lamda.5 with human .lamda.5.
DETAILED DESCRIPTION OF THE INVENTION
[0065] The invention is useful for promoting the appropriate human
IGH repertoire on mature B-cells in the vertebrate (or progeny
thereof) or in transgenic vertebrates derived from non-human
vertebrate cells. At the transition of pre-BI to pre-BII cells, VH
to DH-JH rearrangements are initiated (see, eg, Martensson &
Ceredig, Immunology 2000, 101, 435-441; Role of the surrogate light
chain and the pre-B-cell receptor in mouse B-cell development).
Whenever they occur in-frame, a mu chain can be produced and
presented on the cell surface only if it associates with the
surrogate light chain to form the pre-B-cell receptor (pre-BCR).
The pre-BCR on the cell surface is required for clonal expansion of
pre-BII cells before light chain rearrangement. Compromised
presentation of pre-BCR on the cell surface due to the impairment
of association of a mu chain carrying a certain variable region
with a surrogate light chain will result in no clonal expansion of
such a clone and reduce the representation of this variable region
in the mature B cells. Human VpreB1 only shares a low identity with
rodent VpreB1/2, suggesting that species specificity for the
pre-BCR assembly exists. To this end, the inventors realised the
importance for appropriate VpreB/variable region pairing on
generation of effective antibody diversity in the context of an
antibody heavy chain transgene encoding human variable regions,
when this transgene is harboured in a non-human environment such as
a transgenic mouse or rat.
[0066] The CH1 constant region pairs with the .lamda.5 protein.
Together, the VpreB and .lamda.5 make up the surrogate light chain
(SLC) that pairs with mu heavy chains to form the pre-BCR. For H2
antibodies pairing with the CH1 is not possible (since no CH1 is
present), but the desirability to pair human VH regions with human
VpreB according to the invention still applies.
[0067] Pairing Human Variable Regions of Pre-BCRs with Human
VpreB
[0068] The extent of homology between human VpreB with mouse and
rat VpreB is relatively low (about 73% amino acid identity). As
discussed above, the inventors have realised the advantage of
matching human antibody heavy chain variable regions with human
VpreB in receptors of pre-B cells for promoting B-cell development
in transgenic non-human vertebrates bearing human antibody variable
region genes.
[0069] In a first configuration, the invention thus provides:--
[0070] A non-human vertebrate (eg, a mouse or rat) or cell (eg, a
mouse cell or rat cell) whose genome comprises an antibody heavy
chain transgene, the transgene comprising
[0071] (a) one or more human VH gene segments, one or more human D
gene segments and one or more human JH gene segments operably
connected upstream of a constant region gene so that the transgene
is capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding an antibody
heavy chain having a human variable region and a constant region;
or
[0072] (b) a rearranged VDJ encoding a human variable region
operably connected upstream of a constant region gene so that the
transgene encodes (optionally following VDJ combination with the
constant region) a chimaeric antibody heavy chain having a human
variable region and a constant region;
[0073] the genome further comprising a human VpreB gene capable of
expressing a human VpreB.
[0074] The sequences of VpreB's and .lamda.5's are given
below:--
[0075] SEQ ID NO: 1
[0076] Human VpreB1 nucleotide sequence (GenBank Accession
No=NG_029387.1)
[0077] SEQ ID NO: 2
[0078] Human VpreB1 amino acid sequence (Gen Bank Accession
No=NP_009059.1)
[0079] SEQ ID NO: 3
[0080] Human VpreB3 nucleotide sequence (GenBank Accession
No=NC_000022.10)
[0081] SEQ ID NO: 4
[0082] Human VpreB3 amino acid sequence (Gen Bank Accession
No=NP_037510)
[0083] SEQ ID NO: 5
[0084] Mouse VpreB1 nucleotide sequence (Gen Bank Accession
No=NC_000082.5)
[0085] SEQ ID NO: 6
[0086] Mouse VpreB1 amino acid sequence (GenBank Accession
No=NP_058678)
[0087] SEQ ID NO: 7
[0088] Mouse VpreB2 nucleotide sequence (Gen Bank Accession
No=NC_000082)
[0089] SEQ ID NO: 8
[0090] Mouse VpreB2 amino acid sequence (GenBank Accession
No=NP_058679.1)
[0091] SEQ ID NO: 9
[0092] Rat VpreB1 nucleotide sequence (Gen Bank Accession
No=NM_001108845.1)
[0093] SEQ ID NO: 10
[0094] Rat VpreB1 amino acid sequence (GenBank Accession
No=NP_001102315.1)
[0095] SEQ ID NO: 11
[0096] Rat VpreB2 nucleotide sequence (Gen Bank Accession
No=NC_005110)
[0097] SEQ ID NO: 12
[0098] Rat VpreB2 amino acid sequence (GenBank Accession
No=NP_001128260)
[0099] SEQ ID NO: 13
[0100] Human .lamda.5 nucleotide sequence (GenBank Accession
No=NG_009791)
[0101] SEQ ID NO: 14
[0102] Human .lamda.5 amino acid sequence (GenBank Accession
No=NP_064455)
[0103] SEQ ID NO: 15
[0104] Mouse .lamda.5 nucleotide sequence (Gen Bank Accession
No=AC_000038)
[0105] SEQ ID NO: 16
[0106] Mouse .lamda.5 amino acid sequence (Gen Bank Accession
No=NP_001177254)
[0107] SEQ ID NO: 17
[0108] Rat .lamda.5 nucleotide sequence (Gen Bank Accession
No=NC_005110)
[0109] SEQ ID NO: 18
[0110] Rat .lamda.5 amino acid sequence (Gen Bank Accession
No=NP_001177270)
[0111] All sequences listed under these GenBank Accession numbers
are incorporated herein by reference as though explicitly written
herein and for possible use in the present invention and possible
inclusion of any claim below.
[0112] In one embodiment of any configuration of the invention, the
human VpreB is human VpreB1. In another embodiment, the human VpreB
is human VpreB3.
TABLE-US-00001 TABLE 1 Sequence Identity: VpreB: Human vs. Mouse
vs. Rat Human Mouse Mouse Rat Rat VpreB1 VpreB1 VpreB2 VpreB1
VpreB2 Human VpreB1 72.5 72.5 72.6 72.6 Mouse VpreB1 97.2 84.4 83.7
Mouse VpreB2 86.7 85.9 Rat VpreB1 99.3 Rat VpreB2
TABLE-US-00002 TABLE 2 Sequence Identity: Lambda 5: Human vs. Mouse
vs. Rat Human .lamda.5 Mouse .lamda.5 Rat .lamda.5 Human .lamda.5
55.8 57.2 Mouse .lamda.5 90.4 Rat .lamda.5
[0113] All nucleotide co-ordinates for the mouse are those
corresponding to NCBI m37 for the mouse C57BL/6J strain, e.g. April
2007 ENSEMBL Release 55.37h, e.g. NCBI37 July 2007 (NCBI build 37)
(e.g. UCSC version mm9 see www.genome.ucsc.edu and
http://genome.ucsc.edu/FAQ/FAQreleases.html) unless otherwise
specified. Human nucleotides coordinates are those corresponding to
GRCh37 (e.g. UCSC version hg 19,
http://genome.ucsc.edu/FAQ/FAQreleases.html), February 2009 ENSEMBL
Release 55. or are those corresponding to NCBI36, Ensemble release
54 unless otherwise specified. Rat nucleotides are those
corresponding to RGSC 3.4 Dec. 2004 ENSEMBL release 55.34w, or
Baylor College of Medicine HGSC v3.4 Nov. 2004 (e.g., UCSC rn4, see
www.genome.ucsc.edu and
http://genome.ucsc.edu/FAQ/FAQreleases.html) unless otherwise
specified.
[0114] In one example of the vertebrate or cell, the genome is
homozygous for said transgene and endogenous non-human vertebrate
antibody heavy chain expression has been inactivated. Alternatively
or additionally, endogenous non-human vertebrate antibody light
chain expression has been inactivated. Details on possible methods
of inactivation are explained in more detail below.
[0115] The present invention is applicable to the production of
4-chain antibodies in transgenic animals, where the antibodies each
contain 2 heavy chains and 2 light chains. Alternatively, the
invention can be applied to the production of H2 antibodies (heavy
chain antibodies) which are devoid of CH1 and light chains (see,
eg, Nature. 1993 Jun. 3; 363(6428):446-8; Naturally occurring
antibodies devoid of light chains; Hamers-Casterman C, Atarhouch T,
Muyldermans S, Robinson G, Hamers C, Songa E B, Bendahman N, Hamers
R). These antibodies function to specifically bind antigen, such
antibodies being found in the blood of Camelidae (eg, llamas,
camels, alpacas). Such antibodies with VH pairs can also be
synthetically produced to provide therapeutic and prophylactic
medicaments (eg, see WO1994004678, WO2004041862, WO2004041863).
Transgenic mice also can produce such heavy chain antibodies and
the in vivo production of the antibodies allows the mouse's immune
system to select for human VH-VH pairings, sometimes selecting for
such pairings in which mutations have been introduced in vivo by
the mouse to accommodate the pairing (WO2010109165A2). Thus, in an
embodiment of the present invention, the heavy chain transgene is
devoid of a CH1 gene segment and the genome comprises no functional
antibody light chain locus.
[0116] Throughout this text, and with application to any
configuration, aspect, embodiment or example of the invention, the
term "endogenous" (eg, endogenous constant region gene or
endogenous .lamda.5) in relation to a non-human vertebrate or cell
indicates that the constant region, .lamda.5 etc is a type of
constant region or .lamda.5 that is normally found in the
vertebrate or cell (as opposed to an exogenous constant region or
.lamda.5 whose sequence is not normally found in such a vertebrate
or cell). For example, the endogenous constant region and .lamda.5
can be those encoded by the wild-type genome of the non-human
vertebrate/cell. So, in an example wherein the vertebrate cell is a
mouse ES cell, the endogenous constant region and .lamda.5 would be
mouse constant region and .lamda.5. Going further, the endogenous
regions are, in an example, strain-matched to the vertebrate/cell.
So, in one embodiment, the vertebrate cell is a mouse 129 ES cell,
the endogenous constant region and .lamda.5 would be mouse 129
constant region and .lamda.5. In another embodiment, the vertebrate
cell is a mouse JM8 ES cell, the endogenous constant region and
.lamda.5 would be mouse JM8 constant region and .lamda.5. In
another embodiment, the vertebrate is a Black 6 mouse, the
endogenous constant region and .lamda.5 would be mouse Black 6
constant region and .lamda.5.
[0117] In any configuration, aspect, embodiment or example of the
invention, the constant region of the heavy chain transgene is a
non-human vertebrate constant region (eg, mouse or rat constant
region). Optionally, the constant region is endogenous to said
non-human vertebrate or cell. Alternatively, the constant region of
the heavy chain transgene is human constant region. For example,
the constant region is human and devoid of a CH1. This is useful
for producing human H2 antibodies (especially when the vertebrate
or cell is not capable of expressing light chains).
[0118] In one example of the vertebrate or cell of the invention,
the constant region is a Cmu, eg, a mouse or rat Cmu. For example,
where the vertebrate is a mouse (or cell is a mouse cell), the Cmu
is an endogenous mouse Cmu. The transgene, in an example, comprises
a Smu switch 5' of the Cmu and a Cgamma 3' of the Cmu, with a S
gamma switch between the Cmu and Cgamma. In an embodiment, the Cmu,
Cgamma and switches are endogenous mouse C regions and switches.
For example, the C regions and switches are mouse 129 C regions and
switches; or the C regions and switches are mouse Black 6 C regions
and switches. In another embodiment, the S gamma and C regions are
mouse S gamma and C regions, and the Smu is a rat Smu.
[0119] In an example of any configuration, aspect, embodiment or
example of the invention, the human VpreB gene has a nucleotide
sequence that is at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97,
98 or 99% identical to SEQ ID NO: 1. The VpreB gene encodes a human
VpreB that pairs with the heavy chain human variable region. In an
example, the human VpreB gene has a nucleotide sequence that is
identical to SEQ ID NO:1.
[0120] In an example of any configuration, aspect, embodiment or
example of the invention, the human VpreB gene encodes a human
VpreB comprising an amino acid sequence that is at least 80, 85,
90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to SEQ ID NO:
2. The VpreB gene encodes a human VpreB that pairs with the heavy
chain human variable region. In an example, the human VpreB gene
encodes a human VpreB comprising an amino acid sequence that is
identical to SEQ ID NO:2; or optionally with from one to 15 amino
acid changes (eg, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or
15 changes) compared with SEQ ID NO: 2.
[0121] In any configuration, aspect, embodiment or example of the
invention, the human VpreB gene encodes a human VpreB that pairs
with the heavy chain human variable region, the human VpreB gene
having from one to 25 nucleotide changes (eg, 1, 2, 3, 4, 5, 6, 7,
8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or
25 changes) compared to human VpreB (SEQ ID NO: 1). The VpreB gene
can be manipulated in vitro by creation of a targeting vector
comprising the gene sequence and homology arms flanking the
sequence. This can be introduced into the genome of, for example an
ES cell, using the standard technique of homologous recombination
as will be apparent to the skilled person. Alternatively,
recombinase mediated cassette exchange (RMCE)--another standard
technique--can be used to effect precise insertion of the VpreB
gene into the genome.
[0122] Homologous recombination or RMCE are generally-useful
techniques for the specific, targeted, introduction of sequences
into a genome. One or both of these techniques are readily
applicable for introducing into a vertebrate or cell genome a human
VpreB sequence (wild-type or mutant); V, D, J and C regions;
switches; enhancers and other immunoglobulin control elements; and
.lamda.5 genes. These and other techniques for target insertion are
known to the skilled addressee.
[0123] In an example of any configuration, aspect, embodiment or
example of the invention, the genome does not comprise a non-human
vertebrate (eg, mouse or rat) species VpreB1 and/or VpreB2 gene. In
this embodiment, the possibility of non-human VpreB competing with
the human VpreB for binding to the human variable regions is
eliminated. Thus, pairing of human V regions with human VpreB on
pre-B cells is not hampered by such competition, which is
advantageous for promoting B-cell development.
[0124] In an example of any configuration, aspect, embodiment or
example of the invention, the genome further comprises a .lamda.5
gene (eg, a human, mouse or rat .lamda.5); optionally wherein the
.lamda.5 gene is a .lamda.5 of a non-human vertebrate (eg, mouse or
rat) species and said constant region gene is a constant region
gene of the same non-human vertebrate (eg, mouse or rat) species as
the .lamda.5 gene. For example, the constant region and .lamda.5
genes are mouse constant region and .lamda.5 genes, eg, mouse 129
constant region and .lamda.5 genes; or mouse JM8 constant region
and .lamda.5 genes). For example, the constant region and .lamda.5
genes are rat constant region and .lamda.5 genes. In an example,
constant region gene and .lamda.5 gene are endogenous genes of said
vertebrate or cell. Thus, the invention contemplates close matching
of not only the V-region/VpreB part of pre-BCRs but also close
matching of the Cmu/.lamda.5 part. While not wishing to be bound to
any theory, the inventors believe that this is useful for
stabilising the pre-BCRs to promote B-cell development in vivo,
thus improving the B-cell pool (and potentially diversity) from
which to select antigen-specific antibodies following immunisation
of vertebrates according to the inventions.
[0125] In another embodiment of any configuration, aspect,
embodiment or example of the invention, the .lamda.5 is a chimaeric
.lamda.5 comprising a non-human vertebrate .lamda.5 (eg, endogenous
mouse or rat .lamda.5) in which amino acid sequences have been
replaced by corresponding amino acids from a human .lamda.5. For
example, the region of .lamda.5 that interfaces with VpreB to form
the SLC is replaced with the corresponding part from a human
.lamda.5 to form a chimaeric .lamda.5 with a human part (ie,
species-matched with the human VpreB) and a non-human vertebrate
(eg, mouse or rat) part that is species matched with the CH1 of the
non-human vertebrate Cmu of the heavy chain transgene. In the
alternative embodiment where the .lamda.5 is a human .lamda.5, the
.lamda.5 is advantageously species-matched to interface with the
human .lamda.5.
[0126] In one aspect the non-human vertebrate is able to generate a
diversity of at least 1.times.10.sup.6 different functional
chimaeric antibody sequence combinations.
[0127] In a second configuration, the method provides
[0128] A method of constructing a transgenic non-human vertebrate
cell (eg, an ES cell, eg, a mouse or rat ES cell), the method
comprising
[0129] (i) introducing into the genome of a non-human vertebrate
cell (or an ancestor thereof) one or more human VH gene segments,
one or more human D gene segments and one or more human JH gene
segments so that said gene segments are operably connected upstream
of a constant region gene (optionally an endogenous non-human
vertebrate constant region gene) to form a heavy chain transgene,
wherein in said cell or a progeny thereof the transgene is capable
of undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding an antibody heavy chain
having a human variable region and a constant region; or
[0130] (ii) introducing into the genome of a non-human vertebrate
cell (or an ancestor thereof) a rearranged VDJ encoding a human
variable region so that said VDJ is operably connected upstream of
a constant region gene (optionally an endogenous non-human
vertebrate constant region gene) to form a heavy chain transgene,
wherein in said cell or a progeny thereof the transgene encodes
(optionally following VDJ combination with the constant region) an
antibody heavy chain having a human variable region and a constant
region;
[0131] and wherein the method further comprises introducing into
the cell (before, after or concomitantly with step (i) or (ii)) a
human VpreB gene capable of expressing a human VpreB.
[0132] Targeting of the genome of an ES cell to produce a
transgenic cell and subsequently a transgenic vertebrate (eg, a
mouse) may be carried out using a protocol as explained by
reference to the FIGS. 1-18 and description in WO2011004129, the
disclosure of which is incorporated herein by reference. A suitable
mouse ES cell is selected from AB2.1 cells (available from Baylor
College of Medicine, Texas, USA), AB2.2 cells and JM8 cells.
[0133] In any configuration, aspect, embodiment or example of the
invention, the cell is an ES cell is capable of developing into a
non-human mammal able to produce a repertoire of antibodies which
are chimaeric, said chimaeric antibodies having a non-human mammal
constant region and a human variable region. Optionally the genome
of the cell is modified to prevent expression of fully host-species
specific antibodies.
[0134] In one aspect the cell is an induced pluripotent stem cell
(iPS cell).
[0135] In one aspect cells are isolated non-human mammalian
cells.
[0136] In one aspect a cell as disclosed herein is preferably a
non-human mammalian cell.
[0137] In one aspect the cell is a cell from a mouse strain
selected from C57BL/6, M129 such as 129/SV, BALB/c, and any hybrid
of C57BL/6, M129 such as 129/SV, or BALB/c. In an example, the
mouse is a C57BL/6-129/Sv hybrid.
[0138] Maintaining the performance of the ES cell clones through
multiple rounds of manipulation without the need to test the germ
line potential of the ES cell line at every step may be important
in the method of constructing a transgenic locus. The cell lines
currently in use for the KOMP and EUCOMM global knockout projects
have been modified twice prior to their use for this project and
their germ line transmission rates are unchanged from the parental
cells (these lines are publicly available, see www.komp.org and
www.eucomm.org). This cell line, called JM8, can generate 100% ES
cell-derived mice under published culture conditions (Pettitt, S.
J., Liang, Q., Rairdan, X. Y., Moran, J. L., Prosser, H. M., Beier,
D. R., Lloyd, K. C., Bradley, A., and Skarnes, W. C. (2009). Agouti
C57BL/6N embryonic stem cells for mouse genetic resources. Nature
Methods.). These cells have demonstrated ability to reproducibly
contribute to somatic and germ line tissue of chimaeric animals
using standard mouse ES cell culture conditions. This capability
can be found with cells cultured on a standard feeder cell line
(SNL) and even feeder-free, grown only on gelatine-coated tissue
culture plates. One particular sub-line, JM8A3, maintained the
ability to populate the germ line of chimeras after several serial
rounds of sub-cloning. Extensive genetic manipulation via, for
example, homologous recombination--as could be the case in the
present method--cannot compromise the pluripotency of the cells.
The ability to generate chimeras with such high percentage of ES
cell-derived tissue has other advantages. First, high levels of
chimaerism correlates with germ line transmission potential and
provide a surrogate assay for germ line transmission while only
taking 5 to 6 weeks. Second, since these mice are 100% ES cell
derived the engineered loci can be directly tested, removing the
delay caused by breeding. Testing the integrity of the new Ig loci
is possible in the chimera since the host embryo will be derived
from animals that are mutant for the RAG-1 gene as described in the
next section.
[0139] Another cell line that may be used is an HPRT-negative cell
line, such as AB2.1, as disclosed in "Chromosome engineering in
mice, Ramirez-Solis R, Liu P and Bradley A, Nature 1995; 378; 6558;
720-4.
[0140] RAG-1 Complementation
[0141] While many clones will generate 100% ES derived mice some
will not. Thus, at every step mice can be generated in a
RAG-1-deficient background. This provides mice with 100% ES-derived
B- and T-cells which can be used directly for immunization and
antibody production. Cells having a RAG-2 deficient background, or
a combined RAG-1/RAG-2 deficient background may be used, or
equivalent mutations in which mice produce only ES cell-derived B
cells and/or T cells.
[0142] In order that only the human-mouse IgH (and optionally also
light chain) loci are active in these mice, the human-mouse IgH
(and optionally light chain loci) can be engineered in a cell line
in which one allele of the IgH (and optionally light chain) locus
has already been inactivated. Alternatively the inactivation of the
host Ig locus/loci can be carried out after insertion.
[0143] Mouse strains that have the RAG-1 gene mutated are
immunodeficient as they have no mature B- or T-lymphocytes (U.S.
Pat. No. 5,859,307). T- and B-lymphocytes only differentiate if
proper V(D)J recombination occurs. Since RAG-1 is an enzyme that is
crucial for this recombination, mice lacking RAG-1 are
immunodeficient. If host embryos are genetically RAG-1 homozygous
mutant, a chimera produced by injecting such an embryo will not be
able to produce antibodies if the animal's lymphoid tissues are
derived from the host embryo. However, JM8 cells and AB2.1 cells,
for example, generally contribute in excess of 80% of the somatic
tissues of the chimaeric animal and would therefore usually
populate the lymphoid tissue. JM8 cells have wild-type RAG-1
activity and therefore antibodies produced in the chimaeric animal
would be encoded by the engineered JM8 ES cell genome only.
Therefore, the chimaeric animal can be challenged with an antigen
by immunization and subsequently produce antibodies to that
antigen. This allows one skilled in the art to test the performance
of the engineered human/mouse Ig loci as described in the present
invention.
[0144] One skilled in the art could use the chimaeric animal as
described to determine the extent of antibody diversity (see e.g.
Harlow, E. & Lane, D. 1998, 5.sup.th edition, Antibodies: A
Laboratory Manual, Cold Spring Harbor Lab. Press, Plainview, N.Y.).
For example, the existence in the chimaeric animal's serum of
certain antibody epitopes could be ascertained by binding to
specific anti-idiotype antiserum, for example, in an ELISA assay.
One skilled in the art could also sequence the genomes or heavy
chain RNA or DNA sequences of B-cell clones derived from the
chimaeric animal (naive or immunised) and compare said sequence to
wild-type sequence (ie, minus human VpreB) to assess the B-cell
repertoire and ascertain the level of hypermutation, such
hypermutation being indicative of normal antibody maturation.
[0145] One skilled in the art would also use said chimaeric animal
to examine antibody function wherein said antibodies are encoded
from the engineered Ig loci (see e.g. Harlow, E. & Lane, D.
1998, 5.sup.th edition, Antibodies: A Laboratory Manual, Cold
Spring Harbor Lab. Press, Plainview, N.Y.). For example, antisera
could be tested for binding an antigen, said antigen used to
immunize the chimaeric animal. Such a measurement could be made by
an ELISA assay. Alternatively, one skilled in the art could test
for neutralization of the antigen by addition of the antisera
collected from the appropriately immunized chimaeric animal.
[0146] It is well known to those skilled in the art that positive
outcomes for any of these tests demonstrate the ability of the
engineered Ig loci in the presence of VpreB during B-cell
development according to the instant invention, to encode
antibodies with human variable regions and non-human vertebrate
constant regions, said antibodies capable of functioning in the
manner of wild-type antibodies.
[0147] The introduction of human gene segment DNA into the genome
can be carried out using vectors carrying the DNA, as more fully
explained below. In one aspect such vectors are BACs (bacterial
artificial chromosomes). It will be appreciated that other cloning
vectors may be used in the invention, and therefore reference to
BACs herein may be taken to refer generally to any suitable vector.
As described in WO2011004129, in one aspect the inserted DNA is
built up in the genome of a cell, such as an ES cell, in a stepwise
manner using 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20 or
more separate insertions for the heavy chain gene segments.
Fragments are suitably inserted at the same or substantially the
same cell locus, e.g. ES cell locus, one after another, to form the
complete VDJ region.
[0148] In a further aspect the method comprises the insertion of
human heavy chain gene segments upstream of the non-human
vertebrate constant region by step-wise insertion of multiple
fragments by homologous recombination, preferably using an
iterative process. Suitably fragments of approximately 100 KB from
the human VDJ locus are inserted, suitably to form a VDJ region
after the final iteration of the insertion process, as described in
WO2011004129.
[0149] In one aspect the insertion process commences at a site
where an initiation cassette has been inserted into the genome of a
cell, such as an ES cell, providing a unique targeting region. In
one aspect the initiation cassette is inserted in the non-human
vertebrate heavy chain locus, for use in insertion of human heavy
chain DNA. The initiation cassette suitably comprises a vector
backbone sequence with which a vector having a human DNA fragment
in the same backbone sequence can recombine to insert the human DNA
into the cell (e.g. ES) cell genome, and suitably a selection
marker, such as a negative selection marker. Suitably the vector
backbone sequence is that of a BAC library, to allow BACs to be
used in the construction of the ES cells and mammals. The vector
backbone sequence may however be any sequence which serves as a
target site into which a homologous sequence can insert, for
example by homologous recombination and, for example RMCE, and is
optionally not DNA encoding any of the VDJ or constant region.
[0150] Suitable BACs are available from the Sanger centre, see "A
genome-wide, end-sequenced 129Sv BAC library resource for targeting
vector construction". Adams D J, Quail M A, Cox T, van der Weyden
L, Gorick B D, Su Q, Chan W I, Davies R, Bonfield J K, Law F,
Humphray S, Plumb B, Liu P, Rogers J, Bradley A. Genomics. 2005
December; 86(6):753-8. Epub 2005 Oct. 27. The Wellcome Trust Sanger
Institute, Hinxton, Cambridgeshire CB10 1SA, UK. BACs containing
human DNA are also available from, for example, Invitrogen. A
suitable library (source of human heavy chain gene segments) is
described in Osoegawa K et al, Genome Research 2001. 11: 483-496
and obtainable from the Roswell Park Cancer Institute
(USA)/Invitrogen.
[0151] In any configuration, aspect, embodiment or example of the
invention, non-human vertebrates, such as mice, are generated in a
RAG-1 or RAG-2-deficient background, or other suitable genetic
background which prevents the production of mature host B and T
lymphocytes.
[0152] In any configuration, aspect, embodiment or example of the
invention, the non-human vertebrate is a rodent, suitably a mouse,
and cells of the invention, are rodent cells or ES cells, suitably
mouse ES cells.
[0153] The ES cells of the present invention can be used to
generate animals using techniques well known in the art, which
comprise injection of the ES cell into a blastocyst followed by
implantation of chimaeric blastocystys into females to produce
offspring which can be bred and selected for homozygous
recombinants having the required insertion. In one aspect the
invention relates to a chimeric non-human vertebrate comprised of
ES cell-derived tissue and host embryo derived tissue, wherein the
ES cell is according to the invention. In one aspect the invention
relates to genetically-altered subsequent generation non-human
vertebrates, which include vertebrates homozygous for the human VDJ
region.
[0154] In one any configuration, aspect, example or embodiment, the
genome of the cell or vertebrate comprises: one or more human Ig
light chain kappa V regions and one or more human Ig light chain
kappa J regions upstream of all or part of a kappa constant
region.
[0155] In one any configuration, aspect, example or embodiment, the
genome of the cell or vertebrate comprises: one or more human Ig
light chain lambda V regions and one or more human Ig light chain
lambda J regions upstream of all or part of a lambda constant
region.
[0156] Suitably the light chain Viand C regions are able to form
antibody light chains in vivo capable of forming an antibody with
one or more of the chimaeric heavy chains to form an antibody that
binds a predetermined antigen.
[0157] In such aspects a human kappa and/or lambda region is
inserted into the genome, in combination with insertion of the
heavy chain VDJ region or part thereof, upstream of the host heavy
chain constant region as disclosed herein.
[0158] Suitably the insertion of the human VJC light chain DNA, or
part thereof as disclosed above, is made at the equivalent mouse
locus. In one aspect the human light chain kappa VJC DNA, or part
thereof, is inserted immediately upstream or downstream of the
mouse kappa VJC region. In one aspect, the human light chain lambda
VJC region or part thereof is inserted immediately upstream or
downstream of the mouse lambda VJC region. In one aspect only the
human kappa VJC locus is inserted and not the human lambda VJC
locus. In one aspect only the human lambda VJC locus is inserted
and not the human kappa VJC locus. Insertions may be made using the
techniques disclosed herein, and suitably do not remove the host
sequences from the genome. In one aspect the non-human mammal host
VJC sequences may be inactivated in some way, by mutation, or
inversion, or by insertion of the human variable region DNA, or by
any other means. In one aspect the cell or non-human mammal of the
invention may comprise an insertion of the complete VJC human
region.
[0159] The human kappa variable region DNA might be inserted into
the genome in functional arrangement with a lambda constant region,
for example inserted upstream of a lambda constant region.
Alternatively human lambda region variable DNA might be inserted in
functional arrangement with a kappa constant region, for example
inserted upstream of a kappa constant region.
[0160] In one any configuration, aspect, example or embodiment, the
genome of the cell or vertebrate comprises: one or more non-human
vertebrate control sequences such as the enhancer sequence(s) is
maintained upstream of the nonhuman vertebrate Mu constant region,
suitably in its native position with respect to the distance from
the constant region.
[0161] In one any configuration, aspect, example or embodiment, one
or more non-human mammal control sequences such as an enhancer
sequence(s) are maintained downstream of the nonhuman vertebrate Mu
constant region, suitably in its native position with respect to
the distance from the constant region.
[0162] In one any configuration, aspect, example or embodiment, a
non-human mammal switch sequence, suitably the endogenous switch
sequence, is maintained upstream of the non-human vertebrate Mu
constant region, suitably in its native position with respect to
distance from the constant region.
[0163] In such location the host enhancer or switch sequences are
operative in vivo with the host constant region sequence(s).
[0164] In one aspect a switch sequence is neither human, nor native
in the non-human mammal, for example in one aspect a non-human
mammal switch sequence is not a mouse or human switch sequence. The
switch sequence may be, for example, a rodent or primate sequence,
or a synthetic sequence. In particular the switch sequence may be a
rat sequence where the non-human mammal is a mouse. By way of
example, a mouse or human constant mu sequence may be placed under
the control of a switch sequence from a rat, or chimp, or other
switch sequence, suitably capable of allowing isotype switching to
occur in vivo.
[0165] One combination envisaged is a rat switch with mouse
enhancer sequences and mouse constant regions in a mouse cell.
[0166] In one aspect the human promoter and/or other control
elements that are associated with the different human V, D or J
regions are maintained in after insertion of the human VDJ into the
mouse genome.
[0167] The functional replacement of human promoter or other
control regions by non-human mammal promoter or control regions may
be carried out by use of recombineering, or other recombinant DNA
technologies, to insert a part of the human Ig region (such as a
human V region) into a vector (such as a BAC) containing a
non-human Ig region. The recombineering/recombinant technique
suitably replaces a portion of the non-human (e.g. mouse) DNA with
the human Ig region, and thus places the human Ig region under
control of the non-human mammal promoter or other control region.
Suitably the human coding region for a human V region replaces a
mouse V region coding sequence. Suitably the human coding region
for a human D region replaces a mouse D region coding sequence.
Suitably the human coding region for a human J region replaces a
mouse J region coding sequence. In this way human V, D or J regions
may be placed under the control of a non-human mammal promoter,
such as a mouse promoter.
[0168] In one any configuration, aspect, example or embodiment, the
human DNA inserted into the genome of the non-human vertebrate or
cell are placed under control of the host regulatory sequences or
other (non-human, non-host) sequences, In one aspect reference to
human coding regions includes both human introns and exons, or in
another aspect simply exons and no introns, which may be in the
form of cDNA.
[0169] It is also possible to use recombineering, or other
recombinant DNA technologies, to insert a non-human-mammal (e.g.
mouse) promoter or other control region, such as a promoter for a V
region or
[0170] VpreB, into a BAC containing a human Ig region. The A
recombineering step then places a portion of human DNA under
control of the mouse promoter or other control region.
[0171] Generally, insertion of human variable region DNA at or
close to the equivalent endogenous locus in the recipient genome is
preferred, for example within 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 kb
of the boundary (upstream or downstream) of a host immunoglobulin
locus.
[0172] In one embodiment of the method of the second configuration
of the invention, said genome is homozygous for said transgene and
endogenous non-human vertebrate antibody heavy chain expression is
inactivated.
[0173] In one embodiment of the method of the second configuration
of the invention, endogenous non-human vertebrate antibody light
chain expression is inactivated.
[0174] In one embodiment of the method of the second configuration
of the invention, the heavy chain transgene is devoid of a CH1 gene
segment and the genome comprises no functional antibody light chain
locus.
[0175] In one embodiment of the method of the second configuration
of the invention, said constant region is a Cmu. For example, the
Cmu is a non-human vertebrate Cmu or an endogenous Cmu of said
vertebrate or cell.
[0176] In one embodiment of the method of the second configuration
of the invention, said genome does not comprise a non-human
vertebrate (eg, mouse or rat) species VpreB1 and/or VpreB2
gene.
[0177] In one embodiment of the method of the second configuration
of the invention, the genome further comprises a .lamda.5 gene;
optionally wherein the .lamda.5 gene is a .lamda.5 of a non-human
vertebrate (eg, mouse or rat) species and said constant region gene
is a constant region gene of the same non-human vertebrate (eg,
mouse or rat) species as the .lamda.5 gene.
[0178] In one embodiment of the method of the second configuration
of the invention, said constant region gene and .lamda.5 gene are
endogenous genes of said vertebrate or cell.
[0179] In one embodiment of the method of the second configuration
of the invention, the method comprises making a progeny of the cell
made according to the method, wherein the progeny is homozygous for
said heavy chain transgene and endogenous non-human vertebrate
antibody expression has been inactivated.
[0180] A third configuration of the invention provides
[0181] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0182] (a) providing in a non-human vertebrate embryonic stem (ES)
cell genome an immunoglobulin transgene capable of expressing an
antibody mu heavy chain, wherein the antibody heavy chain comprises
a human variable region and a mu constant region (optionally an
endogenous non-human vertebrate mu constant region); and creating a
first non-human vertebrate from said ES cell or a progeny
thereof;
[0183] (b) providing in a second ES cell genome a second transgene
comprising a human VpreB gene capable of expressing a human VpreB;
and creating a second non-human vertebrate from said ES cell or a
progeny thereof; and
[0184] (c) creating by breeding a third non-human vertebrate
capable of co-expressing the mu antibody heavy chain and human
vpreB wherein a pre-B-cell receptor can form to promote B-cell
development of cells bearing a mu heavy chain in said third
vertebrate; the third vertebrate being made by crossing said first
and second vertebrates or progeny thereof by breeding to create
said third vertebrate, the third vertebrate comprising the first
and second transgenes, and wherein endogenous heavy chain
expression has been inactivated in said third vertebrate.
[0185] In one embodiment of the method of the third configuration
of the invention, in (a) the heavy chain transgene is constructed
to be devoid of a CH1 gene segment and the genome of the third
non-human vertebrate comprises no functional antibody light chain
locus.
[0186] In one embodiment of the method of the third configuration
of the invention, the genome of the third vertebrate does not
comprise a non-human vertebrate (eg, mouse or rat) species VpreB1
and/or VpreB2 gene.
[0187] In one embodiment of the method of the third configuration
of the invention, the third non-human vertebrate expresses a
.lamda.5 of a non-human vertebrate (eg, mouse or rat) species and
said constant region is a constant region of the same non-human
vertebrate (eg, mouse or rat) species as the .lamda.5 gene;
optionally wherein the .lamda.5 and constant region are an
endogenous .lamda.5 and constant region of mouse or rat.
[0188] The invention further provides a transgenic mouse according
to the third vertebrate, or a progeny thereof.
[0189] In a fourth aspect, the invention provides
[0190] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0191] (i) inactivating endogenous heavy chain expression in said
vertebrate;
[0192] (ii) providing in the genome of said vertebrate an
immunoglobulin transgene capable of expressing an antibody mu heavy
chain, wherein the antibody heavy chain comprises a human variable
region and a non-human vertebrate mu constant region (optionally an
endogenous non-human vertebrate mu constant region); and
[0193] (ii) providing in the genome of said vertebrate a second
transgene capable of expressing a human VpreB wherein a pre-B-cell
receptor can form to promote B-cell development of cells bearing a
mu heavy chain in said vertebrate;
[0194] Optionally wherein the genome is homozygous for said first
transgene.
[0195] In one embodiment of the method of the fourth configuration
of the invention, the heavy chain transgene is devoid of a CH1 gene
segment and the genome of the vertebrate comprises no functional
antibody light chain locus.
[0196] In one embodiment of the method of the fourth configuration
of the invention, the genome of the vertebrate does not comprise a
non-human vertebrate (eg, mouse or rat) species VpreB1 and/or
VpreB2 gene.
[0197] In one embodiment of the method of the fourth configuration
of the invention, the non-human vertebrate expresses a .lamda.5 of
a non-human vertebrate (eg, mouse or rat) species and said constant
region is a constant region of the same non-human vertebrate (eg,
mouse or rat) species as the .lamda.5 gene; optionally wherein the
.lamda.5 and constant region are an endogenous .lamda.5 and
constant region of mouse or rat.
[0198] The invention also provides a transgenic mouse according to
the fourth configuration, or a progeny thereof.
[0199] Chimaeric Surrogate Light Chains
[0200] The extent of homology between human .lamda.5 with mouse and
rat .lamda.5 is relatively low (about 56% amino acid identity). The
inventors realised the advantage of species-matching the .lamda.5
in the SLC in a transgenic non-human vertebrate with the species of
mu constant region in the pre-BCRs in such transgenic animals.
Thus, the invention further provides aspects that provide for the
possibility of species-matching in vivo the variable and constant
regions of the antibody heavy chain with both components (VpreB and
.lamda.5) of a chimaeric SLC. This is useful for promoting B-cell
development in the transgenic non-human vertebrate (eg, a mouse or
rat).
[0201] Thus, in an embodiment of the vertebrates, cells and methods
of the invention, the genome further comprises a .lamda.5 gene;
optionally wherein the .lamda.5 gene is a .lamda.5 of a non-human
vertebrate (eg, mouse or rat) species and said constant region gene
is a constant region gene of the same non-human vertebrate (eg,
mouse or rat) species as the .lamda.5 gene. For example, the
vertebrate is a mouse or rat (or cell is a mouse or rat cell) and
the .lamda.5 is a .lamda.5 that is endogenous to the mouse or rat
(or mouse or rat cell). In this example, the constant region of the
heavy chain transgene is an constant region (eg, Cmu) endogenous to
the mouse or rat. In this way, the .lamda.5 is matched for pairing
to the constant region at the cell surface in the pre-BII stage,
and the human VpreB is matched for pairing with the human variable
region encoded by the transgene.
[0202] To this end, the invention provides in a fifth
configuration
[0203] A non-human vertebrate (eg, a mouse or rat) or cell (eg, a
mouse cell or rat cell) whose genome comprises an antibody heavy
chain transgene,
[0204] the transgene comprising
[0205] (a) one or more human VH gene segments, one or more human D
gene segments and one or more human JH gene segments operably
connected upstream of a constant region gene of a non-human
vertebrate (eg, mouse or rat) species so that the transgene is
capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding a chimaeric
antibody heavy chain having a human variable region and a non-human
vertebrate constant region; or
[0206] (b) a rearranged VDJ encoding a human variable region
operably connected upstream of a constant region gene of a
non-human vertebrate (eg, mouse or rat) species so that the
transgene encodes (optionally following VDJ combination with the
constant region) a chimaeric antibody heavy chain having a human
variable region and a non-human vertebrate constant region;
[0207] the genome further comprising one or more genes together
encoding a chimaeric surrogate light chain, the surrogate light
chain comprising a human VpreB and .lamda.5 of said non-human
vertebrate (eg, mouse or rat) species.
[0208] In one embodiment of the method of the fifth configuration
of the invention, said genome is homozygous for said transgene and
endogenous non-human vertebrate antibody heavy chain expression has
been inactivated.
[0209] In one embodiment of the method of the fifth configuration
of the invention, said constant region gene is a Cmu gene.
[0210] In one embodiment of the method of the fifth configuration
of the invention, said constant region gene and .lamda.5 gene are
endogenous genes of said vertebrate or cell.
[0211] In one embodiment of the method of the fifth configuration
of the invention, said genome does not comprise a non-human
vertebrate (eg, mouse or rat) species VpreB1 and/or VpreB2
gene.
[0212] In a sixth configuration, the invention further provides
[0213] A method of constructing a transgenic non-human vertebrate
cell (eg, an ES cell, eg, a mouse or rat ES cell), the method
comprising
[0214] (i) introducing into a non-human vertebrate cell (or an
ancestor thereof) one or more human VH gene segments, one or more
human D gene segments and one or more human JH gene segments so
that said gene segments are operably connected upstream of an
endogenous non-human vertebrate constant region gene, wherein in
said cell or a progeny thereof the transgene is capable of
undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding a chimaeric antibody heavy
chain having a human variable region and a non-human vertebrate
constant region; or
[0215] (ii) introducing into a non-human vertebrate cell (or an
ancestor thereof) a rearranged VDJ encoding a human variable region
so that said VDJ is operably connected upstream of an endogenous
non-human vertebrate constant region gene, wherein in said cell or
a progeny thereof the transgene encodes (optionally following VDJ
combination with the constant region) a chimaeric antibody heavy
chain having a human variable region and a non-human vertebrate
constant region;
[0216] and wherein the method further comprises introducing into
the cell a human VpreB gene such that the cell or a progeny thereof
is capable of expressing a chimaeric surrogate light chain as well
as said chimaeric antibody heavy chain, wherein the surrogate light
chain comprises a human VpreB and an endogenous non-human
vertebrate .lamda.5.
[0217] In one embodiment of the method of the sixth configuration
of the invention, said constant region gene is a Cmu gene.
[0218] In one embodiment of the method of the sixth configuration
of the invention, each endogenous non-human vertebrate VpreB gene
is inactivated or deleted from said genome.
[0219] In one embodiment, the method of the sixth configuration of
the invention comprises making a progeny of the cell made according
to the method, wherein the progeny is homozygous for said heavy
chain transgene and endogenous non-human vertebrate antibody heavy
chain expression has been inactivated.
[0220] In a seventh configuration, the invention provides
[0221] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0222] (a) providing in a non-human vertebrate embryonic stem (ES)
cell an immunoglobulin transgene capable of expressing a chimaeric
antibody mu heavy chain, wherein the chimaeric antibody heavy chain
comprises a human variable region and an endogenous non-human
vertebrate mu constant region; and creating a first non-human
vertebrate from said ES cell or a progeny thereof;
[0223] (b) providing in a second ES cell a second transgene capable
of expressing a human VpreB so that the human VpreB and an
endogenous .lamda.5 form a chimaeric surrogate light chain; and
creating a second non-human vertebrate from said ES cell or a
progeny thereof; and
[0224] (c) creating by breeding a third non-human vertebrate
capable of co-expressing the chimaeric mu antibody heavy chain and
chimaeric surrogate light chain wherein a pre-BCR can form to
promote B-cell development in said third vertebrate; the third
vertebrate being made by crossing said first and second vertebrates
or progeny thereof by breeding to create said third vertebrate, the
third vertebrate comprising the first and second transgenes, and
wherein endogenous heavy chain expression has been inactivated in
said third vertebrate.
[0225] The invention provides a transgenic mouse according to the
vertebrate of this method, or a progeny thereof.
[0226] In an eighth configuration, the invention provides
[0227] A method of promoting B-cell development in a non-human
vertebrate (eg, a mouse or rat), the method comprising
[0228] (i) inactivating endogenous heavy chain expression in said
vertebrate;
[0229] (ii) providing in the genome of said vertebrate an
immunoglobulin transgene capable of expressing a chimaeric antibody
mu heavy chain, wherein the chimaeric antibody heavy chain
comprises a human variable region and an endogenous non-human
vertebrate mu constant region;
[0230] and
[0231] (ii) providing in the genome of said vertebrate a second
transgene capable of expressing a human VpreB so that the human
VpreB and an endogenous .lamda.5 form a chimaeric surrogate light
chain; so that the vertebrate is capable of co-expressing the
chimaeric mu antibody heavy chain and chimaeric surrogate light
chain wherein a pre-BCR can form to promote B-cell development in
said vertebrate;
[0232] Optionally wherein the genome is homozygous for said first
transgene.
[0233] A transgenic mouse according to the vertebrate of this
method, or a progeny thereof, is provided.
[0234] In any configuration, aspect, embodiment or example of the
invention, the inserted human genes may be derived from the same
individual or different individuals, or be synthetic or represent
human consensus sequences.
[0235] Techniques for constructing non-human vertebrates and
vertebrate cells whose genomes comprise a transgene containing
human V, J and D regions are well known in the art. For example,
reference is made to WO2011004192, U.S. Pat. No. 7,501,552, U.S.
Pat. No. 6,673,986, U.S. Pat. No. 6,130,364, WO2009/076464 and U.S.
Pat. No. 6,586,251, the disclosures of which are incorporated
herein by reference in their entirety.
[0236] In one embodiment in any configuration of the invention, the
vertebrate is a non-human mammal and the vertebrate cell is a
non-human mammalian cell. In one embodiment in any configuration of
the invention, the vertebrate is a mouse, rat, rabbit, Camelid (eg,
a llama, alpaca or camel) or shark; or the vertebrate cell is a
mouse, rat, rabbit, Camelid (eg, a llama, alpaca or camel) or shark
cell.
[0237] In one aspect the human heavy chain gene segments are
inserted into the genome so that they are placed under control of
the host regulatory sequences (eg, enhancers, promoters and/or
switches) or other (non-human, non-host) sequences. In one aspect
reference to human coding regions includes both human introns and
exons, or in another aspect simply exons and no introns, which may
be in the form of cDNA.
[0238] Alternatively it is possible to use recombineering, or other
recombinant DNA technologies, to insert a non human-vertebrate
(e.g. mouse) promoter or other control region, such as a promoter
for a V region, into a BAC containing a human Ig region. The
recombineering step then places a portion of human DNA under
control of the mouse promoter or other control region.
[0239] The invention also relates to a cell line which is grown
from or otherwise derived from cells as described herein, including
an immortalised cell line. The cell line may comprise inserted
human V, D or J genes as described herein, either in germline
configuration or after rearrangement following in vivo maturation.
The cell may be immortalised by fusion to a tumour cell to provide
an antibody producing cell and cell line, or be made by direct
cellular immortalisation.
[0240] In one aspect the non-human vertebrate of any configuration
of the invention is able to generate a diversity of at least
1.times.10.sup.6 different functional chimaeric immunoglobulin
sequence combinations.
[0241] Optionally in any configuration of the invention the
constant region is endogenous to the vertebrate and optionally
comprises an endogenous switch. In one embodiment, the constant
region comprises a Cgamma (CY) region and/or a Smu (S.mu.) switch.
Switch sequences are known in the art, for example, see Nikaido et
al, Nature 292: 845-848 (1981) and also WO2011004192, U.S. Pat. No.
7,501,552, U.S. Pat. No. 6,673,986, U.S. Pat. No. 6,130,364,
WO2009/076464 and U.S. Pat. No. 6,586,251, eg, SEQ ID NOs: 9-24
disclosed in
[0242] U.S. Pat. No. 7,501,552. Optionally the constant region
comprises an endogenous S gamma switch and/or an endogenous Smu
switch. One or more endogenous switch regions can be provided, in
one embodiment, by constructing a transgenic immunoglobulin locus
in the vertebrate or cell genome in which at least one human V
region, at least one human J region, and optionally at least one
human D region, or a rearranged VDJ or VJ region, are inserted into
the genome in operable connection with a constant region that is
endogenous to the vertebrate or cell. For example, the human V(D)J
regions or rearranged VDJ or VJ can be inserted in a cis
orientation onto the same chromosome as the endogenous constant
region. A trans orientation is also possible, in which the human
V(D)J regions or rearranged VDJ or VJ are inserted into one
chromosome of a pair (eg, the chromosome 6 pair in a mouse or the
chromosome 4 in a rat) and the endogenous constant region is on the
other chromosome of the pair, such that trans-switching takes place
in which the human V(D)J regions or rearranged VDJ or VJ are
spliced inoperable linkage to the endogenous constant region. In
this way, the vertebrate can express antibodies having a chain that
comprises a variable region encoded all or in part by human V(D)J
or a rearranged VDJ or VJ, together with a constant region (eg, a
Cgamma or Cmu) that is endogenous to the vertebrate.
[0243] Human variable regions are suitably inserted upstream of
non-human vertebrate constant region, the latter comprising all of
the DNA required to encode the full constant region or a sufficient
portion of the constant region to allow the formation of an
effective chimaeric antibody capable of specifically recognising an
antigen.
[0244] In one aspect the chimaeric antibodies or antibody chains
have a part of a host constant region sufficient to provide one or
more effector functions seen in antibodies occurring naturally in a
host vertebrate, for example that they are able interact with Fc
receptors, and/or bind to complement.
[0245] Reference to a chimaeric antibody or antibody chain having a
non-human vertebrate constant region herein therefore is not
limited to the complete constant region but also includes chimaeric
antibodies or chains which have all of the host constant region, or
a part thereof sufficient to provide one or more effector
functions. This also applies to non-human vertebrate mammals and
cells and methods of the invention in which human variable region
DNA may be inserted into the host genome such that it forms a
chimaeric antibody chain with all or part of a host constant
region. In one aspect the whole of a host non-human vertebrate
constant region is operably linked to human variable region
DNA.
[0246] The host non-human vertebrate constant region herein is
optionally the endogenous host wild-type constant region located at
the wild type locus, as appropriate for the heavy or light chain.
For example, the human heavy chain DNA is suitably inserted on
mouse chromosome 12, suitably adjacent the mouse heavy chain
constant region, where the vertebrate is a mouse.
[0247] In one optional aspect where the vertebrate is a mouse, the
insertion of the human DNA, such as the human VDJ region is
targeted to the region between the J4 exon and the C.mu. locus in
the mouse genome IgH locus, and in one aspect is inserted between
coordinates 114,667,090 and 114,665,190, suitably at coordinate
114,667,091, after 114,667,090. In one aspect the insertion of the
human DNA, such as the human light chain kappa VJ is targeted into
mouse chromosome 6 between coordinates 70,673,899 and 70,675,515,
suitably at position 70,674,734, or an equivalent position in the
lambda mouse locus on chromosome 16.
[0248] In one aspect the host non-human vertebrate constant region
for forming the chimaeric antibody may be at a different (non
endogenous) chromosomal locus. In this case the inserted human DNA,
such as the human variable VDJ or VJ region(s) may then be inserted
into the non-human genome at a site which is distinct from that of
the naturally occurring heavy or light constant region. The native
constant region may be inserted into the genome, or duplicated
within the genome, at a different chromosomal locus to the native
position, such that it is in a functional arrangement with the
human variable region such that chimaeric antibodies of the
invention can still be produced.
[0249] In one aspect the human DNA is inserted at the endogenous
host wild-type constant region located at the wild type locus
between the host constant region and the host VDJ region.
[0250] Reference to location of the variable region upstream of the
non-human vertebrate constant region means that there is a suitable
relative location of the two antibody portions, variable and
constant, to allow the variable and constant regions to form a
chimaeric antibody or antibody chain in vivo in the vertebrate.
Thus, the inserted human DNA and host constant region are in
operable connection with one another for antibody or antibody chain
production.
[0251] In one aspect the inserted human DNA is capable of being
expressed with different host constant regions through isotype
switching. In one aspect isotype switching does not require or
involve trans switching. Insertion of the human variable region DNA
on the same chromosome as the relevant host constant region means
that there is no need for trans-switching to produce isotype
switching.
[0252] In the present invention, optionally host non-human
vertebrate constant regions are maintained and it is preferred that
at least one non-human vertebrate enhancer or other control
sequence, such as a switch region, is maintained in functional
arrangement with the non-human vertebrate constant region, such
that the effect of the enhancer or other control sequence, as seen
in the host vertebrate, is exerted in whole or in part in the
transgenic animal. This approach is designed to allow the full
diversity of the human locus to be sampled, to allow the same high
expression levels that would be achieved by non-human vertebrate
control sequences such as enhancers, and is such that signalling in
the B-cell, for example isotype switching using switch
recombination sites, would still use non-human vertebrate
sequences.
[0253] A non-human vertebrate having such a genome would produce
chimaeric antibodies with human variable and non-human vertebrate
constant regions, but these are readily humanized, for example in a
cloning step. Moreover the in vivo efficacy of these chimaeric
antibodies could be assessed in these same animals.
[0254] In one aspect the inserted human IgH VDJ region comprises,
in germline configuration, all of the V, D and J regions and
intervening sequences from a human. Optionally, non-functional V
and/or D and/or J gene segments are omitted. For example, VH which
are inverted or are pseudogenes may be omitted.
[0255] In one aspect 800-1000 kb of the human IgH VDJ region is
inserted into the non-human vertebrate IgH locus, and in one aspect
a 940, 950 or 960 kb fragment is inserted. Suitably this includes
bases 105,400,051 to 106,368,585 from human chromosome 14.
[0256] In one aspect the inserted IgH human fragment consists of
bases 105,400,051 to 106,368,585 from chromosome 14. In one aspect
the inserted human heavy chain DNA, such as DNA consisting of bases
105,400,051 to 106,368,585 from chromosome 14, is inserted into
mouse chromosome 12 between the end of the mouse J4 region and the
Eli region, suitably between co-ordinates 114,667,090 and
114,665,190, or at co-ordinate 114,667,091, after 114,667,090. In
one aspect the insertion is between co-ordinates 114,667,089 and
114,667,090 (co-ordinates refer to NCBI m37, for the mouse C57BL/6J
strain), or at equivalent position in another non-human vertebrate
genome.
[0257] A cell or non-human vertebrate of the invention, in one
embodiment, comprises an insertion of human heavy chain variable
region DNA between co-ordinates 114, 666, 183 and 114, 666, 725,
such as between 114 666 283 and 114 666 625, optionally between
co-ordinates 114,666,335 and 114,666,536, optionally between
114,666,385 and 114,666,486, or between 114,666,425 and
114,666,446, or between 114,666,435 and 114,666,436 of mouse
chromosome 12 with reference to NCBIM37 for the mouse genome,
relating to mouse strain C57BL/6J or an equivalent position of
mouse chromosome 12 from a different mouse strain or an equivalent
position in the genome of another non-human vertebrate, e.g., a
rat. The insertion between co-ordinates 114,666,435 and 114,666,436
relating to mouse strain C57BL/6J is equivalent to an insertion
between co-ordinates 1207826 and 1207827 on chromosome 12 with
reference to the 129/SvJ genomic sequence of the geneBank access
number NT114985.2. An insertion may be made at equivalent position
in another genome, such as another mouse genome. In an example of
this embodiment, the cell or mammal of the invention comprises a
human IgH VDJ region which comprises or consists of nucleotides
106,328,851-107,268,544, such as nucleotides
106,328,901-107,268,494, such as nucleotides
106,328,941-107,268,454, such as nucleotides
106,328,951-107,268,444 of human Chromosome 14, with reference to
the GRCH37/hg19 sequence database, or insertion of equivalent
nucleotides relating to chromosome 14 from a different human
sequence or database. The human insertion may be made between the
regions indicated above.
[0258] In one aspect there is inserted into the genome the human
kappa VJ region which comprises, in germline configuration, all of
the V and J regions and intervening sequences from a human.
Optionally, non-functional V and/or J gene segments are
omitted.
[0259] Suitably this includes bases 88,940,356 to 89,857,000 from
human chromosome 2, suitably approximately 917 kb. In a further
aspect the light chain VJ insert may comprise only the proximal
clusters of V segments and J segments. Such an insert would be of
approximately 473 kb.
[0260] In one aspect the human light chain kappa DNA, such as the
human Ig.kappa. fragment of bases 88,940,356 to 89,857,000 from
human chromosome 2, is suitably inserted into mouse chromosome 6
between coordinates 70,673,899 and 70,675,515, suitably at position
70,674,734.
[0261] In one aspect the human lambda V (or VJ) region is inserted
into the genome, which comprises, in germline configuration, all of
the V (and optionally J) regions and intervening sequences from a
human (which will thus include the human VpreB gene and a
promoter). Suitably this includes analogous bases to those selected
for the kappa fragment, from human chromosome 2. Optionally,
non-functional V and/or J gene segments are omitted.
[0262] All specific human fragments described above may vary in
length, and may for example be longer or shorter than defined as
above, such as 500 bases, 1 KB, 2K, 3K, 4K, 5 KB, 10 KB, 20 KB, 30
KB, 40 KB or 50 KB or more, which suitably comprise all or part of
the human V(D)J region, whilst preferably retaining the requirement
for the final insert to comprise human genetic material encoding
the complete heavy chain region and light chain region, as
appropriate, as described above.
[0263] In one aspect the 3' end of the last inserted human
sequence, generally the last human J sequence, is inserted less
than 2 kb, preferably less than 1 KB from the human/non-human
vertebrate (eg, human/mouse or human/rat) join region.
[0264] Optionally, the genome is homozygous at at least the IgH, or
a second, or all three immunoglobulin loci (IgH, Ig.lamda. and
Ig.kappa..
[0265] In another aspect the genome may be heterozygous at one or
more of the loci, such as heterozygous for DNA encoding a chimaeric
antibody chain and native (host cell) antibody chain. In one aspect
the genome may be heterozygous for DNA capable of encoding 2
different antibody heavy chains encoded by immunoglobulin
transgenes of the invention, for example, comprising 2 different
chimaeric heavy chains and a human lambda light chain.
[0266] In one aspect the invention relates to a non-human
vertebrate or cell, and methods for producing said vertebrate or
cell, as described herein, wherein the inserted human DNA, such as
the human IgH VDJ region and/or light chain V, J regions are found
on only one allele and not both alleles in the mammal or cell. In
this aspect a mammal or cell has the potential to express both an
endogenous host antibody heavy or light chain and a chimaeric heavy
or light chain.
[0267] In one embodiment in any configuration of the invention, the
genome has been modified to prevent or reduce the expression of
fully-endogenous antibody. Examples of suitable techniques for
doing this can be found in WO2011004192, U.S. Pat. No. 7,501,552,
U.S. Pat. No. 6,673,986, U.S. Pat. No. 6,130,364, WO2009/076464,
EP1399559 and U.S. Pat. No. 6,586,251, the disclosures of which are
incorporated herein by reference. In one embodiment, the non-human
vertebrate VDJ region of the endogenous heavy chain immunoglobulin
locus, and optionally VJ region of the endogenous light chain
immunoglobulin loci (lambda and/or kappa loci), have been
inactivated. For example, all or part of the non-human vertebrate
VDJ region is inactivated by inversion in the endogenous heavy
chain immunoglobulin locus of the mammal, optionally with the
inverted region being moved upstream or downstream of the
endogenous Ig locus. For example, all or part of the non-human
vertebrate VJ region is inactivated by inversion in the endogenous
kappa chain immunoglobulin locus of the mammal, optionally with the
inverted region being moved upstream or downstream of the
endogenous Ig locus. For example, all or part of the non-human
vertebrate VJ region is inactivated by inversion in the endogenous
lambda chain immunoglobulin locus of the mammal, optionally with
the inverted region being moved upstream or downstream of the
endogenous Ig locus. In one embodiment the endogenous heavy chain
locus is inactivated in this way as is one or both of the
endogenous kappa and lambda loci.
[0268] Additionally or alternatively, the vertebrate has been
generated in a genetic background which prevents the production of
mature host B and T lymphocytes, optionally a RAG-1-deficient
and/or RAG-2 deficient background. See U.S. Pat. No. 5,859,301 for
techniques of generating RAG-1 deficient animals.
[0269] In one embodiment in any configuration of the invention, the
human V, J and optional D regions are provided by all or part of
the human IgH locus; optionally wherein said all or part of the IgH
locus includes substantially the full human repertoire of IgH V, D
and J regions and intervening sequences. A suitable part of the
human IgH locus is disclosed in WO2011004192. In one embodiment,
the human IgH part includes (or optionally consists of) bases
105,400,051 to 106,368,585 from human chromosome 14 (coordinates
from NCB136). Additionally or alternatively, optionally wherein the
vertebrate is a mouse or the cell is a mouse cell, the human V, J
and optional D regions are inserted into mouse chromosome 12 at a
position corresponding to a position between coordinates
114,667,091 and 114,665,190, optionally at coordinate 114,667,091
(coordinates from NCBIM37, relating to mouse strain C57BL/6J).
[0270] In one embodiment of any configuration of the vertebrate or
vertebrate cell of the invention when the vertebrate is a mouse,
(i) the constant region comprises a mouse or rat S.mu. switch and
optionally a mouse C.mu. region. For example the constant region is
provided by the constant region endogenous to the mouse, eg, by
inserting human V(D)J region sequences into operable linkage with
the endogenous constant region of a mouse genome or mouse cell
genome.
[0271] In one embodiment of any configuration of the vertebrate or
vertebrate cell of the invention when the vertebrate is a rat, (i)
the constant region comprises a mouse or rat S.mu. switch and
optionally a rat C.mu. region. For example the constant region is
provided by the constant region endogenous to the rat, eg, by
inserting human V(D)J region sequences into operable linkage with
the endogenous constant region of a rat genome or rat cell
genome.
[0272] In one embodiment of any configuration of the vertebrate or
vertebrate cell of the invention the genome comprises an antibody
light chain transgene which comprises all or part of the human
Ig.lamda. locus including at least one human JA region and at least
one human CA region, optionally C.sub..lamda.6 and/or
C.sub..lamda.7. Optionally, the transgene comprises a plurality of
human JA regions, optionally two or more of J.sub..lamda.1,
J.sub..lamda.2, J.sub..lamda.6 and J.sub..lamda.7, optionally all
of J.sub..lamda.1, J.sub..lamda.2, and J.sub..lamda.7. The human
lambda immunoglobulin locus comprises a unique gene architecture
composed of serial J-C clusters. In order to take advantage of this
feature, the invention in optional aspects employs one or more such
human J-C clusters inoperable linkage with the constant region in
the transgene, eg, where the constant region is endogenous to the
non-human vertebrate or non-human vertebrate cell. Thus, optionally
the transgene comprises at least one human
J.sub..lamda.-C.sub..lamda. cluster, optionally at least
J.sub..lamda.7-C.sub..lamda.7. The construction of such transgenes
is facilitated by being able to use all or part of the human lambda
locus such that the transgene comprises one or more J-C clusters in
germline configuration, advantageously also including intervening
sequences between clusters and/or between adjacent J and C regions
in the human locus. This preserves any regulatory elements within
the intervening sequences which may be involved in VJ and/or JC
recombination and which may be recognised by AID
(activation-induced deaminase) or AID homologues.
[0273] Where endogenous regulatory elements are involved in CSR
(class-switch recombination) in the non-human vertebrate, these can
be preserved by including in the transgene a constant region that
is endogenous to the non-human vertebrate. In the invention, one
can match this by using an AID or AID homologue that is endogenous
to the vertebrate or a functional mutant thereof. Such design
elements are advantageous for maximising the enzymatic spectrum for
SHM (somatic hypermutation) and/or CSR and thus for maximising the
potential for antibody diversity.
[0274] Optionally, the lambda transgene comprises a human EX
enhancer. Optionally, the kappa transgene comprises a human
E.kappa. enhancer. Optionally, the heavy chain transgene comprises
a heavy chain human enhancer.
[0275] In one embodiment of any configuration of the invention the
constant region is endogenous to the non-human vertebrate or
derived from such a constant region. For example, the vertebrate is
a mouse or the cell is a mouse cell and the constant region is
endogenous to the mouse. For example, the vertebrate is a rat or
the cell is a rat cell and the constant region is endogenous to the
rat.
[0276] In one embodiment of any configuration of the invention the
heavy chain transgene comprises a plurality human IgH V regions, a
plurality of human D regions and a plurality of human J regions,
optionally substantially the full human repertoire of IgH V, D and
J regions.
[0277] In one embodiment of any configuration of the invention, the
vertebrate or cell comprises a heavy chain further transgene, the
further transgene comprising at least one human IgH V region, at
least one human D region and at least one human J region,
optionally substantially the full human repertoire of IgH V, D and
J regions.
[0278] In one embodiment of any configuration of the invention,
[0279] (i) the heavy chain transgene comprises at least one human
IgH V region, at least one human J region, and optionally at least
one human D region; and
[0280] (ii) the vertebrate or cell comprises a kappa transgene, the
kappa transgene comprising at least one human Ig.kappa. V region
and at least one human J region.
[0281] In one embodiment of any configuration of the invention,
[0282] (i) the heavy chain transgene comprises at least one human
IgH V region, at least one human J region, and optionally at least
one human D region; and
[0283] (ii) the vertebrate or cell comprises a lambda transgene,
the lambda transgene comprising at least one human Ig.lamda. V
region and at least one human J region.
[0284] In one embodiment of any configuration of the invention,
[0285] (i) the heavy chain transgene comprises substantially the
full human repertoire of IgH V, D and J regions; and
[0286] (ii) the vertebrate or cell comprises substantially the full
human repertoire of Ig.kappa. V and J regions and/or substantially
the full human repertoire of Ig.lamda. V and J regions.
[0287] An aspect provides a B-cell, hybridoma or a stem cell,
optionally an embryonic stem cell or haematopoietic stem cell,
according to any configuration of the invention. In one embodiment,
the cell is a BALB/c, JM8 or AB2.1 or AB2.2 embryonic stem cell
(see discussion of suitable cells, and in particular JM8 and AB2.1
cells, in WO2011004192, which disclosure is incorporated herein by
reference). In one aspect the ES cell is derived from the mouse
BALB/c, C57BL/6N, C57BL/6J, 12955 or 129Sv strain.
[0288] An aspect provides a method of isolating an antibody or
nucleotide sequence encoding said antibody, the method
comprising
[0289] (a) immunising (see e.g. Harlow, E. & Lane, D. 1998,
5.sup.th edition, Antibodies: A Laboratory Manual, Cold Spring
Harbor Lab. Press, Plainview, N.Y.; and Pasqualini and Arap,
Proceedings of the National Academy of Sciences (2004) 101:257-259)
a vertebrate according to any configuration or aspect of the
invention with an antigen such that the vertebrate produces
antibodies; and
[0290] (b) isolating from the vertebrate an antibody that
specifically binds to said antigen and/or a nucleotide sequence
encoding at least the heavy and/or the light chain variable regions
of said antibody;
[0291] optionally wherein the variable regions of said antibody are
subsequently joined to a human constant region. Such joining can be
effected by techniques readily available in the art, such as using
conventional recombinant DNA and RNA technology as will be apparent
to the skilled person. See e.g. Sambrook, J and Russell, D. (2001,
3'd edition) Molecular Cloning: A Laboratory Manual (Cold Spring
Harbor Lab. Press, Plainview, N.Y.).
[0292] Suitably an immunogenic amount of the antigen is delivered.
The invention also relates to a method for detecting a target
antigen comprising detecting an antibody produced as above with a
secondary detection agent which recognises a portion of that
antibody.
[0293] Isolation of the antibody in step (b) can be carried out
using conventional antibody selection techniques, eg, panning for
antibodies against antigen that has been immobilised on a solid
support, optionally with iterative rounds at increasing stringency,
as will be readily apparent to the skilled person.
[0294] As a further optional step, after step (b) the amino acid
sequence of the heavy and/or the light chain variable regions of
the antibody are mutated to improve affinity for binding to said
antigen.
[0295] Mutation can be generated by conventional techniques as will
be readily apparent to the skilled person, eg, by error-prone PCR.
Affinity can be determined by conventional techniques as will be
readily apparent to the skilled person, eg, by surface plasmon
resonance, eg, using Biacore.TM..
[0296] Additionally or alternatively, as a further optional step,
after step (b) the amino acid sequence of the heavy and/or the
light chain variable regions of the antibody are mutated to improve
one or more biophysical characteristics of the antibody, eg, one or
more of melting temperature, solution state (monomer or dimer),
stability and expression (eg, in CHO or E coli).
[0297] An aspect provides an antibody produced by the method of the
invention, optionally for use in medicine, eg, for treating and/or
preventing a medical condition or disease in a patient, eg, a
human.
[0298] An aspect provides a nucleotide sequence encoding the
antibody of the invention, optionally wherein the nucleotide
sequence is part of a vector. Suitable vectors will be readily
apparent to the skilled person, eg, a conventional antibody
expression vector comprising the nucleotide sequence together in
operable linkage with one or more expression control elements.
[0299] An aspect provides a pharmaceutical composition comprising
the antibody of the invention and a diluent, excipient or carrier,
optionally wherein the composition is contained in an IV container
(eg, and IV bag) or a container connected to an IV syringe.
[0300] An aspect provides the use of the antibody of the invention
in the manufacture of a medicament for the treatment and/or
prophylaxis of a disease or condition in a patient, eg a human.
[0301] In a further aspect the invention relates to a method for
producing an antibody specific to a desired antigen the method
comprising immunizing a transgenic non-human vertebrate as above
with a predetermined antigen and recovering a chimaeric antibody
(see e.g. Harlow, E. & Lane, D. 1998, 5.sup.th edition,
Antibodies: A Laboratory Manual, Cold Spring Harbor Lab. Press,
Plainview, N.Y.; and Pasqualini and Arap, Proceedings of the
National Academy of Sciences (2004) 101:257-259). Suitably an
immunogenic amount of the antigen is delivered. The invention also
relates to a method for detecting a target antigen comprising
detecting an antibody produced as above with a secondary detection
agent which recognises a portion of that antibody.
[0302] In a further aspect the invention relates to a method for
producing a fully humanised antibody comprising immunizing a
transgenic non-human vertebrate as above with a predetermined
antigen, recovering a chimaeric antibody or cells expressing the
antibody, and then replacing the non-human vertebrate constant
region with a human constant region. This can be done by standard
cloning techniques at the DNA level to replace the non-human
vertebrate constant region with an appropriate human constant
region DNA sequence--see e.g. Sambrook, J and Russell, D. (2001,
3'd edition) Molecular Cloning: A Laboratory Manual (Cold Spring
Harbor Lab. Press, Plainview, N.Y.).
[0303] In a further aspect the invention relates to humanised
antibodies and antibody chains produced according to the present
invention, both in chimaeric and fully humanised form, and use of
said antibodies in medicine. The invention also relates to a
pharmaceutical composition comprising such an antibody and a
pharmaceutically acceptable carrier or other excipient.
[0304] Antibody chains containing human sequences, such as
chimaeric human-non-human antibody chains, are considered humanised
herein by virtue of the presence of the human protein coding
regions region. Fully humanised antibodies may be produced starting
from DNA encoding a chimaeric antibody chain of the invention using
standard techniques.
[0305] Methods for the generation of both monoclonal and polyclonal
antibodies are well known in the art, and the present invention
relates to both polyclonal and monoclonal antibodies of chimaeric
or fully humanised antibodies produced in response to antigen
challenge in non-human vertebrates of the present invention.
[0306] In a yet further aspect, chimaeric antibodies or antibody
chains generated in the present invention may be manipulated,
suitably at the DNA level, to generate molecules with antibody-like
properties or structure, such as a human variable region from a
heavy chain absent a constant region, for example a domain
antibody; or a human variable region with any constant region from
either heavy or light chain from the same or different species; or
a human variable region with a non-naturally occurring constant
region; or human variable region together with any other fusion
partner. The invention relates to all such chimaeric antibody
derivatives derived from chimaeric antibodies identified according
to the present invention.
[0307] In an example, the genome of the cell or non-human
vertebrate of the invention encodes an antibody comprising an
antibody chain having a human heavy chain variable region upstream
of a mouse light chain constant region in combination with one
of:
[0308] a fully human antibody light chain;
[0309] a non-human vertebrate (e.g., mouse or rat) antibody light
chain;
[0310] a chimaeric non-human vertebrate (e.g., mouse or rat)--human
antibody chain; or an antibody chain having a human heavy chain
variable region upstream of a non-human vertebrate (e.g., mouse or
rat) light chain constant region;
[0311] In a further aspect, the invention relates to use of
non-human vertebrates of the present invention in the analysis of
the likely effects of drugs and vaccines in the context of a
quasi-human antibody repertoire.
[0312] The invention also relates to a method for identification or
validation of a drug or vaccine, the method comprising delivering
the vaccine or drug to a vertebrate of the invention and monitoring
one or more of: the immune response, the safety profile; the effect
on disease.
[0313] The invention also relates to a kit comprising an antibody
or antibody derivative as disclosed herein and either instructions
for use of such antibody or a suitable laboratory reagent, such as
a buffer, antibody detection reagent.
[0314] The invention also relates to a method for making an
antibody, or part thereof, the method comprising providing:
[0315] (i) a nucleic acid encoding an antibody, or a part thereof,
obtained according to the present invention; or
[0316] (ii) sequence information from which a nucleic acid encoding
an antibody obtained according to the present invention, or part
thereof, can be expressed to allow an antibody to be produced.
[0317] In an embodiment, the invention provides
[0318] The non-human vertebrate, mouse, rat, cell or method of any
preceding configuration, wherein the genome comprises
[0319] (a) said antibody heavy chain transgene; and
[0320] (b) an antibody kappa light chain transgene and/or an
antibody lambda chain transgene; wherein all of the V, D and J in
said transgenes are human V, D and J;
[0321] wherein endogenous antibody heavy and light chain expression
has been inactivated; and optionally wherein said genome is
homozygous for said heavy and light chain transgenes.
[0322] In an embodiment, the the kappa and lambda chain transgenes
comprise constant regions of said non-human vertebrate species
capable of pairing with the constant region of the heavy chain.
[0323] In an embodiment, the heavy chain transgene comprises a
substantially complete human functional VH, D and JH
repertoire.
[0324] In an embodiment, the kappa chain transgene comprises a
substantially complete human functional V.kappa. and J.kappa.
repertoire; and the lambda chain transgene comprises a
substantially complete human functional VA and JA repertoire.
[0325] In a ninth embodiment, the invention provides
[0326] A transgenic mouse or rat, or a transgenic mouse or rat cell
(eg, an ES cell), whose genome comprises
[0327] (a) an antibody heavy chain transgene, the transgene
comprising a substantially complete human functional VH, D and JH
repertoire operably connected upstream of an endogenous (mouse or
rat) mu constant region gene so that the transgene is capable of
undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding an antibody heavy chain
having a human variable region and an endogenous mu constant
region;
[0328] (b) an antibody kappa light chain transgene and/or an
antibody lambda chain transgene; [0329] wherein all of the V, D and
J in said transgenes are human V, D and J; [0330] wherein the kappa
chain transgene comprises a substantially complete human functional
V.kappa. and J.kappa. repertoire; and the lambda chain transgene
comprises a substantially complete human functional VA and JA
repertoire; [0331] wherein the kappa and/or lambda chain transgenes
comprise endogenous constant regions capable of pairing with the
constant region of the heavy chain;
[0332] (c) a human VpreB gene capable of expressing a human VpreB;
[0333] optionally wherein the human VpreB gene is operably linked
to an endogenous VpreB promoter; and
[0334] (d) an endogenous .lamda.5 gene capable of expressing an
endogenous .lamda.5; [0335] wherein endogenous antibody heavy and
light chain expression has been inactivated; and [0336] optionally
wherein said genome is homozygous for said heavy and light chain
transgenes.
[0337] In a tenth embodiment, the invention provides
[0338] A transgenic mouse or rat, or a transgenic mouse or rat cell
(eg, an ES cell), whose genome comprises
[0339] (a) an antibody heavy chain transgene, the transgene
comprising a substantially complete human functional VH, D and JH
repertoire operably connected upstream of an endogenous (mouse or
rat) mu constant region gene so that the transgene is capable of
undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding an antibody heavy chain
having a human variable region and an endogenous mu constant
region; [0340] wherein all of the V, D and J in said transgene are
human V, D and J; [0341] wherein the heavy chain transgene is
devoid of a CH1 gene segment and the genome of the vertebrate
comprises no functional antibody light chain locus; [0342] wherein
endogenous antibody heavy chain expression has been inactivated;
and [0343] optionally wherein said genome is homozygous for said
heavy chain transgene;
[0344] (c) a human VpreB gene capable of expressing a human VpreB;
[0345] optionally wherein the human VpreB gene is operably linked
to an endogenous VpreB promoter; and
[0346] (d) an endogenous .lamda.5 gene capable of expressing an
endogenous .lamda.5.
[0347] Insertion of Human VpreB Gene
[0348] As described above, precise insertion of exogenous DNA (such
as human VpreB or antibody gene segment DNA) can be effected by
homolgous recombination, RMCE or other techniques that will be
apparent to the skilled person. Vector manipulation can be effected
using recombineering as is well known.
[0349] The human VpreB gene is found in human cells within the
human antibody VA gene segment cluster (in the nucleotide region
between human Ig.lamda. V gene segments IV-53 and 5-52 (the
nucleotide region being positions 22599200 to 22599926 on human
chromosome 22)). Thus, in one embodiment, a nucleotide sequence
found between human Ig.lamda. V gene segments IV-53 and 5-52, eg,
positions 22599200 to 22599926 on human chromosome 22, is inserted
into the genome of the cell or vertebrate, wherein the nucleotide
sequence comprises a human VpreB gene and optionally the associated
human promoter. For example, the nucleotide sequence is inserted in
the endogenous lambda antibody locus upstream of the endogenous
lambda constant region. In one embodiment, a region of the human VA
gene segment cluster comprising at least one (or substantially all)
human VA gene segments and the human VpreB and promoter is inserted
upstream of the endogenous (eg, mouse or rat) CA. In one example,
the insertion is between the most 3' endogenous JA and the
endogenous CA. In another embodiment, the insertion is in the
endogenous VA cluster, optionally replacing the VA in whole or in
part. In one embodiment, all of the human lambda VA gene segment
cluster (including introns) is inserted into the genome so that it
replaces the enogenous VA gene segment cluster. In one embodiment,
the cell or vertebrate is a mouse or rat, so "endogenous" refers to
the regions found in the genome of a mouse or rat.
[0350] Expression of the .lamda.5 and VpreB genes is B-cell lineage
restricted and is also subject to stage-specific regulation during
B-cell development. Binding sites for the transcription factors
EBF, E47, Pax-5 and Ikaros are present in the the .lamda.5 and
VpreB promoters. The mouse VpreB1 and .lamda.5 genes are both
located in the .lamda.5--VpreB1 locus and 4 kb away from each
other. A locus control region (LCR) located within the
.lamda.5--VpreB1 locus provides the regulatory elements for these
genes are. Hence, the region around the two genes are important for
the transcription of the VpreB1 and .lamda.5 genes. Furthermore,
these two genes are subject to tight stage-specific control during
B-cell development. For activation at the pro-B cell stage, early B
cell factor (EBF) initiates the activation of the .lamda.5--VpreB1
locus. It has been observed that the EBF with some other factors
(E2As) bind the promoters of the two genes. The transcription of
these two genes has to be silenced during the transition from the
pre-B to the immature B cell stage, in order for light chain
rearrangement and binding with heavy chain. Ikaros gene acts as a
repressor by competing with EBF for binding to the same sites in
the promoters of the VpreB1 and .lamda.5 genes. In summary, the
.lamda.5--VpreB1 locus seems to be important for the
temporally-controlled activation and inactivation of the surrogate
light chain during B-cell development. See:-- [0351] Mol Cell Biol.
1999 January; 19(1):671-9; Analysis of mice with single and
multiple copies of transgenes reveals a novel arrangement for the
lambda5-VpreB1 locus control region; Sabbattini P, Georgiou A,
Sinclair C, Dillon N. [0352] Seminars in Immunology, 2005 April;
17(2):121-7; The lambda5-VpreB1 locus--a model system for studying
gene regulation during early B cell development; Sabbattini P,
Dillon N.
[0353] Thus, in one embodiment the invention provides a non-human
vertebrate, mouse, rat, cell or method according to any
configuration, aspect, embodiment or example, wherein the
expression of the human VpreB gene is under endogenous control. For
example, the vertebrate is a mouse or rat or the cell is a mouse or
rat cell (eg, an ES cell) and the human VpreB is under the control
of the gene expression control elements of the mouse or rat (cell).
This can be achieved, in one example, by replacing an endogenous
VpreB (eg, VpreB1) gene with a human VpreB gene at the location
where the former usually resides in the genome. Precise gene
replacement in genomes can be carried out by homolgous
recombination or RMCE as herein described.
[0354] Mouse VpreB1 and VpreB2 are found at the following position
in a mouse genome:--
[0355] Mouse VpreB1: chromosome 16: 16868494 to 16869348
[0356] Mouse VpreB2: chromosome 16: 17980658 to Ser. No.
17/981,173
[0357] Thus, the invention provides a non-human vertebrate, mouse,
rat, cell or method according to any configuration, aspect,
embodiment or example, wherein the human VpreB gene is operably
linked to an endogenous promoter, optionally an endogenous VpreB
promoter (eg, a VpreB1 or VpreB2 promoter). Thus, where the
vertebrate (or cell) is a mouse or rat (cell), the human VpreB is
operably linked to a VpreB1 or VpreB2 promoter of said mouse or rat
(cell). Operable linkage enables the promoter to control expression
of the human gene. It is desirable to use endogenous gene
expression control (eg, using an endogenous promoter) for human
VpreB expression since this will harness the endogenous (eg, mouse
or rat) temporal expression control for turning on and off the
human VpreB gene (and coordinating this with .lamda.5 expression)
during the various stages of B-cell development, particularly up to
the point where light chain pairing with heavy chains occurs in
immature B-cells. Thereafter, the usual switching off of
SLC-component gene expression can be controlled properly by the
endogenous control mechanisms when the pre-BCR is no longer
participating in B-cell maturation.
[0358] Thus, the invention provides a non-human vertebrate, mouse,
rat, cell or method according to any configuration, aspect,
embodiment or example, wherein the human VpreB gene is operably
linked to an endogenous VpreB-.lamda.5 locus control region (LCR).
Thus, where the vertebrate (or cell) is a mouse or rat (cell), the
human VpreB is operably linked to a VpreB-.lamda.5 LCR of said
mouse or rat (cell). LCRs are dominant activating sequences that
are able to activate gene expression at any location in the genome.
Optionally, the LCR is present at the wild-type position in the
genome of the vertebrate or cell. In another example, the LCR is
not at the wild-type position in the genome of the vertebrate or
cell. In this case, therefore, the human VpreB is positioned away
from the endogenous VpreB gene in the genome, which may be
advantageous for controlling the human VpreB expression
independently of the endogenous .lamda.5.
[0359] In an embodiment, the invention provides a non-human
vertebrate, mouse, rat, cell or method according to any
configuration, aspect, embodiment or example, wherein the human
VpreB gene is operably linked to an endogenous VpreB locus control
region (LCR). Thus, where the vertebrate (or cell) is a mouse or
rat (cell), the human VpreB is operably linked to a VpreB LCR of
said mouse or rat (cell). Optionally, the LCR is present at the
wild-type position in the genome of the vertebrate or cell. In
another example, the LCR is not at the wild-type position in the
genome of the vertebrate or cell. In this case, therefore, the
human VpreB is positioned away from the endogenous VpreB gene in
the genome, which may be advantageous for controlling the human
VpreB expression independently of the endogenous .lamda.5.
[0360] Optionally one or more DNase I hypersensitive sites (HS) is
operably linked in the genome to the human VpreB gene. For example,
the HS forms part of the LCR or is 3' of the LCR or 3' of the
LCR-human VpreB (see, Sabbattini et al 1999, supra).
[0361] Optionally in any configuration, aspect, embodiment or
example of the inventions, the human VpreB gene is present in
multiple copies in the genome, eg, the genome comprises 2, 3, 4, 5,
6, 7, 8, 9 or 10 copies of the human VpreB gene. For example, 2, 3,
4 or 5 copies are operably linked to the control element (eg,
promoter and/or LCR) mentioned above.
[0362] Assessing the Development of the B-Cell Repertoire
[0363] Some assays can be used to investigate if the invention
leads to promotion of B-cell development and repertoire. Although
described in the context of transgenic mice below, these comments
apply equally to other transgenic non-human vertebrates of the
invention.
[0364] 1. In chimaeric mouse, after introducing the human DNA
fragment covering several human Vs, all Ds and Js between mouse Js
and mouse Cs, the usage of the inserted human Vs can be tested by
sequencing the mRNA products of the IgH locus in chimaeric mouse.
In this case, human Vs will compete with endogenous mouse Vs for
formation of the heavy chain. The usage of human Vs vs mouse Vs
will be compared in mice with and without introduction of human
VpreB gene into the chimaeric mouse with/without the endogenous
mouse VpreB gene. More detail is provided in the non-limiting
example below.
[0365] 2. The use of human VpreB or mouse VpreB protein for pre-BCR
assembly can be analysed in pre-B cell populations from mice with
or without the human VpreB. Surrogate light chain can only be
detected in the transitional pre-BI and large pre-BII stages in
bone marrow. To enrich the cell populations in bone marrow for
investigating pre-BCR, the deregulation of surrogate light chain
can be blocked by inactivation of SLP65 gene (Nature Immunol. 2003
4, 38-43; The adaptor protein SLP-65 acts as a tumor suppressor
that limits pre-B cell expansion. Flemming, A., Brummer, T., Reth,
M. & Jumaa, H.) or both IRF4 (interferon-regulatory factor 4)
and IRF8 genes (Genes Dev. 2003 17, 1703-1708; IRF-4,8 orchestrate
the pre-B-to-B transition in lymphocyte development. Lu, R.,
Medina, K. L., Lancki, D. W. & Singh, H). It has been reported
that pre-BII cells from mice that are deficient in these factors
continue to express surrogate-light-chain genes and therefore
retain pre-BCR expression. The unlimited supply of surrogate light
chains lead to a hyperplastic pre-Ill-cell phenotype in vivo and
provide large number of pre-B cells for us to analyze.
[0366] 3. In instances (eg, as described in part 1 above), where
mouse Vs are retained following insertion of human gene segments,
the mouse endogenous heavy chain VDJ is inactivated, and this may
be done while leaving mouse Vs intact. Thus, for the formation of
chimaeric heavy chain genes, the heavy chain V regions should only
be transcribed from human heavy VDJs. To assess the relative use of
human v mouse Vs for heavy chain gene formation, the B-cell
repertoire and diversity will be compared between mice having human
VpreB gene v mice lacking the human VpreB (eg, mice with mouse
VpreB only). Pairing of human Vs with human VpreB will be
preferable to pairing of mouse Vs with human VpreB, and thus
antibody heavy chains comprising human variable regions will be
selected during B-cell development.
[0367] As cells transit from the pre-BI to pre-BII stage, the
pre-BCR induces a signal for proliferative expansion. Pre-BCR
controls the number of developing pre-B cells by controlling
proliferation, which represents clonal expansion. Pre-BII cells
enter two to seven rounds of cell division when Ig.mu. chain
assembles into pre-BCRs. This ultimately results in a more diverse
antibody repertoire, as later in development, each cell will
recombine and express a unique L chain. In this process, the
association of surrogate light chain with .mu. chain monitors the
cells to determine whether it has successfully completed VDJH
recombination and expresses a functional .mu.H chain which will
form the pre-PCR for downstream signalling. In this case, the
strength of the pairing between the .mu.H and SL chains may
determine the amplitude of the transmitted signal, and thereby, the
extent of proliferation (J. Immunol. 2006, 177 pp. 2242-2249; Pre-B
cell receptor assesses the quality of IgH chains and tunes the
Pre-B cell repertoire by delivering differential signals. Y.
Kawano, S. Yoshikawa, Y. Minegishi and H. Karasuyama). Therefore,
in the mouse with chimaeric heavy chain (human VDJs and mouse
Cs)--by introducing the human VpreB gene to provide complete
species-matching with the chimaeric heavy chain, It is expected
that the repertoire and so the diversity of chimaeric antibodies
will be improved by using human VpreB instead of mouse VpreB for
association with the heavy chains. The improvement for B cell
repertoire and diversity can be showed by increased usage of human
heavy VDJs and/or a shift in VH gene family usage in mouse
expressing human VpreB (see the examples below for possible
techniques).
[0368] The invention provides the following aspects:-- [0369] 1. A
non-human vertebrate (eg, a mouse or rat) or cell (eg, a mouse cell
or rat cell) whose genome comprises an antibody heavy chain
transgene, [0370] the transgene comprising [0371] (a) one or more
human VH gene segments, one or more human D gene segments and one
or more human JH gene segments operably connected upstream of a
constant region gene so that the transgene is capable of undergoing
VDJ recombination in vivo to produce an antibody gene comprising a
rearranged VDJC encoding an antibody heavy chain having a human
variable region and a constant region; or [0372] (b) a rearranged
VDJ encoding a human variable region operably connected upstream of
a constant region gene so that the transgene encodes (optionally
following VDJ combination with the constant region) an antibody
heavy chain having a human variable region and a constant region;
[0373] the genome further comprising [0374] (i) a human VpreB gene
capable of expressing a human VpreB, and [0375] (ii) a non-human
vertebrate (eg, mouse or rat) .lamda.5 gene; [0376] wherein the
vertebrate or cell is capable of expressing a chimaeric surrogate
light chain comprising human VpreB and non-human vertebrate
.lamda.5 for pairing with the heavy chain. [0377] 2. The vertebrate
or cell of aspect 1, wherein the constant region is a non-human
vertebrate (eg, mouse or rat) constant region so that the chimaeric
surrogate light chain is species- or strain-matched with the heavy
chain. [0378] 3. A mouse or mouse cell according to aspect 1 or 2,
wherein the constant region and the .lamda.5 gene are mouse
constant region and mouse .lamda.5 gene, optionally of the same
mouse strain. [0379] 4. The vertebrate or cell of aspect 2 or 3,
wherein the strain is a 129-derived, mouse black 6-derived or
JM8-derived strain (eg, a C57BL/6--129/Sv hybrid strain). [0380] 5.
The vertebrate or cell of aspect 2 or 3, wherein the constant
region is a mouse 129 or mouse
[0381] Black 6 constant region and the .lamda.5 gene is a mouse 129
or mouse Black 6 .lamda.5 gene. [0382] 6. The vertebrate or cell of
any preceding aspect, wherein said constant region gene and
.lamda.5 gene are endogenous genes of said vertebrate or cell.
[0383] 7. The vertebrate or cell of any preceding aspect, wherein
said genome is homozygous for said transgene, human VpreB gene and
non-human vertebrate .lamda.5 gene. [0384] 8. The vertebrate or
cell of any preceding aspect, wherein endogenous non-human
vertebrate antibody heavy chain expression has been inactivated.
[0385] 9. The vertebrate or cell of any preceding aspect, wherein
endogenous non-human vertebrate antibody light chain expression has
been inactivated. [0386] 10. The vertebrate or cell of any
preceding aspect, wherein the heavy chain transgene is devoid of
a
[0387] CH1 gene segment and the genome comprises no functional
antibody light chain locus. [0388] 11. The vertebrate or cell of
any preceding aspect, wherein the heavy chain transgene is devoid
of a gamma CH1 gene segment and the genome comprises no functional
antibody light chain locus. [0389] 12. The vertebrate or cell of
any preceding aspect, wherein the heavy chain transgene is devoid
of a mu CH1 gene segment and the genome comprises no functional
antibody light chain locus. [0390] 13. The vertebrate or cell of
any preceding aspect, wherein said constant region is a mu constant
region, optionally endogenous mu constant region. [0391] 14. The
vertebrate or cell of any preceding aspect, wherein the human VpreB
gene has a nucleotide sequence that is at least 85% identical to
SEQ ID NO: 1. [0392] 15. The vertebrate or cell of any preceding
aspect, wherein said genome does not comprise a non-human
vertebrate (eg, mouse or rat) species VpreB1 and/or VpreB2 gene.
[0393] 16. The cell of any preceding aspect, wherein the cell is an
ES cell, an iPS cell, a hybridoma, an immortalised cell or a B-cell
(eg, an immortalised B-cell). [0394] 17. The cell of aspect 16,
wherein the cell is derived from C57BL/6, M129 (eg, 129/SV), BALB/c
or a hybrid of C57BL/6, M129 or BALB/c (eg, a C57BL/6--129/Sv
hybrid). [0395] 18. The vertebrate or cell of any preceding aspect,
wherein the genome comprises an insertion of a human lambda V (or
VJ) region comprising all of the V (and optionally also J) regions
and intervening sequences, wherein the lambda V (or VJ) region
comprises a human VpreB gene. [0396] 19. The vertebrate or cell of
aspect 18, wherein non-functional V and/or J gene segments are
omitted. [0397] 20. The vertebrate or cell of aspect 18 or 19,
wherein the lambda V (or VJ) region comprises a human VpreB gene
and its associated human promoter. [0398] 21. The vertebrate or
cell of any preceding aspect, wherein the genome comprises an
insertion of DNA corresponding to positions 22599200 to 22599926 on
human chromosome 22. [0399] 22. The vertebrate or cell of any one
of aspects 18 to 21, wherein the insertion is an insertion into an
antibody light chain locus; optionally an insertion into endogenous
lambda locus upstream of the endogenous lambda constant region or
an insertion into endogenous kappa locus upstream of the endogenous
kappa constant region. [0400] 23. The vertebrate or cell of any one
of aspects 18 to 22, wherein the insertion replaces the endogenous
VA in whole or in part. [0401] 24. The vertebrate or cell of any
preceding aspect, wherein the human VpreB gene is not within the
endogenous (non-human vertebrate or cell) VpreB-.lamda.5 locus.
[0402] 25. The vertebrate or cell of any preceding aspect, wherein
the expression of the human VpreB gene is under endogenous
(non-human vertebrate or cell) control. [0403] 26. The vertebrate
or cell of any preceding aspect, wherein the human VpreB gene is
operably linked to one or more DNase I hypersensitive sites. [0404]
27. The vertebrate or cell of any preceding aspect, wherein the
human VpreB gene is present in the genome in 2, 3, 4, 5, 6, 7, 8, 9
or 10 copies. [0405] 28. The vertebrate or cell of any preceding
aspect, which is a rodent, mouse or rat; or a rodent, mouse or rat
cell. [0406] 29. The vertebrate or cell of any preceding aspect,
wherein all .lamda.5 sequences in the genome are non-human
vertebrate .lamda.5 sequences. [0407] 30. The vertebrate or cell of
any preceding aspect, wherein the genome is devoid of a human
.lamda.5 nucleotide sequence. [0408] 31. A non-human vertebrate
(eg, a mouse or rat) or cell (eg, a mouse cell or rat cell) whose
genome comprises an antibody heavy chain transgene for producing
heavy chains that are devoid of a CH1, [0409] the transgene
comprising [0410] (a) one or more human VH gene segments, one or
more human D gene segments and one or more human JH gene segments
operably connected upstream of a constant region gene so that the
transgene is capable of undergoing VDJ recombination in vivo to
produce an antibody gene comprising a rearranged VDJC encoding an
antibody heavy chain having a human variable region and a constant
region; or [0411] (b) a rearranged VDJ encoding a human variable
region operably connected upstream of a constant region gene so
that the transgene encodes (optionally following VDJ combination
with the constant region) an antibody heavy chain having a human
variable region and a constant region; [0412] the genome further
comprising a human VpreB gene capable of expressing a human VpreB;
[0413] wherein the constant region is devoid of a functional CH1
gene; and [0414] wherein the vertebrate or cell is capable of
expressing a human VpreB for pairing with the heavy chains devoid
of CH1. [0415] 32. The vertebrate or cell of aspect 31, wherein the
human VpreB gene does not comprise a .lamda.5 sequence or constant
region sequence. [0416] 33. The vertebrate or cell of aspect 31 or
32, wherein the constant region is a human constant region. [0417]
34. The vertebrate or cell of aspect 31 or 32, wherein the constant
region is a non-human vertebrate (eg, mouse or rat) constant
region; optionally of a strain as recited in aspect 4. [0418] 35.
The vertebrate or cell of any one of aspects 31 to 34, wherein said
genome is homozygous for said transgene and human VpreB gene.
[0419] 36. The vertebrate or cell of any one of aspects 31 to 35,
wherein endogenous non-human vertebrate antibody heavy chain
expression has been inactivated. [0420] 37. The vertebrate or cell
of any one of aspects 31 to 36, wherein endogenous non-human
vertebrate antibody light chain expression has been inactivated.
[0421] 38. The vertebrate or cell of any one of aspects 31 to 37,
wherein the genome comprises no functional antibody light chain
locus. [0422] 39. The vertebrate or cell of any one of aspects 31
to 38, wherein the heavy chain transgene is devoid of a gamma CH1
gene segment and the genome comprises no functional antibody light
chain locus. [0423] 40. The vertebrate or cell of any one of
aspects 31 to 39, wherein the heavy chain transgene is devoid of a
mu CH1 gene segment and the genome comprises no functional antibody
light chain locus. [0424] 41. The vertebrate or cell of any aspects
31 to 40, wherein said constant region is a mu constant region
(optionally endogenous mu constant region) or a gamma constant
region (optionally endogenous gamma constant region). [0425] 42.
The vertebrate or cell of any one of aspects 31 to 41, wherein the
human VpreB gene has a nucleotide sequence that is at least 85%
identical to SEQ ID NO: 1. [0426] 43. The vertebrate or cell of any
one of aspects 31 to 42, wherein said genome does not comprise a
non-human species VpreB gene. [0427] 44. The cell of any one of
aspects 31 to 43, wherein the cell is an ES cell, an iPS cell, a
hybridoma, an immortalised cell or a B-cell (eg, an immortalised
B-cell). [0428] 45. The cell of aspect 44, wherein the cell is
derived from C57BL/6, M129 (eg, 129/SV), BALB/c or a hybrid of
C57BL/6, M129 or BALB/c (eg, a C57BL/6--129/Sv hybrid). [0429] 46.
The vertebrate or cell of any one of aspects 31 to 45, wherein the
genome comprises an insertion of a human lambda V (or VJ) region
comprising all of the V (and optionally also J) regions and
intervening sequences, wherein the lambda V (or VJ) region
comprises a human VpreB gene. [0430] 47. The vertebrate or cell of
aspect 46, wherein non-functional V and/or J gene segments are
omitted. [0431] 48. The vertebrate or cell of aspect 46 or 47,
wherein the lambda V (or VJ) region comprises a human VpreB gene
and its associated human promoter. [0432] 49. The vertebrate or
cell of any one of aspects 31 to 48, wherein the genome comprises
an insertion of DNA corresponding to positions 22599200 to 22599926
on human chromosome 22. [0433] 50. The vertebrate or cell of any
one of aspects 46 to 49, wherein the insertion is an insertion into
an antibody light chain locus; optionally an endogenous lambda
locus upstream of the endogenous lambda constant region. [0434] 51.
The vertebrate or cell of any one of aspects 46 to 50, wherein the
insertion replaces the endogenous VA in whole or in part. [0435]
52. The vertebrate or cell of any one of aspects 31 to 51, wherein
the human VpreB gene is not within the endogenous (non-human
vertebrate or cell) VpreB-.lamda.5 locus. [0436] 53. The vertebrate
or cell of any one of aspects 31 to 52, wherein the expression of
the human VpreB gene is under endogenous (non-human vertebrate or
cell) control. [0437] 54. The vertebrate or cell of any one of
aspects 31 to 53, wherein the human VpreB gene is operably linked
to one or more DNase I hypersensitive sites. [0438] 55. The
vertebrate or cell of any one of aspects 31 to 54, wherein the
human VpreB gene is present in the genome in 2, 3, 4, 5, 6, 7, 8, 9
or 10 copies. [0439] 56. The vertebrate or cell of any one of
aspects 31 to 55, which is a rodent, mouse or rat; or a rodent,
mouse or rat cell. [0440] 57. The vertebrate or cell of any one of
aspects 31 to 56, wherein the genome is devoid of a human .lamda.5
gene. [0441] 58. The vertebrate or cell of any one of aspects 31 to
57, wherein the genome is devoid of a .lamda.5 gene. [0442] 59. A
method of constructing a transgenic non-human vertebrate cell (eg,
an ES cell, eg, a mouse or rat ES cell), the method comprising
[0443] (i) introducing into the genome of a non-human vertebrate
cell (or an ancestor thereof) one or more human VH gene segments,
one or more human D gene segments and one or more human JH gene
segments so that said gene segments are operably connected upstream
of a constant region gene (optionally an endogenous non-human
vertebrate constant region gene) to form a heavy chain transgene,
wherein in said cell or a progeny thereof the transgene is capable
of undergoing VDJ recombination in vivo to produce an antibody gene
comprising a rearranged VDJC encoding an antibody heavy chain
having a human variable region and a constant region; or [0444]
(ii) introducing into the genome of a non-human vertebrate cell (or
an ancestor thereof) a rearranged VDJ encoding a human variable
region so that said VDJ is operably connected upstream of a
constant region gene (optionally an endogenous non-human vertebrate
constant region gene) to form a heavy chain transgene, wherein in
said cell or a progeny thereof the transgene encodes (optionally
following VDJ combination with the constant region) an antibody
heavy chain having a human variable region and a constant region;
[0445] and wherein the method further comprises introducing into
the cell a human VpreB gene in the absence of a .lamda.5 sequence,
wherein the cell (or a progeny cell or vertebrate) is capable of
expressing human VpreB for pairing with the human variable region
of the heavy chain. [0446] 60. The method of aspect 59, wherein the
genome of the product cell of the method is as recited in any one
of aspects 1 to 58. [0447] 61. The method of aspect 59 or 60,
further comprising making a progeny (progeny cell or vertebrate) of
the product cell made according to aspect 59 or 60, wherein the
progeny is homozygous for said heavy chain transgene and endogenous
non-human vertebrate antibody expression has been inactivated.
[0448] 62. The method of aspect 61, wherein the progeny cell is an
ES cell, an iPS cell, a hybridoma, an immortalised cell or a B-cell
(eg, an immortalised B-cell); optionally a cell derived from a
strain or hybrid as recited in aspect 17. [0449] 63. The method of
aspect 61, wherein the progeny vertebrate is a rodent, mouse or
rat. [0450] 64. A method of promoting B-cell development in a
non-human vertebrate (eg, a mouse or rat), the method comprising
[0451] (a) providing in a non-human vertebrate embryonic stem (ES)
cell genome an immunoglobulin transgene capable of expressing an
antibody mu heavy chain, wherein the antibody heavy chain comprises
a human variable region and a mu constant region (optionally an
endogenous non-human vertebrate mu constant region); and creating a
first non-human vertebrate from said ES cell or a progeny thereof;
[0452] (b) providing in a second ES cell genome a second transgene
comprising a human VpreB gene capable of expressing a human VpreB;
and creating a second non-human vertebrate from said ES cell or a
progeny thereof; and [0453] (c) creating by breeding a third
non-human vertebrate capable of co-expressing the mu antibody heavy
chain and human VpreB wherein a pre-B-cell receptor can form to
promote B-cell development of cells bearing a mu heavy chain in
said third vertebrate; the third vertebrate being made by crossing
said first and second vertebrates or progeny thereof by breeding to
create said third vertebrate, the third vertebrate comprising the
first and second transgenes, and wherein endogenous heavy chain
expression has been inactivated in said third vertebrate. [0454]
65. The method of aspect 64, wherein in (a) the heavy chain
transgene is constructed to be devoid of a CH1 gene segment and the
genome of the third non-human vertebrate comprises no functional
antibody light chain locus. [0455] 66. The method of aspect 64 or
65, wherein the genome of the third non-human vertebrate is as
recited in any one of aspects 1 to 58. [0456] 67. The method of any
one of aspects 64 to 65, wherein the genome of the third vertebrate
does not comprise a non-human vertebrate (eg, mouse or rat) species
VpreB1 and/or VpreB2 gene. [0457] 68. The method of any one of
aspects 64 to 67, wherein the third non-human vertebrate expresses
a .lamda.5 of a non-human vertebrate (eg, mouse or rat) species and
said constant region is a constant region of the same non-human
vertebrate (eg, mouse or rat) species as the .lamda.5 gene;
optionally wherein the .lamda.5 and constant region are an
endogenous .lamda.5 and constant region of mouse or rat. [0458] 69.
A transgenic mouse or rat according to the third vertebrate of any
one of aspects 64 to 68, or a progeny thereof. [0459] 70. A method
of promoting B-cell development in a non-human vertebrate (eg, a
mouse or rat), the method comprising [0460] (i) inactivating
endogenous heavy chain expression in said vertebrate; [0461] (ii)
providing in the genome of said vertebrate an immunoglobulin
transgene capable of expressing an antibody mu heavy chain, wherein
the antibody heavy chain comprises a human variable region and a
non-human vertebrate mu constant region (optionally an endogenous
non-human vertebrate mu constant region); and [0462] (ii) providing
in the genome of said vertebrate a second transgene capable of
expressing a human VpreB wherein a pre-B-cell receptor can form to
promote B-cell development of cells bearing a mu heavy chain in
said vertebrate;
[0463] Optionally wherein the genome is homozygous for said first
transgene. [0464] 71. The method of aspect 70, wherein in (a) the
heavy chain transgene is constructed to be devoid of a CH1 gene
segment and the genome of the third non-human vertebrate comprises
no functional antibody light chain locus. [0465] 72. The method of
aspect 70 or 71, wherein the genome of the vertebrate is as recited
in any one of aspects 1 to 58. [0466] 73. The method of any one of
aspects 70 to 72, wherein the genome of the vertebrate does not
comprise a non-human vertebrate (eg, mouse or rat) species VpreB1
and/or VpreB2 gene. [0467] 74. The method of any one of aspects 70
to 73, wherein the third vertebrate expresses a .lamda.5 of a
non-human vertebrate (eg, mouse or rat) species and said constant
region is a constant region of the same non-human vertebrate (eg,
mouse or rat) species as the .lamda.5 gene; optionally wherein the
.lamda.5 and constant region are an endogenous .lamda.5 and
constant region of mouse or rat. [0468] 75. A transgenic mouse or
rat obtained or obtainable by the method of any one of aspects 70
to 74, or a progeny thereof. [0469] 76. A non-human vertebrate,
mouse, rat, cell or method according to any preceding aspect,
wherein the expression of the human VpreB gene is under edogenous
control. [0470] 77. The non-human vertebrate, mouse, rat, cell or
method according to aspect 76, wherein the human VpreB gene is
operably linked to an endogenous promoter, optionally an endogenous
VpreB promoter (eg, a VpreB1 promoter). [0471] 78. The non-human
vertebrate, mouse, rat, cell or method of any preceding aspect,
wherein the genome comprises [0472] (a) said antibody heavy chain
transgene; and [0473] (b) an antibody kappa light chain transgene
and/or an antibody lambda chain transgene; [0474] wherein all of
the V, D and J in said transgenes are human V, D and J; [0475]
wherein endogenous antibody heavy and light chain expression has
been inactivated; and [0476] optionally wherein said genome is
homozygous for said heavy and light chain transgenes. [0477] 79.
The non-human vertebrate, mouse, rat, cell or method of aspect 78,
wherein the kappa and lambda chain transgenes comprise constant
regions of said non-human vertebrate species capable of pairing
with the constant region of the heavy chain. [0478] 80. The
non-human vertebrate, mouse, rat, cell or method of aspect 78 or
79, wherein the heavy chain transgene comprises a substantially
complete human functional VH, D and JH repertoire. [0479] 81. The
non-human vertebrate, mouse, rat, cell or method of aspect 78, 79
or 80, wherein the kappa chain transgene comprises a substantially
complete human functional V.kappa. and J.kappa. repertoire; and the
lambda chain transgene comprises a substantially complete human
functional VA and JA repertoire. [0480] 82. A transgenic mouse or
rat, or a transgenic mouse or rat cell (eg, an ES cell), whose
genome comprises [0481] (a) an antibody heavy chain transgene, the
transgene comprising a substantially complete human functional VH,
D and JH repertoire operably connected upstream of an endogenous
(mouse or rat) mu constant region gene so that the transgene is
capable of undergoing VDJ recombination in vivo to produce an
antibody gene comprising a rearranged VDJC encoding an antibody
heavy chain having a human variable region and an endogenous mu
constant region; [0482] (b) an antibody kappa light chain transgene
and/or an antibody lambda chain transgene; [0483] wherein all of
the V, D and J in said transgenes are human V, D and J; [0484]
wherein the kappa chain transgene comprises a substantially
complete human functional V.kappa. and J.kappa. repertoire; and the
lambda chain transgene comprises a substantially complete human
functional VA and JA repertoire; [0485] wherein the kappa and/or
lambda chain transgenes comprise endogenous constant regions
capable of pairing with the constant region of the heavy chain;
[0486] (c) a human VpreB gene capable of expressing a human VpreB;
[0487] optionally wherein the human VpreB gene is operably linked
to an endogenous VpreB promoter or its associated human promoter;
and [0488] (d) an endogenous .lamda.5 gene capable of expressing an
endogenous .lamda.5; [0489] wherein endogenous antibody heavy and
light chain expression has been inactivated; and [0490] optionally
wherein said genome is homozygous for said heavy and light chain
transgenes. [0491] 83. A transgenic mouse or rat, or a transgenic
mouse or rat cell (eg, an ES cell), whose genome comprises [0492]
(a) an antibody heavy chain transgene, the transgene comprising a
substantially complete human functional VH, D and JH repertoire
operably connected upstream of an endogenous (mouse or rat) mu
constant region gene so that the transgene is capable of undergoing
VDJ recombination in vivo to produce an antibody gene comprising a
rearranged VDJC encoding an antibody heavy chain having a human
variable region and an endogenous mu constant region; [0493]
wherein all of the V, D and J in said transgene are human V, D and
J; [0494] wherein the heavy chain transgene is devoid of a CH1 gene
segment (eg, a gamma CH1) and the genome of the vertebrate
comprises no functional antibody light chain locus; [0495] wherein
endogenous antibody heavy chain expression has been inactivated;
and [0496] optionally wherein said genome is homozygous for said
heavy chain transgene; [0497] (c) a human VpreB gene capable of
expressing a human VpreB; [0498] optionally wherein the human VpreB
gene is operably linked to an endogenous VpreB promoter or its
associated human promoter; and [0499] (d) optionally an endogenous
.lamda.5 gene capable of expressing an endogenous .lamda.5. [0500]
As demonstrated in Example below, the present invention is useful
for influencing the repertoire of human heavy chain variable
domains and variable region DNA and RNA sequences that can be
produced in a non-human vertebrate. Thus, the invention provides:--
[0501] 84. A mouse according to any one of aspects 1 to 58 or 75 to
83, which expresses a repertoire of Ig heavy chain variable regions
that significantly differs (eg, as indicated by a probability of
less than 0.05 in a chi-squared test) from the heavy chain variable
region repertoire of a control vertebrate in the proportion (eg,
percentage) of use of heavy chain variable gene segments, wherein
the control and said non-human vertebrate genomes are of the same
background mouse strain and both comprise said antibody heavy chain
transgene, the transgenes being identical in the control and said
mouse, and wherein the control does not express a human VpreB.
[0502] In an example of any aspect, the mouse and control strains
are 129 or 129-derived (eg, 129 crossed with C57BL/6). [0503] In an
example of any aspect, each repertoire is a repertoire of heavy
chain variable region RNA. Optionally, the variable regions are
provided as part of IgH heavy chains or corresponding RNA. [0504]
In an example of any aspect, each transgene comprises at least 11
human gene segments, all or substantially all human D gene segments
and all or substantially all human JH gene segments. For example,
each transgene comprises human D1-1, 2-2, 3-9, 3-10, 4-11, 5-12,
6-13, 1-14, 2-15, 3-16, 4-17, 5-18, 6-19, 1-20, 2-21, 3-22, 4-23,
5-24, 6-25, 1-26 and 7-27. For example, each transgene comprises
human J1, J2, J3, J4, J5 and J6. For example, each transgene
comprises (optionally in 5' to 3' order) VH3-13, 3-11, 3-9, 1-8,
3-7, 2-5, 7-4-1, 4-4, 1-3, 1-2 and 6-1. [0505] 85. A mouse
according to any one of aspects 1 to 58 or 75 to 84, which
expresses a repertoire of Ig heavy chain variable regions that
significantly differs (eg, as indicated by a probability of less
than 0.05 in a binomial distribution test) from the IgH heavy chain
variable region repertoire of a control vertebrate in the
proportion (eg, percentage) of use of heavy chain JH gene segments,
wherein the control and said non-human vertebrate genomes are of
the same background mouse strain and both comprise said antibody
heavy chain transgene, the transgenes being identical in the
control and said mouse, and wherein the control does not express a
human VpreB. [0506] 86. A mouse according to any one of aspects 1
to 58 or 75 to 85, which expresses a repertoire of Ig heavy chain
variable regions that significantly differs (eg, as indicated by a
probability of less than 0.05 in a binomial distribution test) from
the IgH heavy chain variable region repertoire of a control
vertebrate in the proportion (eg, percentage) of use of one, more
or all heavy chain variable gene segments selected from VH6-1,
VH1-3, VH3-7, VH1-8, VH3-9, VH3-11, JH1 and JH6, wherein the
control and said non-human vertebrate genomes are of the same
background mouse strain and both comprise said antibody heavy chain
transgene, the transgenes being identical in the control and said
mouse, and wherein the control does not express a human VpreB.
[0507] 87. The mouse of any one of aspects 84 to 86, wherein use of
one, more or all of VH6-1, VH1-3, VH3-9 and JH1 is higher in the
repertoire of said mouse than in the repertoire of the control.
[0508] 88. The mouse of any one of aspects 84 to 87, wherein use of
one, more or all of VH3-7, VH1-8, VH3-11 and JH6 is lower in the
repertoire of said mouse than in the repertoire of the control.
[0509] In an example of any of aspects 84 onwards, the IgH heavy
chain variable region repertoire is naive, ie, has not been
preselected against a predetermined target antigen. [0510] In an
example of any of aspects 84 onwards, the scope is not limited to a
mouse, but the scope of the aspect relates to a non-human
vertebrate (eg, a mouse or a rat). Aspects 84 onwards can in the
alternative, therefore, be read with this scope and for possible
inclusion in claims herein.
[0511] It will be understood that particular embodiments described
herein are shown by way of illustration and not as limitations of
the invention. The principal features of this invention can be
employed in various embodiments without departing from the scope of
the invention. Those skilled in the art will recognize, or be able
to ascertain using no more than routine study, numerous equivalents
to the specific procedures described herein. Such equivalents are
considered to be within the scope of this invention and are covered
by the claims. All publications and patent applications mentioned
in the specification are indicative of the level of skill of those
skilled in the art to which this invention pertains. All
publications and patent applications are herein incorporated by
reference to the same extent as if each individual publication or
patent application was specifically and individually indicated to
be incorporated by reference. The use of the word "a" or "an" when
used in conjunction with the term "comprising" in the claims and/or
the specification may mean "one," but it is also consistent with
the meaning of "one or more," "at least one," and "one or more than
one." The use of the term "or" in the claims is used to mean
"and/or" unless explicitly indicated to refer to alternatives only
or the alternatives are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or." Throughout this application, the term "about" is used to
indicate that a value includes the inherent variation of error for
the device, the method being employed to determine the value, or
the variation that exists among the study subjects.
[0512] As used in this specification and claim(s), the words
"comprising" (and any form of comprising, such as "comprise" and
"comprises"), "having" (and any form of having, such as "have" and
"has"), "including" (and any form of including, such as "includes"
and "include") or "containing" (and any form of containing, such as
"contains" and "contain") are inclusive or open-ended and do not
exclude additional, unrecited elements or method steps
[0513] The term "or combinations thereof" as used herein refers to
all permutations and combinations of the listed items preceding the
term. For example, "A, B, C, or combinations thereof is intended to
include at least one of: A, B, C, AB, AC, BC, or ABC, and if order
is important in a particular context, also BA, CA, CB, CBA, BCA,
ACB, BAC, or CAB. Continuing with this example, expressly included
are combinations that contain repeats of one or more item or term,
such as BB, AAA, MB, BBC, AAABCCCC, CBBAAA, CABABB, and so forth.
The skilled artisan will understand that typically there is no
limit on the number of items or terms in any combination, unless
otherwise apparent from the context.
[0514] Any part of this disclosure may be read in combination with
any other part of the disclosure, unless otherwise apparent from
the context.
[0515] All of the compositions and/or methods disclosed and claimed
herein can be made and executed without undue experimentation in
light of the present disclosure. While the compositions and methods
of this invention have been described in terms of preferred
embodiments, it will be apparent to those of skill in the art that
variations may be applied to the compositions and/or methods and in
the steps or in the sequence of steps of the method described
herein without departing from the concept, spirit and scope of the
invention. All such similar substitutes and modifications apparent
to those skilled in the art are deemed to be within the spirit,
scope and concept of the invention as defined by the appended
claims.
[0516] The present invention is described in more detail in the
following non limiting prophetic exemplification (Examples 1-5). An
additional example, Example 6, not prophetic, but was actually
performed and yielded data whose results demonstrate the present
invention.
[0517] EXAMPLES
Example 1: Introduction of Human DNA Gene Segments into ES
Cells
[0518] By way of illustration, the following example is provided on
the introduction of human antibody gene segment DNA into Cell
culture of C57BL/6N-derived cell lines, such as the JM8 male ES
cells. This will follow standard techniques. The JM8 ES cells have
been shown to be competent in extensively contributing to somatic
tissues and to the germline, and are being used for large mouse
mutagenesis programs at the Sanger Institute such as EUCOMM and
KOMP (Pettitt, S. J., Liang, Q., Rairdan, X. Y., Moran, J. L.,
Prosser, H. M., Beier, D. R., Lloyd, K. C., Bradley, A., and
Skarnes, W. C. (2009). Agouti C57BL/6N embryonic stem cells for
mouse genetic resources. Nature Methods.). JM8 ES cells
(1.0.times.10.sup.7) will be electroporated (500 .mu.F, 230V;
BioRad) with 10 .mu.g I-Scel linearized human BAC DNA. The
transfectants will be selected with either Puromycin (3 .mu.g/ml)
or G418 (150 .mu.g/ml). The selection will begin either 24 hours
(with G418) or 48 hours (with Puromycin) post electroporation and
proceed for 5 days. 10 .mu.g linearized human BAC DNA can yield up
to 500 Puromycin or G418 resistant ES cell colonies. The antibiotic
resistant ES cell colonies will be picked into 96-well cell culture
plates for genotyping to identify the targeted clones.
[0519] Once targeted mouse ES cell clones are identified, they will
be analyzed by array Comparative Genomic Hybridization (CGH) for
total genome integrity (Chung, Y. J., Jonkers, J., Kitson, H.,
Fiegler, H., Humphray, S., Scott, C., Hunt, S., Yu, Y., Nishijima,
I., Velds, A., et al. (2004). A whole-genome mouse BAC microarray
with 1-Mb resolution for analysis of DNA copy number changes by
array comparative genomic hybridization. Genome research 14,
188-196. and Liang, Q., Conte, N., Skarnes, W. C., and Bradley, A.
(2008). Extensive genomic copy number variation in embryonic stem
cells. Proceedings of the National Academy of Sciences of the
United States of America 105, 17453-17456.). ES cells that have
abnormal genomes do not contribute to the germline of the chimaeric
mice efficiently. BAC integrity will be examined by PCR-amplifying
each known functional V gene in the BAC. For example, in one
approach the first human BAC chosen for the IgH locus has 6
functional VH gene segments and all human D and JH gene segments.
To confirm the integrity of this BAC for the presence of these IgH
genes, pairs of PCR primers will be designed and used to
PCR-amplify genomic DNA from the targeted ES cells. The human
wild-type size and sequence of these fragments will ensure that the
inserted BAC has not been rearranged. More detailed CGH will also
confirm the integrity of the inserted BACs. For example, one
skilled in the art could use an oligo aCGH platform, which is
developed by Agilent Technologies, Inc. This platform not only
enables one to study genome-wide DNA copy number variation at high
resolution (Barrett, M. T., Scheffer, A., Ben-Dor, A., Sampas, N.,
Lipson, D., Kincaid, R., Tsang, P., Curry, B., Baird, K., Meltzer,
P. S., et al. (2004). Comparative genomic hybridization using
oligonucleotide microarrays and total genomic DNA. Proceedings of
the National Academy of Sciences of the United States of America
101, 17765-17770.), but permit examination of a specific genome
region using custom designed arrays. Comparing the traditional aCGH
techniques which rely on cDNA probes or whole BAC probes, the
60-mer oligonucleotides probes can ensure specific hybridization
and high sensitivity and precision that is needed in order to
detect the engineered chromosome alterations that we have made. For
example, oligos designed to hybridize at regular intervals along
the entire length of the inserted BAC would detect even quite short
deletions, insertions or other rearrangements. Also, this platform
provides the greatest flexibility for customized microarray
designs. The targeted ES cell genomic DNA and normal human
individual genomic DNA will be labelled separately with dyes and
hybridized to the array. Arrays slides will be scanned using an
Aglient Technologies DNA microarray scanner. Reciprocal
fluorescence intensities of dye Cy5 and dye Cy3 on each array image
and the log 2 ratio values will be extracted by using Bluefuse
software (Bluegnome). Spots with inconsistent fluorescence patterns
("confidence"<0.29 or "quality"=0) will be excluded before
normalizing all log 2 ratio values. Within an experiment, Log 2
ratio between -0.29 and +0.29 for the signal from any oligo probe
are regarded as no copy number change. The log 2 ratio threshold
for "Duplication" is usually >0.29999, and for deletion is
<0.29999.
Example 2: Introducing the Human VpreB Gene into the Mouse Lambda
Locus by Inserting the Human Lambda V Gene Segment Cluster
[0520] The human VpreB gene is inserted into a mouse genome by
introducing human lambda gene segment DNA, wherein the nucleotide
sequence of the DNA comprises a human VpreB gene and optionally the
associated human promoter. Human VpreB1 and VpreB3 genes are both
located in chromosome 22. The human VpreB1 gene is between human
Ig.lamda. V gene segments IV-53 and 5-52 (Chromosome 22: 22599200
to 22599926). Therefore, the human lambda gene segment which covers
the human VpreB1 gene and contains multiple Vs flanking this gene
is inserted in the endogenous lambda antibody locus upstream of the
endogenous lambda constant region between the most 3' endogenous JA
and the endogenous CA following the approach in Example 1 and as
further explained in WO2011004129.
Example 3: Introducing the Human VpreB Gene within the Mouse
VpreB-.lamda.5 Locus and Targeting into the Mouse Heavy or Lambda
Locus
[0521] The following example illustrates the insertion of the human
VpreB1 gene within the mouse VpreB-.lamda.5 locus to bring the
human gene under the endogenous LCR influence. The mouse VpreB1 and
.lamda.5 genes are closely associated, both within a 19-kb fragment
called the .lamda.5-VpreB1 locus. Apart from these two genes, this
locus contains a locus control region (LCR) required for correct
levels of expression and tissue-specificity of .lamda.5 and VpreB1.
Locus control regions (LCRs) are sequences that mediate
reorganisation of chromatin and activation of transcription by
sequence-specific transcription factors. The characteristic of an
LCR is the ability to drive gene expression in transgenic mice at
any site of integration at levels that are substantially equivalent
to those of the gene in its natural location. It has been shown
that the LCR in the .lamda.5-VpreB1 locus is able to promote
efficient and stage-specific expression of both genes in transgenic
mice at all sites of integration tested.
[0522] To make sure that the expression of the inserted human
VpreB1 gene is properly controlled in mouse, the mouse
.lamda.5-VpreB1 locus is retrieved and cloned into a vector
(pBlueScript II SK(+)). The mouse VpreB1 nucleotide sequence is
replaced by the human VpreB1 sequence by cloning. The construct
containing the fragment of mouse .lamda.5-human VpreB1 locus is
then cloned into a BAC containing a human heavy chain locus
fragment. Then it is targeted into the genome of a mouse ES cell
following the introduction of the human BAC into the mouse heavy
chain locus upstream of the endogenous heavy chain mu constant
region. In this case, the human VpreB function can be directly
tested in the F1 mouse generated from the ES cells. Manipulation of
constructs and BACs can be effected by standard recombineering.
[0523] Insertion of the mouse .lamda.5-human VpreB1 can be carried
out using homologous recombination or RMCE. Homologous combination
can employ homology arms corresponding to the endogenous sequences
flanking the mouse .lamda.5-mouse VpreB1 in the mouse ES genome, so
that insertion of the mouse .lamda.5-human VpreB1 replaces (and
thus deletes) the endogenous mouse .lamda.5-mouse VpreB1 and places
the inserted construct under the control of the endogenous LCR.
[0524] RMCE can be used to insert the mouse .lamda.5-human VpreB1
construct (optionally with the endogenous mouse .lamda.5-mouse
VpreB1 LCR) anywhere in the genome. RMCE can also be used to
precisely delete the endogenous mouse .lamda.5-mouse VpreB1 so that
the inserted mouse .lamda.5-human VpreB1 construct is the only
source of a VpreB1 gene.
[0525] In the alternative, the method can be modified to insert the
mouse lambda 5-human VpreB1 construct into the endogenous
lambda5-VpreB locus on the mouse lambda locus, for example to bring
the human VpreB1 gene under endogenous control (eg, control of the
lambda5-VpreB LCR). To do this, the cloned mouse lambda 5-human
VpreB1 construct (produced by standard recombineering) is inserted
into a homologous recombination vector using in vitro
recombineering to add homology arms flanking the construct. Using
homologous recombination in the presence of a marker carried by the
vector, the construct is inserted precisely to replace the
endogenous mouse lambda 5-mouse VpreB1 in the genome of a mouse ES
cell. Alternatively, instead of homologous recombination, standard
RMCE can be used to effect precise insertion into the genome.
[0526] A suitable protocol is provided in Example 5.
Example 4: Assessing the B-Cell Development and Repertoire in
Chimaeric Mouse Containing Human VpreB Gene
[0527] The following example is provided on assessing the advantage
of having the human VpreB gene in the chimaeric mouse.
[0528] The mouse embryonic stem cells (eg, AB2.1 cells; Baylor
College of Medicine) containing the targeted human VpreB1 gene are
grown on a feeder layer of SNL7 fibroblasts (Baylor College of
Medicine) in embryonic stem cell medium containing 15% serum. Then
the cells are microinjected into blastocysts which are transferred
to the uteri of pseudopregnant F.sub.1 female mice. To test for
germline transmission, male chimeras are bred to
C57BL/6-Tyr.sup.c-Brd albino female mice (Baylor College of
Medicine). After obtaining mice with both chimaeric heavy chain
gene (human V region and mouse C region) and human VpreB1 gene, the
following assays are performed to show the advantage of human VpreB
v mouse VpreB.
[0529] 1. Pre-B Cell Populations Containing Pre-BCR from Human
VpreB v Mouse VpreB
[0530] In the pre-B cells, .mu. heavy chain associated with
surrogate light chain will deposit on the cell surface to signal
the cell survival and proliferation. The pre-B cell populations
with the pre-BCR from human VpreB protein v mouse VpreB protein are
analyzed by flow cytometry.
[0531] Cells from bone marrow are surface stained with
fluorescence-labelled mAb and then analysied with MACSQuant
(Miltenyi Biotech) on B220.sup.+ cells. Pre-B cell population can
be detected using pre-BCR-specific mAB and/or mouse .lamda.5.sup.+
cells. The cells with pre-BCR of human VpreB v mouse VpreB are
distinguished by using monoclonal antibody specifically to human or
mouse VpreB.
[0532] 2. Usage of Human Vs in the Mouse with Chimaeric
Antibody
[0533] In the mouse with the insertion of human
V.sub.HD.sub.HJ.sub.Hs between endogenous mouse
V.sub.HD.sub.HJ.sub.Hs and C.sub.Hs, the usage of human Vs v
endogenous mouse Vs are compared by sequencing the heavy chain
products in naive mice.
[0534] Approach: [0535] a. Total RNA extraction (use TRIzol.RTM.
Reagent) from mouse spleen [0536] b. By a standard 5' RACE (Rapid
amplification of 5' complementary DNA ends) method, using a mouse
C.mu.-specific primer, PCR fragments from mouse synthesized heavy
chain mRNAs can be amplified. [0537] c. The PCR products are cloned
into a vector and then sequenced. [0538] d. The sequences map to
heavy V D J sequences which contain either mouse V or human V. Then
we compare the usage of human Vs v mouse Vs. [0539] e. The usage of
human Vs v mouse Vs is analysed in the mice with/without a human
VpreB1 gene. We expect by introducing human VpreB1 gene, the human
V usage will increase in the mouse with chimaeric IgH gene.
[0540] 3. Improvement of Repertoire and Diversity of Chimaeric
Antibody
[0541] In this embodiment, in mice with the chimaeric heavy locus,
endogenous mouse V genes are inactivated by deletion or inversion
of the mouse V locus. Therefore, all the heavy chain products are
transcribed from human Vs.
[0542] Using the same methods in Example 3, the heavy chain
products from naive and/or immunized mice are sequenced and map to
human V.sub.HD.sub.HJ.sub.HS with different CDR sequences.
[0543] The repertoire of heavy V D J selected by surrogate light
chain from human VpreB and mouse VpreB can be compared from several
aspects. First is the improvement of usage of human heavy V D Js
and hypervariabilities for mice having human VpreB. Second is the
shift of usage in terms of human heavy V gene families caused by
human VpreB v mouse VpreB.
Example 5: Surrogate Light Chain Targeting Protocol
[0544] Mouse .lamda.5 and VpreB1 sequences will be substituted with
human .lamda.5 and VPREB1 sequences. The regulation and expression
will be controlled by mouse endogenous regulatory elements (FIG. 1;
references 1 & 2) that are used during B cell development. In a
mouse genome this VpreB1 is found on chromosome 16 at coordinates
16,868,494-16,869,348. In a human genome VPREB1 is found on
chromosome 22 at coordinates 22,599,087-22,599,927.
REFERENCES
[0545] 1. Minaee S, Farmer D, Georgiou A, Sabbattini P, Webster Z,
Chow C M, Dillon N, Mapping and functional analysis of regulatory
sequences in the mouse lambda5-VpreB1 domain, Mol Immunol. 2005
July; 42(11):1283-92. [0546] 2. Sabbattini P, Georgiou A, Sinclair
C, Dillon N., Analysis of mice with single and multiple copies of
transgenes reveals a novel arrangement for the lambda5-VpreB1 locus
control region, Mol Cell Biol. 1999 January; 19(1):671-9.
[0547] Insertion of Human VpreB1 into Mouse BAC
[0548] A bacterial artificial chromosome (BAC) containing mouse
.lamda.5 and VpreB1 genes will be used for recombineering in
bacteria (E. coli) to replace mouse genes with human genes. A
suitable source of BACs is mouse BAC library collection,
RP23-220N17 (BacPac Resource Center; http://bacpac.chori.org). The
following steps will be followed to generate a targeting construct
that will be used further for targeting of DNA into mouse AB2.1 ES
cells and generation of a transgenic mouse harbouring the human
sequences.
[0549] The first step is to delete the mouse VpreB1 gene on a BAC
containing this mouse gene, by using a positive/negative selection
cassette flanked by 5' and 3' 50 bp homology arms (ie, stretches of
mouse genomic sequence that flank the endogenous VpreB1 gene in the
mouse genome--see sequences A and B below and denoted as BAC Arms A
and B respectively in FIG. 1B). The cassette contains ampicillin
and streptomycin genes between the homology arms. This cassette is
able to select clones that have been correctly targeted, FIGS. 1A
and 1B. The selection cassette will be inserted and targeted using
homologous recombination to replace the endogenous mouse VpreB1
gene. Positive clones will be checked using positive selection,
ampicillin, followed by PCR based confirmation (denoted by the
arrows on the second schematic in FIG. 1A and by means of PRIMER1
to PRIMER4 in FIG. 1B). As shown, the PCR based confirmation will
be performed using specific primers situated within the inserted
DNA sequence whereas, other primers will be outside the targeted
region. A positive amplification product can only be achieved if
the newly inserted DNA is targeted correctly to the desired locus.
Using 50 bp homology arms (sequences A and B below) that are added
to flank the human VPREB1 gene, a vector will be constructed and
used to target and replace the positive/negative selection cassette
specifically using homologous recombination (bottom schematics in
FIGS. 1A and B). Correctly targeted clones containing human VPREB1
(targeted mouse BACs) will be screened using a negative selection,
streptomycin and PCR based method. A source of human DNA for the
human VPREB1 gene is RP11-373H24 BAC (Invitrogen; Roswell Park
Cancer Institute).
TABLE-US-00003 Sequence A: 5' Arm
acctggccaaactgagcatgacctttgacctagccagctc
ttaaacttgttctgagatcacaaaccagccagaccaaatt Sequence B: 3' Arm
tcctcccagaatgcttccctgggtcaaacccagagccaca
aaggcttccattagaccattctggtaagtgacagagtcac
[0550] Retrieval of 19 kb DNA from Mouse BAC
[0551] Next, the 19 kb of DNA (see Sabbattini references cited
supra) containing human VPREB1, mouse .lamda.5 and the mouse
regulatory elements will be removed from the BAC using homologous
recombination in E coli. The region will be retrieved from the
previously targeted mouse BAC into a smaller vector containing 5'
and 3' mouse homology arms (FIG. 2; Mouse Arms 1 and 2). The arms
are constructed using mouse BAC as a DNA template to maintain high
nucleotide homology. Amplified arms are digested with specific
restriction enzymes and cloned into targeting vector (the resulting
targeting vector is shown in the top schematic in FIG. 2). The
targeting vector is linearised between two homology arms and
electroporated into E. coli which contains the previously targeted
human VPREB1 gene.
TABLE-US-00004 Mouse Arm 1 Sequence:
AAAAAAAAAAAAGCCCAGCTAGCTTAGTTGGTAGAGCATGAGACTCTT
AATCTCAGAGTCATGGGTTCAGGCCTCATGTTTGGCACCATCTATAGT
GTGCAGTTATAAATCAAACAGTTCACGATGTGGCTGGCTAGGCACTGG
CAACTGCAGTCTCACCTGCTCCCATGGTTCCCAGTTCCCACAGCTAGT
TTGCTGCCAGGCTGTTCACACTTCCCAGGTCATCTACCCACTGTGGCA
AGCCTGCAGAAAGCCTGCTATTGCTAGCTCAGATTCCCTTAGCCCTAT
AAAATGATAACACCACAGACTTTTACTATACCATCCAGATTTATAACA GTAATTCTCCAACCC
Mouse Arm 2 Sequence:
CAGGAGTACACCAAAATGTCTAGCCAAAATTTTTATATATGATCACTT
AAATAAGACTCCTTAACATAAACCTACATGATATACCAAGTCTTTTCT
GCCAAGGCTCTGACACTATAGTTTGTCCTATTCTGGAGTTAGGTAAGC
AAAGGGCTATTTAGGTGTGGATTGCAAAGAGAGAATAGCAAGACAACC
TGCCCATTCTTTGCCACACCTCACTAATCAGTGTCCCTTGGAAAGCAC
TGTAAATATGGAGGTTTCTTTTTGTATTATGTAGTAGTGGATTTAACT
TGAGGAGCCCCAAAAGGGGTCAGCAAAGCATGGGAAATCTAAGAATTT
AACACTTCAGTGACTTTTAATCACCTACAGATCCAGGAAAATAAGCCT GTCTCTT
[0552] The resulting vector contains the 19 kb sequence containing
mouse .lamda.5 and human VPREB1 genes (second schematic in FIG. 2).
This vector will allow for amplification of the retrieved 19 kb
sequence and use for further insertion into a human BAC of choice
(eeg, a BAC containing human antibody gene segments, such as a BAC
obtainable from the RPCI-11 library available from Invitrogen). The
insertion of the 19 kb DNA fragment will be targeted into a BAC
containing human IgH V gene segments (FIGS. 3A and 3B; which can be
read in conjunction with the disclosure of WO2011004192, the
disclosure of which is incorporated herein by reference), eg, to
target the 19 kb sequence directly 5' of the most distal 5' end of
the human IgH locus to avoid any possible interference with normal
IgH rearrangement subsequently in a mouse or B-cell progeny. To
this end, using a series of BACs, human Ig gene segments (VDJ) are
inserted in a series of steps into the genome of a mouse ES cell
(eg, an AB2.1 cell) using sequential recombinase mediated cassette
exchange (sRMCE) or homologous recombination as is known in the
art. The 19 kb sequence can be inserted directly 5' of the 5' VH in
the last BAC to be used, thus providing the 19 kb sequence
immediately 5' of the first human VH in a transgenic IgH locus
after insertion of the 19 kb sequence and human VH sequences into
the mouse ES cell genome. Thus, a human VPREB1/mouse .lamda.5 gene
insert is provided for expression of chimaeric surrogate light
chain (SLC) in a subsequent progeny mouse or B-cell.
[0553] Humanisation of .lamda.5
[0554] Similar procedures of targeting and genetic engineering
steps will be used to modify the second gene of SLC, namely the
.lamda.5 (FIG. 4), in order to replace mouse .lamda.5 with human
.lamda.5.
[0555] Correctly targeted ES will be used to generate a transgenic
mouse. Analyses will be performed using animals which harbour (i)
the human VPREB1 and mouse .lamda.5 (humanVB1/mouse .lamda.5) or
(ii) human VPREB1 and human .lamda.5 (human VB1/.lamda.5).
Differences in populations of expressed antibodies between a
control wild type (WT) mouse and (i) or (ii) will be recorded using
Fluorescence-Activated Cell Sorting (FACS). The end point data will
be generated using mice spleen to analyse the contribution of human
VPREB1 only or in conjunction with human .lamda.5 in expansion of B
cell population harbouring human sequences and the generation of
more diverse antibody repertoires.
Example 6: Engineering of Non-Human Vertebrate Genome--Chimaeric
Surrogate Light Chains Significantly Change Human Variable Region
Repertoires In Vivo
[0556] Construction of Transgenic IgH Loci
[0557] Insertion of human heavy gene segments from a 1st IGH BAC
(RP11-1065N8) into the IGH locus of mouse AB2.1 ES cells (Baylor
College of Medicine) was performed to create a heavy chain allele
denoted the 51 allele. The inserted human sequence corresponds to
the sequence of human chromosome 14 from position 106494908 to
position 106328951 and comprises functional heavy gene segments
V.sub.H2-5, V.sub.H7-4-1, V.sub.H4-4, V.sub.H1-3, V.sub.H1-2,
V.sub.H6-1, D1-1, D2-2, D3-9, D3-10, D4-11, D5-12, D6-13, D1-14,
D2-15, D3-16, D4-17, D5-18, D6-19, D1-20, D2-21, D3-22, D4-23,
D5-24, D6-25, D1-26, D7-27, J.sub.H1, J.sub.H2, J.sub.H3, J.sub.H4,
J.sub.H5 and J.sub.H6 (in 5' to 3' order), wherein the JH6 was
chosen to be the human JH6*02 variant. The insertion was made
between positions 114666435 and 114666436 on mouse chromosome 12,
which is upstream of the mouse C.mu. region. The mouse V.sub.H, D
and J.sub.H gene segments were retained in the locus, immediately
upstream of (5' of) the inserted human heavy chain DNA.
[0558] A second allele, S2 was constructed in which more human
functional V.sub.H gene segments were inserted upstream (5') of the
5'-most V.sub.H inserted in the 51 allele by the sequential
insertion of human DNA from a second BAC (BAC2). The inserted human
sequence from BAC2 corresponds to the sequence of human chromosome
14 from position 106601551 to position 106494909 and comprises
functional heavy chain gene segments V.sub.H3-13, V.sub.H3-11,
V.sub.H3-9, V.sub.H1-8, V.sub.H3-7. The mouse V.sub.H, D and
J.sub.H gene segments were retained in the locus, immediately
upstream of (5' of) the inserted human heavy chain DNA.
[0559] Mice bearing the S2 insertion into an endogenous heavy chain
locus were generated from the ES cells using standard procedures.
The other endogenous heavy chain locus was inactivated in the mice
by insertion of an inactivating sequence comprising neo.sup.n into
the mouse J.sub.H-C.mu. intron (to produce the "HA" allele). The
mice retained mouse VpreB and .lamda.5, but no human VpreB gene
(control, S2 mouse) or a human VpreB gene was included in the
genome (S2/hVpreB mouse, ie, chimaeric surrogate light chain mouse
according to the invention comprising a human VpreB1 gene with
mouse VpreB1 promoter-driven expression). The human VpreB was
inserted from a BAC using recombinase mediated cassette exchange
(RMCE) upon construction of the S2/hVpreB mouse according to the
invention. The latter mouse was a chimaeric mouse having around 30%
Agouti coat colour, which is indicative of the potential fraction
of B cells derived from the injected ES cells bearing the human
VpreB gene. Thus, in the chimaeric mouse of the invention most
B-cells do not have the human VpreB. This provides for a more
challenging test versus control, as explained below. An alternative
would be to breed a mouse of the invention where all cells harbour
a human VpreB gene, and this is expected to show the advantage of
the invention in producing a different repertoire as demonstrated
below for the chimaeric test mouse.
[0560] Specifically, the following human gene segments were
included (in 5' to 3' order):-- [0561] human VH gene segments
VH3-13, 3-11, 3-9, 1-8, 3-7, 2-5, 7-4-1, 4-4, 1-3, 1-2 and 6-1;
[0562] human D gene segments D1-1, 2-2, 3-9, 3-10, 4-11, 5-12,
6-13, 1-14, 2-15, 3-16, 4-17, 5-18, 6-19, 1-20, 2-21, 3-22, 4-23,
5-24, 6-25, 1-26 and 7-27; and. [0563] Human JH gene segments J1,
J2, J3, J4, J5 and J6.
[0564] RNA was extracted from the spleens of both the control and
S2/hVpreB mouse of the invention. RT-PCR was performed as described
in the VDJ sequencing methodology below. The mouse C.mu.
transcripts were captured and sequenced, and only human JH
transcripts were used for usage analysis to ensure use of
transcripts only derived from the transgenic IgH loci bearing human
variable region gene segments.
[0565] VDJ-Sequencing Methodology
[0566] The following methodology was performed to sequence human
IgH variable regions from RNA samples obtained from the mouse of
the invention comprising a transgenic IgH locus and a human VpreB
gene. Comparison of the control with a chimaeric mouse of the
invention is more challenging than comparison with a mouse of the
invention that is 100% transgenic (ie, where all cells bear the
transgenic IgH locus and human VpreB gene). In the chimaeric mouse,
only a proportion of the cells comprise the transgenic IgH locus
and human VpreB gene, and in those cells the IgH is present in one
copy (heterozygous). Thus, the comparison in this example
surprisingly was still able to show a difference in repertoires
produced in the control and invention mice despite the chimaeric
nature of the latter.
[0567] Sequences were filtered so that the resulting data set
related to human variable regions only (and not variable regions
having mouse sequence).
[0568] V gene usage frequency was assessed by next generation
sequencing of VDJ recombined transcripts using the Illumina Miseq
platform (see, eg, Nature. 2008 Nov. 6; 456(7218):53-9; "Accurate
whole human genome sequencing using reversible terminator
chemistry"; Bentley D R et al). Libraries of VDJ sequences were
generated with standard adapter sequences at either end that were
compatible with Illumina sequencers. The Illumina adapter sequences
are termed P5 and P7 permit the binding of DNA fragments to the
Illumina flowcell and are the initiation sites of the sequencing
reactions. The VDJ libraries were generated using the following
methodology: 5' RACE was performed on 5 .mu.g of total RNA to
generate cDNA with a known sequence at the 5' end using the
ExactSTART Eukaryotic mRNA 5'- & 3' RACE kit (Epicentre) using
the manufacturer's protocol with the following modifications: The
5' RACE acceptor oligo was replaced with an RNA oligo (P7 RNA
oligo: AGACGUGUGCUCUUCCGAUCU) specific to a 21 bp portion of the
Illumina P7 adapter. The first-strand cDNA was synthesised using a
reverse primer (IgM RT primer: GAAGACATTTGGGAAGGACTG) specific to
the first exon of the IgM constant region. Second strand synthesis,
and enrichment of VDJ sequences was achieved by performing 15
cycles of PCR using a primer specific to the ligated RNA oligo (P7
PCR 1: [GTGACTGGAGTTC]AGACGTGTGCTCTTCCGATCT) that also included
additional Illumina P7 sequence at the 5' end (shown by square
brackets). Paired with a primer specific to the IgM constant
region/J segment splice junction (IgM P5 PCR 1:
[ACACTCTTTCCCTACACGACGCTCTTCCGATCTNN]GGGAAGGACTGACTCTCTGA) that
also included additional Illumina P5 sequence, and two bases of
random nucleotides, at the 5' end (shown by square brackets).
[0569] The PCR reaction was purified using gel electrophoresis and
the major PCR product that corresponded to VDJ transcripts
(.about.600 bp) was excised and purified using a Qiagen gel
extraction kit according to the manufacturer's protocol. A second
round of 15-cycle PCR was performed to add the remaining portions
of the Illumina P5 & P7 adapter sequence and to incorporate a
barcode, so multiple samples could be pooled and sequenced together
in a single run. The forward primer was specific to the P5 sequence
with the additional P5 flowcell binding sequence shown within
square brackets (P5 PCR 2:
[AATGATACGGCGACCACCGAGATCT]ACACTCTTTCCCTACACGACGCTCTT). The reverse
primer was specific to the P7 sequence and incorporated a 6 bp
barcode and the P7 flowcell binding sequence shown within square
brackets (P7 PCR 2 index X:
[CAAGCAGAAGACGGCATACGAGAT******]GTGACTGGAGTTCAGACGTGT). The 6 bp
barcodes were standard Illumina 6 bp indexes, 4 different indexes
were used in this case and the sequences were: CGTGAT, GCCTAA,
GATCTG, & TCAAGT. The final PCR products were purified using
AMPure XP beads (Beckman Coulter) and were pooled together and
sequenced on the consisted of a VDJ transcribed gene with a
complete P5 and P7 Illumina adapter on either end. This construct
was suitable for next generation sequencing on the Illumina Mi-Seq
system using the TruSeq DNA sequencing program2.times.150 bp paired
end sequencing program.
[0570] Bioinformatics & Statistical Analysis
[0571] The sequences from the Illumina MiSeq were obtained as a set
of 4 BAM files from the machine, each file corresponding to a
different barcode. Barcodes 1 and 3 were from the surrogate light
chain samples, while barcodes 7 and 8 were from the control
samples. These BAM files were converted into fastq using bam2fastq
using the command: bam2fastq <file>.bam -o<file>#.fastq
which splits the paired reads into two different fastq files.
[0572] These fastq files were then converted into fasta using
fastq_to_fasta -I<file>.fastq -o<file>.fasta -Q33. This
yielded a set of 8 fasta files.
[0573] The fasta files were then analysed with Basic Local
Alignment Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/) to
find J and V segments from mice and humans. The paired reads were
used to identify the J and V used, with the read from the constant
region end being used to find the J and the read from the 5' end of
the RNA being used to identify the V gene used. As the
transcription occurred before the start of the V segment, 5' UTR
sequence from Ensemble (http://www.ensembl.org) was used to search
against to find the V genes used.
[0574] An InforSense workflow was used to then combine the results
from the paired reads by matching their unique identifier to the
results from the two Blast searches. These combined results were
then filtered for sequences which used a Human J gene and a Human V
gene. Because the sample with the chimaeric surrogate light chain
was a wild type/transgenic chimaera, there were far fewer samples
with a Human J than in the control, which is expected.
[0575] To avoid any errors due to PCR duplication events sequences
with identical CDR3 regions, as determined by the IMGT numbering
scheme, were treated as one sequence. This reduced the number of
sequences in the control sample from 2,632,503 to 168,551 and in
the surrogate light chain sample from 2,543,248 to 590,462.
[0576] The final counts after filtering for Human J, Human V and
treating each CDR3 string as single sequence gave 10,781 sequences
for the control, and 267 for the surrogate light chain sample. The
low percentage of sequences with an identified Human V is due to
the 150 bp reads from the Illumina MiSeq not extending very far
into the variable part of the V genes. The results are shown in
Table 3. In the table, the mouse of the invention is labelled
"Chimaeric SLC" and significant changes in gene segment usage are
underlined.
TABLE-US-00005 TABLE 3 Chimaeric Chimaeric Control Total SLC Total
Control % SLC % V6-1 587 38 5.44% 14.23% V1-2 155 3 1.44% 1.12%
V1-3 1167 43 10.82% 16.10% V4-4 984 33 9.13% 12.36% V2-5 409 7
3.79% 2.62% V3-7 4095 66 37.98% 24.72% V1-8 1315 21 12.20% 7.87%
V3-9 893 40 8.28% 14.98% V3-11 443 3 4.11% 1.12% V3-13 733 13 6.80%
4.87% sum 10781 267 IGHJ1*01 131 13 1.21% 4.87% IGHJ2*01 260 13
2.41% 4.87% IGHJ3*02 1011 34 9.37% 12.73% IGHJ4*02 5467 153 50.69%
57.30% IGHJ5*02 867 12 8.04% 4.49% IGHJ6*02 3050 42 28.28% 15.73%
sum 10786 267
[0577] The usage between the two samples was compared using a
standard Pearson's chi-squared test (see eg, NIST/SEMATECH
e-Handbook of Statistical Methods,
http://www.itl.nist.gov/div898/handbook/, April 2012). This gave
the probabilities that the distribution of the surrogate light
chain sample and the control sample being the same was 5.8E-15 for
the V genes and 8.2E-12 for the J genes. These are below the
standard 5% (ie, 0.05) probability cut off and thus are
significant.
[0578] The individual V and J genes which showed the most
significant differences between the two are summarised in the Table
4 below. The probability shown is the probability of obtaining by
chance that number or more in the case of an increase or that
number or less in the cast of a decrease, using a binomial
distribution using the probabilities from the ratios obtained from
the control sample. The individual V and J genes in the table have
a probability score below the standard 5% (ie, 0.05) probability
cut off and thus are significant.
TABLE-US-00006 TABLE 4 Expected Chimaeric from Gene Usage SLC Count
Control Probability IGHV6-1 Increased 38 14.5 2.38E-08 IGHJ1
Increased 13 3.2 6.31E-06 IGHV3-9 Increased 40 22.1 9.80E-05
IGHV1-3 Increased 43 28.9 3.21E-03 IGHJ6 Decreased 42 75.5 1.09E-06
IGHV3-7 Decreased 66 101.4 2.94E-06 IGHV3-11 Decreased 3 11.0
4.42E-03 IGHV1-8 Decreased 21 32.574 1.52E-02
TABLE-US-00007 SEQUENCE LISTING SEQ ID NO: 1 Human VpreB1
nucleotide sequence (GenBank Accession No = NG_029387.1)
gagtcagagctctgcatgtctgcaccatgtcctgggctcctgtcctgctcatgctgtttgtctactgcacaggt-
gaggga
acccccagatcccaaagactcctgccccttccttcatcctgccctgcccccacggcccacatgcatctgtgtca-
ccaggt
tgtggtcctcagccggtgctgcatcagccgccggccatgtcctcggcccttggaaccacaatccgcctcacctg-
caccct
gaggaacgaccatgacatcggtgtgtacagcgtctactggtaccagcagaggccgggccaccctcccaggttcc-
tgctga
gatatttctcacaatcagacaagagccagggcccccaggtcccccctcgcttctctggatccaaagatgtggcc-
aggaac
agggggtatttgagcatctctgagctgcagcctgaggacgaggctatgtattactgtgctatgggggcccgcag-
ctcgga
gaaggaggagagggagagggagtgggaggaagaaatggaacccactgcagccaggacacgtgtcccttgaactg-
aagaca
gcagaggcacgcatccccttggagagactgtcatggaagagggtggagccgccgcccgaagcgccgaggaggct-
gagcca
ctcagcatctcctggtcctgcagtgttgctgtaaatccccattggagactgcattagggaattaaagctgcttg-
tcactt tttgctg SEQ ID NO: 2 Human VpreB amino acid sequence
(GenBank Accession No = NP_009059.1)
mswapvllmlfvyctgcgpqpvlhqppamssalgttirltctlrndhdigvysvywyqqrpghpprfllryfsq-
sdksqg
pqvpprfsgskdvarnrgylsiselqpedeamyycamgarssekeerereweeemeptaartrvp
SEQ ID NO: 3 Human VpreB3 nucleotide sequence (GenBank Accession No
= NC_000022.10)
cttcccagccctgtgccccaaagcacctggagcatatagccttgcagaacttctacttgcctgcctccctgcct-
ctggcc
atggcctgccggtgcctcagcttccttctgatggggaccttcctgtcaggtgaatctttcctgggcctcagtca-
cctggg
tgtggggtggggaacagtactggccccagaaggcccctgcaaggaggcaaatcgatggggacagtagggcaggt-
cctggg
aggggtattttttttttttttgagacggagttttgctcttgttgcccaggctggagtgcaacggtgcaatctcg-
gctcac
tgcacctctgcctcccaggttcaagcgattcttctgcctcagcgtcctgagtagctgggattacaggcatgcgc-
caccac
gcctggctaattttgtatttttagtagagacaaggtttcttcatgttggtcaggctggtctcaaactcctgacc-
tcaggt
gatccgcccacctcagcttcccaaagtgctaggattacaggcttgagccactgcacctggctgggaggcgtatt-
caggta
gaggggtgacctggcttcagacagctctgcccttgacctggggcaaatcacttccctgtgtgggccttggtttt-
ctcatt
cgtgaatgaccagatcactagagccctggactctgactttgggtctccttcttagtttttcacaggggaagcta-
ttgtgg
gttggtccctaccccacagggcctgaggcaatctaacctccctgagagggtccctgcagccagttgcctgaggc-
tgagtt
gatgtgtgggacagcccaggaggttcctgggggtggttagtctgtattcagggtttggaagagctgaagtgaag-
tgggcg
gggaagtgggggagaggggtgcagttctgcagagaaacgtgggtgggtagcagagggacctagaggctgctagt-
ccaacc
ttctgagctctgggcctttaactgaacacagatccttgaggatatggcactaatggagatttgggggctaactc-
caaacc
cctcactcacaaagggagatggaggtccagatagggcaccctaagtcacacagaaccaggcctcctgcaccccg-
ttcatt
gctaatcccatagcactgggctatgagccctttgggactgggagtctccatggagtccaaccaagccttcacag-
ggcagg
ggtgggagggaaggggctcaggctgagtgggtttgtgtctcgcagtttcccagacagtcctggcccagctggat-
gcactg
ctggtcttcccaggccaagtggctcaactctcctgcacgctcagcccccagcacgtcaccatcagggactacgg-
tgtgtc
ctggtaccagcagcgggcaggcagtgcccctcgatatctcctctactaccgctcggaggaggatcaccaccggc-
ctgctg
acatccccgatcgattctcggcagccaaggatgaggcccacaatgcctgtgtcctcaccattagtcccgtgcag-
cctgaa
gacgacgcggattactactgctctgttggctacggctttagtccctaggggtggggtgtgagatgggtgcctcc-
cctctg
cctcccatttctgcccctgaccttgggtcccttttaaactttctctgagccttgcttcccctctgtaaaatggg-
ttaata atattcaacatgtcaacaaca SEQ ID NO: 4 Human VpreB3 amino acid
sequence (GenBank Accession No = NP_037510)
macrclsfllmgtflsvsqtvlaqldallvfpgqvaqlsctlspqhvtirdygvswyqqragsapryllyyrse-
edhhrp adipdrfsaakdeahnacvltispvqpeddadyycsvgygfsp SEQ ID NO: 5
Mouse VpreB1 nucleotide sequence (GenBank Accession No =
NC_000082.5)
agagcccagaaagcctgggagggtggtgagcaggaaccaggggtgcagtgaccctctccccaaagcagggagga-
gagtgc
ttcccagctggtcagggcccaggagcagtggctgtagggggcagggtgctgcaggtctggagccatggcctgga-
cgtctg
tcctgctcatgctgctggcctatctcacaggtaaggaaactcttggggcccagggcttctttgctcctcctatg-
gccttg
ctctgccccagtgatggacatgcttctatcttctcaggttgtggccctcagcccatggtgcatcagccaccatt-
agcatc
ttcttcccttggagccaccatccgcctctcctgtaccctgagcaacgaccataacattggcatttacagcattt-
actggt
accagcagaggccgggccaccctcccaggttcctgctgagatacttctcacactcagacaagcaccagggtccc-
gatatc
ccacctcgcttctccgggtccaaagatacgaccaggaacctggggtatctgagcatctctgaactgcagcctga-
ggacga
ggctgtgtattactgtgccgtggggctccggagccaggaaaagaagaggatggagagggagtgggaaggagaaa-
agtcgt
atacagatttgggatcttaggctctggagacattcagaccctgaactgaagacagagtttgctttgctcggcta-
gtctgg
tatgggaaggaggggtagaacgtgaggttttgcagagcctagaagatggaattatgcagcttttccttgttctg-
cggtgt tgctatgagcccccattggaggctggattgtagaattaaagctgtttttactgaa SEQ
ID NO: 6 Mouse VpreB1 amino acid sequence (GenBank Accession No =
NP_058678)
mawtsvllmllayltgcgpqpmvhqpplassslgatirlsctlsndhnigiysiywyqqrpghpprfllryfsh-
sdkhqg
pdipprfsgskdttrnlgylsiselqpedeavyycavglrsqekkrmerewegeksytdlgs SEQ
ID NO: 7 Mouse VpreB2 nucleotide sequence (GenBank Accession No =
NC_000082)
atggcctggacgtctgtcctgctcatgctgctggcccacctcacaggtaagggaactcttggggtccagggctt-
ccttgc
tcctcctgtggccttgctctgccccagtgatggacatgcttctatcttctcaggttgtggccctcagcccatgg-
tgcatc
agccaccatcagcatcttcttcccttggagccaccatccgcctctcctgtaccctgagcaacgaccataacatt-
ggcatt
tacagcatttactggtaccagcagaggccgggccaccctcccaggttcctgctgagatacttctcacactcaga-
caagca
ccagggtcccgatatcccacctcgcttctccgggtccaaagatacggccaggaacctggggtatctgagcatct-
ctgaac
tgcagcctgaggacgaggctgtgtattactgcgctgtggggctccggagccacgaaaagaagagaatggagaga-
gagtgg gaaggagaaaagtcgtatacagatttgggatcttag SEQ ID NO: 8 Mouse
VpreB2 amino acid sequence (GenBank Accession No = NP_058679.1)
mawtsvllmllahltgcgpqpmvhqppsassslgatirlsctlsndhnigiysiywyqqrpghpprfllryfsh-
sdkhqg
pdipprfsgskdtarnlgylsiselqpedeavyycavglrshekkrmerewegeksytdlgs SEQ
ID NO: 9 Rat VpreB1 nucleotide sequence (GenBank Accession No =
NM_001108845.1)
ccagaaagcctgggagggtggtgagcaggaaccagtggtgcaaagcaggggcgagactgcttcctagctggtca-
gggcac
cggagcagtggctgtaggggtcagggtgctgcaggtctggaaccatggcctggacgtctgccctgctcatactg-
ctggcc
catctcacaggtacgggaactcttggggcccagagcctccttgctcctcctcttgccttgctctgccgcagtga-
tgggca
cgcttctattttctcaggttgtggccctcagcccgtgctgcatcagccaccatcggcctcttccttccttggaa-
cctcca
tccgcctcacctgtgccctgagcagcaaccataacattggcatttacagcatttactggtaccagcagaggccg-
ggccac
cctcccacgttcctgctgagattcttctcacactcagacaagctccagggtcccaagatcccccctcgcttctc-
cggatc
caaagatacagccaggaacctggggtacctgagcatctctgacctgcagccagaggacgaggctgtgtattact-
gcgccg
tggggcttcggagctgggaaaaggagaagaggatggagagggagtgggaagaagaaaagtagcggacagattcg-
ggatct
taggctctggagacattcagacctagaaccgaagacggagtttgctttgctcggctaggctggtttggggagga-
ggggta
gaacaccgggcttcgcagagccaggaaggtggagccagccgcttttccttgtattgcagtgttgctatgcgccc-
catcgg
aggctggattgtagaattaaagctgttttttttttttttgttttgtttttttgttttttgtttcttttttctta-
actg SEQ ID NO: 10 Rat VpreB1 amino acid sequence (GenBank
Accession No = NP_001102315.1)
mawtsallillahltgcgpqpvlhqppsassflgtsirltcalssnhnigiysiywyqqrpghpptfllrffsh-
sdklqg pkipprfsgskdtarnlgylsisdlqpedeavyycavglrswekekrmereweeek SEQ
ID NO: 11 Rat VpreB2 nucleotide sequence (GenBank Accession No =
NC_005110)
atggcctggacgtctgccctgctcatactgctggcccatctcacaggtacgggaactcttggggcccagagcct-
ccttgc
tcctcctcttgccttgctctgccgcagtgatgggcacgcttctattttctcaggttgtggccctcagcccgtgc-
tgcatc
agccaccatcggcctcttccttccttggaacctccatccgcctcacctgtgccctgagcagcaaccataacatt-
ggcatt
tacagcatttactggtaccagcagaggccgggccaccctcccacgttcctgctgagattcttctcacactcaga-
caagct
ccagggtcccaagatcccccctcgcttctccggatccaaagatatagccaggaacctggggtacctgagcatct-
ctgacc
tgcagccagaggacgaggctgtgtattactgcgccgtggggcttcggagctgggaaaaggagaagaggatggag-
agggag
tgggaagaagaaaagtagcggacagattcgggatcttaggctctggagacattcagacctagaaccgaagacgg-
agtttg
ctttgctcggctaggctggtttggggaggaggggtagaacaccgggcttcgcagagccaggaaggtggagccag-
ccgctt
ttccttgtattgcagtgttgctatgcgccccatcggaggctggattgtagaattaaagctgttttttactg
SEQ ID NO: 12 Rat VpreB2 amino acid sequence (GenBank Accession No
= NP_001128260)
mawtsallillahltgcgpqpvlhqppsassflgtsirltcalssnhnigiysiywyqqrpghpptfllrffsh-
sdklqg pkipprfsgskdiarnlgylsisdlqpedeavyycavglrswekekrmereweeek SEQ
ID NO: 13 Human .lamda.5 nucleotide sequence (GenBank Accession No
= NG_009791)
ggccacatggactggggtgcaatgggacagctgctgccagcgagagggaccagggcaccactctctagggagcc-
cacact
gcaagtcaggccacaaggacctctgaccctgagggccgatgaggccagggacaggccaggggggccttgaggcc-
cctggt
gagccaggccccaacctcaggcagcgctggcccctgctgctgctgggtctggccgtggtaacccatggcctgct-
gcgccc
aacagctgcatcgcagagcagggccctgggccctggagcccctggaggaagcagccggtccagcctgaggagcc-
ggtggg
gcaggtaaggggtgagagattccaggggatgtgggggtctgggtggcagaggcgggaaaggatgaccaagggga-
gacgag
ccagaggggtgaggaggaaggttaatccctggaggggagccacagacactgactttaactaaagtgtcaagatt-
ttgtcc
atctttgaattaatttttattgcttaatgtcatattaaaatattatttatcttgattcctgagatttcttcccc-
cactta
catttggcaccaaggccaatgtctccctcacctccccctagtccttggggtagggcaggactggaggcaggggc-
aggacg
tccacaggagtggtggccgctatccctgaaggatgcccaggcctctccctcctcctcctcccactcctcctccc-
ccccct
cctcttttccccttggcctatgtcacctgtccactcccaccctcactgggcaggggccactccctggagctcca-
gctaag
gtgtgaggggcctttcctggagtccctgggtcactagacctcagccagcatcgcctcctgaaaccagcccctag-
gagaca
caagcttatccagggtgcaagtgcctccaaagaagaagcccaggagaggctctagggaggccacaactccctgt-
gtgacc
tcagccattgccaccactctgcgtgtggtgggaggtccccagacaaagcaccaagcatcggggtccatttatga-
gcattt
gggacacaacagcctgttcactggtgcatgttatacccacaggcgataatcatttcaggggcagaacctccctc-
tcggtg
gccccataggcaggtcctgctgtgatcccctttgtgcagacggggatagagcccggagaggtgaggtgacccgt-
ccgagt
cactcagctcatgggcacagattctaaggcccaagctatcccctctagctctcccctgtcccatcctctaagct-
gatcga
gcggacacgtgcatctctgggacctgagtttccctttttctctcttttttttctttttcaaataaagtttcaca-
gagttt
cactcttgtcgcccagtctggagtgcaatggcgagatcttggctcattgaaacctccgtctcccaggttcaaga-
cattct
cctgcctcagcttccggagtagctgggattacaggcatctgccaccacacctggctaattttgtgtattttttt-
ttagta
aagacagagtttcaccatgttggccaggctggtctcaaactcctgacctcaggtgatccacccacctcagcctc-
ccaaag
tgctgggattacaggcatgagacaccacaccgggcctgagtttccccttctgcaatctgaggggccctgactgg-
tgaggg
ccttcagcgtcccacccacccagaggatgctggggtggctgtggtgagagctccagcagtggcagccgacctga-
cccaca
ccaggagcccggccatggaggcggggtcagcatggtggcaggccgggaccgggtgtcagtgtcctgcacggact-
tctgag
caaggagtccccatcagggtcaggctctgtgctggggctgaggtcccagaggatctagatttgccccaattcaa-
gtccac
aaggagcgggggccgggtgaggagacagccacatgcagggtgatgcctacagaacagagactgggatggggaag-
gcccga
ggggtctccacaagggacgggtgacaggtggagggagacacagataataaaaaatggtattatgttggggggct-
attaat
gtaagtttttatattagaatctttagaaatcttatagaaatactatgggccgggtgctgtgtctcatgcctgta-
atccca
gcactttaggacgccaagatgggcagatcacgaggtcaggagattgagaccatcctggccaacatggcaaaact-
ccgtct
ctactaaaaatacaaaaactagctgggcgtggtggcgcgagcctatagtcccagctactcgggaggggaggcag-
gagaat
cgcttgaatcagggaggtggaggttgcagtgagctgagattgcaccgctgcactccagcctggacgacagaacg-
agactc
ccactcaaaaaaaaaaaaaggtattatgctgggggggatatgaatatgagtttttataatctttagaaatacta-
tgggcc
aggtgcagtggctcatgcctgtaatcccacaactttgggaggctgaggcgggattgtttgagcccaggagtttg-
agatca
gcctgagcaacatagcaagaccccatttctacaaaacatataaaaactagctagtcatggtggcacttgcctgt-
ggtccc
agctacttaggaggctggtgagaggattgcttaagcctcggaggttgaggatgcagtaagctgagatcccacca-
ctgcac
tccagcctgggtgacagaaggagaccctgtctcaaaaaaaaaaaaaaaaaaaaaagactgattattcctgtaga-
attctg
gtaaatatctcctatcaaataaatgacttttctattcatagcttattaaaagatattttcattgtttttaagaa-
ataggt
tgtgtatcactttttatatttagttgtaaatttatttgttttatttatttttttagagatgggggtctcactat-
gttgcc
tgggctggcctccaactgctgggctcaagcaatatccctgcctcagcgtccccagtagctgggactacaagcat-
gcgcta
ccacaccggcataattttttgtagagatgaggtttcgccatgttgcctgggctggtcttgaacccctgggctca-
agccat
ccacccgcctcggcctcctaaagtgctgagattacagacgtgagccaccctacctagcctgtactatttttaat-
aggtct
taataggttttgaatgttaattatttttaaattaatttcaaaaatcttctacaacatggatgaaacctgaagac-
attata
cttagtgaaataagccagacacaaaaggacaaatgtcatttgaatccacttctatgaggtacctagaataggca-
aattca
cttggacaaaaagtagatttgaggttagcagggtgagggggagggaagaatgggggactgtagttaacgggttt-
agagtt
tctgtttgggaagatgaaagagttctggagatggatggtggtgaaggttgcccaacggtgtgaatgtacttagt-
gccacg
gagctgtacgtttaaaaatagttaaagtggaaatattgatgctatgtataaaaatggagcggggtgtggtggct-
cacacc
tataatcccagcactttgagaggccaaggtgggcagatcacctgaggtcgggagttcgagaccagcctgacaaa-
catgga
gaaacaccgtctctactgaaaatacaaaaaattagccaagtgtgctggcacatgcctgtaatcccagctactcg-
ggaggc
tgaagcaggagaatcgcttgaacccaggatgtggaggttgcggtgagccaaggtggcaccattgcactccagcc-
tgggcg
acaagggtgaaattccatttcaaaaaaataaaaggaaatgggactgtacatagcaggagagagagggagagatc-
aatatg
acacttctttttttttttttttttttttgggacagtcttgctctgttgccaggctgcactccagcctgggcaac-
agagcg
agactctgtctcaaaaaaaaaaagaatgtctagatgcagtagctaagttcgcagaagccatttcagtgtgggag-
gcgagg
tgactgagtccagggactccaggtttctggctgaggggttgagaccgcccatggtcattgtgatgagatgaaga-
cagaaa
atgagctgggctgggggaaggtggtcatctcctctggacgtgattagtttgaggctcctgttgggtagcccact-
gggcaa
ggtcagtaggcaattgaggagctgagagggtttggagctgggatagactccagcctcaccatgtgggcaatagt-
gggggt
cacagagtgtgaaaatggctaagaaagaggtctgggtggggtctggggagtcagcagccaggcatgggccatgg-
agaaac
agatgccaggggaagaggaaaggggagtctcagaccccaaggggaaaagagtcactggaaagaggggccagccc-
tgtgtc
gcatccagcggagacaccaggtacagcagaaggaccttggacatgaccatgaggagggccttgttgaccatggc-
ctggga
gagatgggggtgagagcctgggggaccacaccatgtccccagcacacagtgcctggtagacaggatggatttat-
ggatgg
acggacaggtagatggatggacgaatggacagatgatagatggatgcaaagacagatgaatagatggacagatg-
cataga
tggacagatggacagatggatggacggacggatggaatgaatgatcagaaaaggcttcatgaacaaagtgagac-
tgagct
gcatctccatgggtagatataaaagcagaggactctcctcttgagtcaggaatgacccaatgtcctggtccagg-
gaggaa
gtcagcctccttgactggggacacttgtggcagatttcagaggcccttaaaatgaggccaagtgaggtggacag-
gtccga
gccagctgaggactcctcagccacacggcacagctgcctgaggggatgtgtcactcagggagttgctgggacct-
actggg
cccagcgttgccatcagcaccaacagtttcagagagggggacacacgctggggcagcacctgcctcagagaagg-
gacagg
cacagagacactactgggggacactactgggacactggccacccccctaccctgtgcctgggtcacagcctaca-
cactgc
agccctgtgcccctcactcccagcaggttcctgctccagcgcggctcctggactggccccaggtgctggccccg-
ggggtt
tcaatccaagcataactcagtgacgcatgtgtttggcagcgggacccagctcaccgttttaagtaagtggctct-
aacttc
ccaggctgtcccaccctctcctgtctctggaaaatgtgttttctctctctggggcttcttcccctctgccctcc-
cagcct
taagcactgacccctacctttgtccatggggcctggaggagatgtgttagtctcagggtaatggcaggaagggc-
ccccac
agtgggagcagccgccttcaggttccaacagcaggacacagcctggtcccagggcctgggctgggattgggcgg-
ggtcag
ggctcctcccctctcccagggcagatgtctgagtgagggacagaggctggttctgatgaggggccctgcagtgg-
ccttag
agacagtccctgggaccccaggttctaggctgagggctggatgcccatccagcctgggagggccacacgggggc-
ctgggg
acacaggggtcacccccaggggagaccaatggagggcacagagagggctctgggtctaggctgcagctctgtgg-
cctctg
ctgggtcttcagggcatggggacacagaggaacggatgaggtcccagagcccagccctcccaggacagtcacca-
gaaagg
agagggtctcttagtgcagagatgtgcctgtccctggagccctgtcatctctggggcctggtgtctctctgttc-
atgggt
cgacctcccaccttcatttgaggaagggcaccttagactcagaaggtgactagcggggagtaaacgggagtgca-
gagaac
tccatggctgccaggtgaagtccaggggcatcagaggctgctggggtgggcatgggggctgcggtgccccaaag-
tctggg
ggagcagccccaagaacccagccgatgtgaagggtcctgtggtcgggctggtggggacaggggcgacggcagag-
ccccag
ggtgtgtctgggtggagcccacgcttcaccaggagagctgagtgggccaggctggggcacagcctggtgcccca-
ggggat
gggaagctccaggccatgccaggcttgggtctccccacatcctgccagtatagttttgtgtgctgtgagggaga-
ccccta
gattccaaactcagactccagaaaccaggaaggagggagcacagcctgccctgggtgcacacggggaaaccgag-
gctgca
gaggaaagggctgggccaggacacctgggaaaggtgacttgggaagggctcctaggaaggcacagggctgtctg-
ctctcc
agagggctccagtggaaaggagggaatgaggagggaaggagaggccctgggtggaccaggcggccacaccatga-
accctc
ccagagactttagacagagagaggcgctccacaacaccccacactccctctgccatctctcaccccctcctctg-
tccaca
caggtcagcccaaggccaccccctcggtcactctgttcccgccgtcctctgaggagctccaagccaacaaggct-
acactg
gtgtgtctcatgaatgacttttatccgggaatcttgacggtgacctggaaggcagatggtacccccatcaccca-
gggcgt
ggagatgaccacgccctccaaacagagcaacaacaagtacgcggccagcagctacctgagcctgacgcccgagc-
agtgga
ggtcccgcagaagctacagctgccaggtcatgcacgaagggagcaccgtggagaagacggtggcccctgcagaa-
tgttca
taggttcccagccccgaccccacccaaaggggcctggagctgcaggatcccaggggaagggtctctctctgcat-
cccaag
ccatccagcccttctccctgtacccagtaaaccctaaataaataccctctttgtcaaccagaaa
SEQ ID NO: 14 Human .lamda.5 amino acid sequence (GenBank Accession
No = NP_064455)
mrpgtgqggleapgepgpnlrqrwpllllglavvthgllrptaasqsralgpgapggssrsslrsrwgrfllqr-
gswtgp
rcwprgfqskhnsythvfgsgtqltvlsqpkatpsytlfppsseelqankatlyclmndfypgiltytwkadgt-
pitqgv emttpskqsnnkyaassylsltpeqwrsrrsyscqvmhegstvektvapaecs SEQ ID
NO: 15 Mouse .lamda.5nucleotide sequence (GenBank Accession No =
AC_000038)
ctggaatagcttttggccaccagaggaggaacaatccttttgccgggagatctacactgcaagtgaggctagag-
ttgact
ttggacttgagggtcaatgaagctcagagtaggacagactctgggcactatccccaggcagtgtgaagttctcc-
tcctgc
tgctgctgttgggtctagtggatggtgtccaccacatactttccccaagctcagcagaaaggagcagagctgtg-
ggccct
ggagcttcagtgggaagcaacaggcctagcctatgggcccttcccggcaggtaagagacttgctttttggggaa-
ggtacg
cgtgtaggtccacggactagaggctagaatgagtgactgggaaggaaggtggctattgaggccatgggtgtgag-
aaggaa
ggatctgcctaagaggagggggctgtgcaaatgctagcttaaacttggtacctcgatcattgcaaggccagtgt-
tctacc
aatgaaccacatccatagcccacctccattttccatttattttgagaagaggtcttgctaggtttcccaggctg-
atctta
ctctctgtagcctatgcaagatttgaacgtcctatagctttcctagatccttcctccttcctaagtcctcttta-
gtagct
agaattaagactgtggtggcgcgtttgtttttgttttttgttttttgtttttttgtgtgtgtgtgtgtgtgtgt-
catggt
cctagttcatttagaattaaatgtgtgtgtttatcgtagtcaggtagttgcagttctagaagtttattcttagg-
taatta
ttaaaacatccattaaatattgtgagggtgtcttgggttgggaggaggagacaccatggccatggagatcaccc-
agtcaa
gaagaccttgcctgtaaagcatgaggacttaattcagactctcagcaaccattcatctactatcaagatgtttt-
tactca
gataaatagaaaaaaaaaaaaaaaaggtttggtgtggtggcacaccttttatatcccagcagttgggaggcaga-
ggcagg
cagatctttgtgagtttgaggccagcctggtctacatagtagtctcatgatagaaataaaaacaaaagaatcct-
tgcaat
atagtgtgcatgggtcctgggaggaagcatagggccagtaggaactgatgcacacacgcatgtatgcacacacg-
cacaag
cacatatgcacacacaaatattcaccagagattcctggttccaccacacccaccagagaagatataccacccag-
gaattt
ctgagaatctgctgggcctgatattgccatcaacactgaaaaaattcagagatggaagtaagagatggatagat-
ggactt
gtcgggatactggctgctcatctattttctgccaaggacatagtttatttcctgaagttctgtgtctgactcac-
ccaaca
ggctcctgttccagatcatcccacggggagcaggtcccaggtgctcgccccataggcttccatctaagccccag-
ttttgg
tatgtctttggtggtgggacccagctcacaatcctaggtaagtggttctcatggtctcatgatccagctggctc-
agggaa
gtccatttttgctctggggaattcttactatctgcctttcctagccttgcagtctgaactgtaaaggcagtagt-
aattct
aaggtaaatcacagggaaaggccctaacagcttcatctactcttctgaggcagatgcccaaaaagagatcaagg-
aatgag
atttttcaggccatagagaccactacacctcagcatctaaaccgaggcccagatgcccatccagactaagaaga-
ccacat
agtaggtgcagggacatggctggtgccatgaaccccaccttcaaagattcaggccaccctagatagaaaaccac-
agaggc
tgagagagaaatttggttcaatttaatcttctgctggcccatgaggtcacagagacacacaaaaggctcagagt-
gatcag
gttactagaaccaggtcctcccaggatgattactagaaaagaaatgtagactgtctattgttcctgagggctgg-
agcctg
ttgtctaacttgtccatcttcctcaaatatccttagacttagatgaggaatgaaggagcaaatggggccaagtg-
aaatca
ggagtaaccagagacttcctggatggtcaggggtttgctatccttcctagtctgggagatggagcctcaggaac-
acagcc
agtataggtcttgtgattactgtggacaaagcagtaggtccttggaggagttggaggatttttctggatggaat-
ctaatc
ctcggtgagataactaaatggaatctggagcacaggccccgaagcccttatacagcaggcacacctcaagacca-
actctc
caggaccagtcttgcagaataaatgagcagcaattctcagaggagtctctgagcactggagaagcaattcaggt-
tgggga
gctgccctctgcctcaccagaaggccagggtcagatcccaattcactaccaggaggcctgggttagatcccaaa-
tcaggt
tccagcttcaaggggctagagaattcagctggtcttagtctcagcgggggaactgagattgcaagggtctgggt-
ctgggt
cattttatctggaagaggaacatgttctaatgggatgctaggctgtctgctctccaggggactcaagtggtcag-
aggaga
agaaggaagcatccctggatggaagactgatgctgtagtgaatggccacagagctcctgataagagaaggacgc-
ttcctt
atcacgtgggctctcctatgctaactcttatctccttctctatctgcgcaggtcagcccaagtctgaccccttg-
gtcact
ctgttcctgccttccttaaagaatcttcaggccaacaaggccacactagtgtgtttggtgagcgaattctaccc-
aggtac
tttggtggtggactggaaggtagatggggtccctgtcactcagggtgtagagacaacccaaccctccaaacaga-
ccaaca
acaaatacatggtcagcagctacctgacactgatatctgaccagtggatgcctcacagtagatacagctgccgg-
gtcact
catgaaggaaacactgtggagaagagtgtgtcacctgctgagtgttcttagaccacaatcctccctgaagcctc-
aggggc
ctggatctgaagtgccagaaaaagttgttttttgttttgttttttgttttttttcccattaaccatctcactgt-
ctttcc tgtgcctaatactcaataaatatcttaccaccaac SEQ ID NO: 16 Mouse
.lamda.5amino acid sequence (GenBank Accession No = NP_001177254)
mklrygqtlgtiprqcevlllllllglvdgvhhilspssaersravgpgasvgsnrpslwalpgrllfqiiprg-
agprcs
phrlpskpqfwyvfgggtqltilgqpksdplvtlflpslknlqankatlvclvsefypgtlvvdwkvdgvpvtq-
gvettq pskqtnnkymvssyltlisdqwmphsryscrvthegntveksyspaecs SEQ ID NO:
17 Rat .lamda.5nucleotide sequence (GenBank Accession No =
NC_005110)
atgaagctcagggcaggacagacactgggcactatccccaggcaatgtgaaattctccttctgttgctgctgtt-
gggcct
ggtggatggtgtccaccatatactttccccaagctcagcacaaaggggcagagctgtgggccctggagcctcag-
tgggaa
gcagcaggtctagcctgtggacccttccaggcaggtaagagactttcttataggggaatgtatgtgtgtgggtc-
catgga
ctggaggctgaaatgggtgactgggaaggaaggtaaccattgaggccataggtgtgagaaggaaggatctgcct-
aagagg
agggggctgggcaaatgctagcttaaacttagtacctaactcatgcaaggccagtattctatcaatgagccata-
tccata
gcccacctcccttttccatttatttagagaagagggcttgcctgattgcctaggctgatcttactttctgtagc-
ctatgc
aagatttgacctcctagatccttcctccttcctaagtcctctttagtagctggaattaaggctggtaccaggtt-
atttta
gtgtgtcatggtcctagttcattcagaattgtgtgtgctcatcttagtcaaatagttgcagttttagaagttta-
ttctta
ggcaattatcaaaacatccattaaatattctaagagtgtcttgggctgggaagagtagacactggggacatgga-
gaccac
ccagtgaagaagactttgactgtcaagcatgaggacctagttcagactctcagcactcatgcatctgctatcaa-
gataca
atcacatgtttttttactcagataaatagaaaaaaattaaggtttggtgtggtggcacatcccttatatcccag-
cagttg
gcaggcagaggcagatagacctttgtgagtttgaggccagtctggtttacatagtggcctcatgacagaaataa-
aacaaa
agaattctcacaaaatatagtgtgcatgggtcctgggatgaagcacaggaccaggaggaatacacacacacaca-
cacaca
cacacacacacacacacacacacacacacaaatacacatcagagattcctggttccaccacactcaccagagaa-
gatata
ccacccagaacttttctgagaatcagttgggcctggtgttgccatcaactggatggaaataggagatggataga-
tggact
tattttctgccaaggacacagttcatttcctgaagtccggtgcctacctcacccaacaggttcctgttccagat-
catccc
acggggagcaggtcccaggtgctggccccataggcttccatccaagtcccagttatggtacgtctttggtagtg-
ggaccc
agctcacaatcctaggtaagcgattcccatggtctcatgatccagctgtcttagggaagtccctttttcctctg-
gggagt
tcttctcacctgcctttcctagtcttgtagtctgaatggtacctttttctgtgagtgaggggaaggcaagtagt-
tctaag
gtaaaccacaggaaaggtcccaatagcttcagctactcttccgaggcagatgtccaaaaagggatcaggggctg-
aggttt
tcaggctgtagagaccactgcacttcagcatctaaactgaggcccagatgcccatccagattaagaaggccaca-
tagtag
gtgcagggatatgactggtgccatgattcctgcctttaaagattcaggtaaccctagatagaaaaccacagagg-
ctgaga
gaagaatctggcccagtttaatcttctgctggccaatgaggtcatagagacacagaaaaggcttagagtgacca-
ggtaac
tagaaccagctcctcccaggatgattactagaaaaaaaatgtagactgtctattgttcctggggtttctcaggc-
ctggag
cctgttgtctaacttgtccatctccctcaaatgtccttagagttagatgaggaatgagggagcaaatggcgcca-
agtgaa
atcaggagtcaccagagacttcctgggtggtcaggggtttgctatccttcctagtctgggagacggagccccag-
gagcac
agtcagagtaggtcttgtgattactgtggacaaagcatcaggcccttggaggagttcctaggacttttcaggat-
ggaatc
taatccttggtgagataactaaatagaatctggagcacaggcccgggagcccttatacagcaggcacacctcaa-
gaccaa
ctccccaggaccagtcttgcagaataaatgagcagtaattctcagaggaggctctgacactggagaagcaatgg-
gggttg
gggagctgctccctgaactcccccacccccataggaggccagcgtcagatcccaattcagattccagctcctag-
tggcta
gagagtacagatggccttggtcttagtggggaaactgagattgcaaggggcagggtgtgggtcatttcacctgg-
aagagg
aacacggtctaatggggcaccaggctgtctgctctccaggggactcaggtgggcagaggaaaagaaggaagcat-
ccttga
tggaacactctgagctgtagtgaatggctacagggctcctgataagaggaggatgcttccctgtcatgtgggct-
ctccta
tgccaactcttatccccttctctatctgcacagggcagcccaagtctgaccccttggtcactctgttcctgcct-
tcctta
aagaatctccaggttaagaaggcgacactagtgtgtctggtgagcgaattctacccaggtactttggtggtgga-
ctggaa
ggtagatgggatccctgtcactcagggtgtggagacaacccaaccctccaaacagaccaacaacaagtacgtgg-
ccagca
gctacctgacactgatgtctgaccaatggatgcctcacagtagatacacctgccaggtcactcatgaaggaaac-
actgtg gagaagagtgtgtcacctgctgaatgttcttag SEQ ID NO: 18 Rat
.lamda.5amino acid sequence (GenBank Accession No = NP_001177270)
mklragqtlgtiprqceilllllllglvdgvhhilspssaqrgravgpgasvgssrsslwtlpgrflfqiiprg-
agprcw
phrlpsksqlwyvfgsgtqltilgqpksdplvtlflpslknlqvkkatlvclvsefypgtlvvdwkvdgipvtq-
gvettq pskqtnnkyvassyltlmsdqwmphsrytcqythegntveksyspaecs SEQ ID NO:
19 5' homology arm
acctggccaaactgagcatgacctttgacctagccagctcttaaacttgttctgagatcacaaaccagccagac-
caaatt SEQ ID NO: 20 3' homology arm
tcctcccagaatgcttccctgggtcaaacccagagccacaaaggcttccattagaccattctggtaagtgacag-
agtcac SEQ ID NO: 21 5' homology arm
AAAAAAAAAAAAGCCCAGCTAGCTTAGTTGGTAGAGCATGAGACTCTTAATCTCAGAGTCATGGGTTCAGGC
CTCATGTTTGGCACCATCTATAGTGTGCAGTTATAAATCAAACAGTTCACGATGTGGCTGGCTAGGCACTGGC
AACTGCAGTCTCACCTGCTCCCATGGTTCCCAGTTCCCACAGCTAGTTTGCTGCCAGGCTGTTCACACTTCCCA
GGTCATCTACCCACTGTGGCAAGCCTGCAGAAAGCCTGCTATTGCTAGCTCAGATTCCCTTAGCCCTATAAAAT
GATAACACCACAGACTTTTACTATACCATCCAGATTTATAACAGTAATTCTCCAACCC SEQ ID
NO: 22 3' homology arm
CAGGAGTACACCAAAATGTCTAGCCAAAATTTTTATATATGATCACTTAAATAAGACTCCTTAACATAAACCTA
CATGATATACCAAGTCTTTTCTGCCAAGGCTCTGACACTATAGTTTGTCCTATTCTGGAGTTAGGTAAGCAAAG
GGCTATTTAGGTGTGGATTGCAAAGAGAGAATAGCAAGACAACCTGCCCATTCTTTGCCACACCTCACTAATC
AGTGTCCCTTGGAAAGCACTGTAAATATGGAGGTTTCTTTTTGTATTATGTAGTAGTGGATTTAACTTGAGGAG
CCCCAAAAGGGGTCAGCAAAGCATGGGAAATCTAAGAATTTAACACTTCAGTGACTTTTAATCACCTACAGAT
CCAGGAAAATAAGCCTGTCTCTT
Sequence CWU 1
1
261727DNAHomo sapiens 1gagtcagagc tctgcatgtc tgcaccatgt cctgggctcc
tgtcctgctc atgctgtttg 60tctactgcac aggtgaggga acccccagat cccaaagact
cctgcccctt ccttcatcct 120gccctgcccc cacggcccac atgcatctgt
gtcaccaggt tgtggtcctc agccggtgct 180gcatcagccg ccggccatgt
cctcggccct tggaaccaca atccgcctca cctgcaccct 240gaggaacgac
catgacatcg gtgtgtacag cgtctactgg taccagcaga ggccgggcca
300ccctcccagg ttcctgctga gatatttctc acaatcagac aagagccagg
gcccccaggt 360cccccctcgc ttctctggat ccaaagatgt ggccaggaac
agggggtatt tgagcatctc 420tgagctgcag cctgaggacg aggctatgta
ttactgtgct atgggggccc gcagctcgga 480gaaggaggag agggagaggg
agtgggagga agaaatggaa cccactgcag ccaggacacg 540tgtcccttga
actgaagaca gcagaggcac gcatcccctt ggagagactg tcatggaaga
600gggtggagcc gccgcccgaa gcgccgagga ggctgagcca ctcagcatct
cctggtcctg 660cagtgttgct gtaaatcccc attggagact gcattaggga
attaaagctg cttgtcactt 720tttgctg 7272145PRThomo sapiens 2Met Ser
Trp Ala Pro Val Leu Leu Met Leu Phe Val Tyr Cys Thr Gly 1 5 10 15
Cys Gly Pro Gln Pro Val Leu His Gln Pro Pro Ala Met Ser Ser Ala 20
25 30 Leu Gly Thr Thr Ile Arg Leu Thr Cys Thr Leu Arg Asn Asp His
Asp 35 40 45 Ile Gly Val Tyr Ser Val Tyr Trp Tyr Gln Gln Arg Pro
Gly His Pro 50 55 60 Pro Arg Phe Leu Leu Arg Tyr Phe Ser Gln Ser
Asp Lys Ser Gln Gly 65 70 75 80 Pro Gln Val Pro Pro Arg Phe Ser Gly
Ser Lys Asp Val Ala Arg Asn 85 90 95 Arg Gly Tyr Leu Ser Ile Ser
Glu Leu Gln Pro Glu Asp Glu Ala Met 100 105 110 Tyr Tyr Cys Ala Met
Gly Ala Arg Ser Ser Glu Lys Glu Glu Arg Glu 115 120 125 Arg Glu Trp
Glu Glu Glu Met Glu Pro Thr Ala Ala Arg Thr Arg Val 130 135 140 Pro
145 31701DNAhomo sapiens 3cttcccagcc ctgtgcccca aagcacctgg
agcatatagc cttgcagaac ttctacttgc 60ctgcctccct gcctctggcc atggcctgcc
ggtgcctcag cttccttctg atggggacct 120tcctgtcagg tgaatctttc
ctgggcctca gtcacctggg tgtggggtgg ggaacagtac 180tggccccaga
aggcccctgc aaggaggcaa atcgatgggg acagtagggc aggtcctggg
240aggggtattt tttttttttt tgagacggag ttttgctctt gttgcccagg
ctggagtgca 300acggtgcaat ctcggctcac tgcacctctg cctcccaggt
tcaagcgatt cttctgcctc 360agcgtcctga gtagctggga ttacaggcat
gcgccaccac gcctggctaa ttttgtattt 420ttagtagaga caaggtttct
tcatgttggt caggctggtc tcaaactcct gacctcaggt 480gatccgccca
cctcagcttc ccaaagtgct aggattacag gcttgagcca ctgcacctgg
540ctgggaggcg tattcaggta gaggggtgac ctggcttcag acagctctgc
ccttgacctg 600gggcaaatca cttccctgtg tgggccttgg ttttctcatt
cgtgaatgac cagatcacta 660gagccctgga ctctgacttt gggtctcctt
cttagttttt cacaggggaa gctattgtgg 720gttggtccct accccacagg
gcctgaggca atctaacctc cctgagaggg tccctgcagc 780cagttgcctg
aggctgagtt gatgtgtggg acagcccagg aggttcctgg gggtggttag
840tctgtattca gggtttggaa gagctgaagt gaagtgggcg gggaagtggg
ggagaggggt 900gcagttctgc agagaaacgt gggtgggtag cagagggacc
tagaggctgc tagtccaacc 960ttctgagctc tgggccttta actgaacaca
gatccttgag gatatggcac taatggagat 1020ttgggggcta actccaaacc
cctcactcac aaagggagat ggaggtccag atagggcacc 1080ctaagtcaca
cagaaccagg cctcctgcac cccgttcatt gctaatccca tagcactggg
1140ctatgagccc tttgggactg ggagtctcca tggagtccaa ccaagccttc
acagggcagg 1200ggtgggaggg aaggggctca ggctgagtgg gtttgtgtct
cgcagtttcc cagacagtcc 1260tggcccagct ggatgcactg ctggtcttcc
caggccaagt ggctcaactc tcctgcacgc 1320tcagccccca gcacgtcacc
atcagggact acggtgtgtc ctggtaccag cagcgggcag 1380gcagtgcccc
tcgatatctc ctctactacc gctcggagga ggatcaccac cggcctgctg
1440acatccccga tcgattctcg gcagccaagg atgaggccca caatgcctgt
gtcctcacca 1500ttagtcccgt gcagcctgaa gacgacgcgg attactactg
ctctgttggc tacggcttta 1560gtccctaggg gtggggtgtg agatgggtgc
ctcccctctg cctcccattt ctgcccctga 1620ccttgggtcc cttttaaact
ttctctgagc cttgcttccc ctctgtaaaa tgggttaata 1680atattcaaca
tgtcaacaac a 17014123PRThomo sapiens 4Met Ala Cys Arg Cys Leu Ser
Phe Leu Leu Met Gly Thr Phe Leu Ser 1 5 10 15 Val Ser Gln Thr Val
Leu Ala Gln Leu Asp Ala Leu Leu Val Phe Pro 20 25 30 Gly Gln Val
Ala Gln Leu Ser Cys Thr Leu Ser Pro Gln His Val Thr 35 40 45 Ile
Arg Asp Tyr Gly Val Ser Trp Tyr Gln Gln Arg Ala Gly Ser Ala 50 55
60 Pro Arg Tyr Leu Leu Tyr Tyr Arg Ser Glu Glu Asp His His Arg Pro
65 70 75 80 Ala Asp Ile Pro Asp Arg Phe Ser Ala Ala Lys Asp Glu Ala
His Asn 85 90 95 Ala Cys Val Leu Thr Ile Ser Pro Val Gln Pro Glu
Asp Asp Ala Asp 100 105 110 Tyr Tyr Cys Ser Val Gly Tyr Gly Phe Ser
Pro 115 120 5855DNAMus musculus 5agagcccaga aagcctggga gggtggtgag
caggaaccag gggtgcagtg accctctccc 60caaagcaggg aggagagtgc ttcccagctg
gtcagggccc aggagcagtg gctgtagggg 120gcagggtgct gcaggtctgg
agccatggcc tggacgtctg tcctgctcat gctgctggcc 180tatctcacag
gtaaggaaac tcttggggcc cagggcttct ttgctcctcc tatggccttg
240ctctgcccca gtgatggaca tgcttctatc ttctcaggtt gtggccctca
gcccatggtg 300catcagccac cattagcatc ttcttccctt ggagccacca
tccgcctctc ctgtaccctg 360agcaacgacc ataacattgg catttacagc
atttactggt accagcagag gccgggccac 420cctcccaggt tcctgctgag
atacttctca cactcagaca agcaccaggg tcccgatatc 480ccacctcgct
tctccgggtc caaagatacg accaggaacc tggggtatct gagcatctct
540gaactgcagc ctgaggacga ggctgtgtat tactgtgccg tggggctccg
gagccaggaa 600aagaagagga tggagaggga gtgggaagga gaaaagtcgt
atacagattt gggatcttag 660gctctggaga cattcagacc ctgaactgaa
gacagagttt gctttgctcg gctagtctgg 720tatgggaagg aggggtagaa
cgtgaggttt tgcagagcct agaagatgga attatgcagc 780ttttccttgt
tctgcggtgt tgctatgagc ccccattgga ggctggattg tagaattaaa
840gctgttttta ctgaa 8556142PRTMus musculus 6Met Ala Trp Thr Ser Val
Leu Leu Met Leu Leu Ala Tyr Leu Thr Gly 1 5 10 15 Cys Gly Pro Gln
Pro Met Val His Gln Pro Pro Leu Ala Ser Ser Ser 20 25 30 Leu Gly
Ala Thr Ile Arg Leu Ser Cys Thr Leu Ser Asn Asp His Asn 35 40 45
Ile Gly Ile Tyr Ser Ile Tyr Trp Tyr Gln Gln Arg Pro Gly His Pro 50
55 60 Pro Arg Phe Leu Leu Arg Tyr Phe Ser His Ser Asp Lys His Gln
Gly 65 70 75 80 Pro Asp Ile Pro Pro Arg Phe Ser Gly Ser Lys Asp Thr
Thr Arg Asn 85 90 95 Leu Gly Tyr Leu Ser Ile Ser Glu Leu Gln Pro
Glu Asp Glu Ala Val 100 105 110 Tyr Tyr Cys Ala Val Gly Leu Arg Ser
Gln Glu Lys Lys Arg Met Glu 115 120 125 Arg Glu Trp Glu Gly Glu Lys
Ser Tyr Thr Asp Leu Gly Ser 130 135 140 7516DNAMus musculus
7atggcctgga cgtctgtcct gctcatgctg ctggcccacc tcacaggtaa gggaactctt
60ggggtccagg gcttccttgc tcctcctgtg gccttgctct gccccagtga tggacatgct
120tctatcttct caggttgtgg ccctcagccc atggtgcatc agccaccatc
agcatcttct 180tcccttggag ccaccatccg cctctcctgt accctgagca
acgaccataa cattggcatt 240tacagcattt actggtacca gcagaggccg
ggccaccctc ccaggttcct gctgagatac 300ttctcacact cagacaagca
ccagggtccc gatatcccac ctcgcttctc cgggtccaaa 360gatacggcca
ggaacctggg gtatctgagc atctctgaac tgcagcctga ggacgaggct
420gtgtattact gcgctgtggg gctccggagc cacgaaaaga agagaatgga
gagagagtgg 480gaaggagaaa agtcgtatac agatttggga tcttag 5168142PRTMus
musculus 8Met Ala Trp Thr Ser Val Leu Leu Met Leu Leu Ala His Leu
Thr Gly 1 5 10 15 Cys Gly Pro Gln Pro Met Val His Gln Pro Pro Ser
Ala Ser Ser Ser 20 25 30 Leu Gly Ala Thr Ile Arg Leu Ser Cys Thr
Leu Ser Asn Asp His Asn 35 40 45 Ile Gly Ile Tyr Ser Ile Tyr Trp
Tyr Gln Gln Arg Pro Gly His Pro 50 55 60 Pro Arg Phe Leu Leu Arg
Tyr Phe Ser His Ser Asp Lys His Gln Gly 65 70 75 80 Pro Asp Ile Pro
Pro Arg Phe Ser Gly Ser Lys Asp Thr Ala Arg Asn 85 90 95 Leu Gly
Tyr Leu Ser Ile Ser Glu Leu Gln Pro Glu Asp Glu Ala Val 100 105 110
Tyr Tyr Cys Ala Val Gly Leu Arg Ser His Glu Lys Lys Arg Met Glu 115
120 125 Arg Glu Trp Glu Gly Glu Lys Ser Tyr Thr Asp Leu Gly Ser 130
135 140 9878DNARattus norvegicus 9ccagaaagcc tgggagggtg gtgagcagga
accagtggtg caaagcaggg gcgagactgc 60ttcctagctg gtcagggcac cggagcagtg
gctgtagggg tcagggtgct gcaggtctgg 120aaccatggcc tggacgtctg
ccctgctcat actgctggcc catctcacag gtacgggaac 180tcttggggcc
cagagcctcc ttgctcctcc tcttgccttg ctctgccgca gtgatgggca
240cgcttctatt ttctcaggtt gtggccctca gcccgtgctg catcagccac
catcggcctc 300ttccttcctt ggaacctcca tccgcctcac ctgtgccctg
agcagcaacc ataacattgg 360catttacagc atttactggt accagcagag
gccgggccac cctcccacgt tcctgctgag 420attcttctca cactcagaca
agctccaggg tcccaagatc ccccctcgct tctccggatc 480caaagataca
gccaggaacc tggggtacct gagcatctct gacctgcagc cagaggacga
540ggctgtgtat tactgcgccg tggggcttcg gagctgggaa aaggagaaga
ggatggagag 600ggagtgggaa gaagaaaagt agcggacaga ttcgggatct
taggctctgg agacattcag 660acctagaacc gaagacggag tttgctttgc
tcggctaggc tggtttgggg aggaggggta 720gaacaccggg cttcgcagag
ccaggaaggt ggagccagcc gcttttcctt gtattgcagt 780gttgctatgc
gccccatcgg aggctggatt gtagaattaa agctgttttt tttttttttg
840ttttgttttt ttgttttttg tttctttttt cttaactg 87810136PRTRattus
norvegicus 10Met Ala Trp Thr Ser Ala Leu Leu Ile Leu Leu Ala His
Leu Thr Gly 1 5 10 15 Cys Gly Pro Gln Pro Val Leu His Gln Pro Pro
Ser Ala Ser Ser Phe 20 25 30 Leu Gly Thr Ser Ile Arg Leu Thr Cys
Ala Leu Ser Ser Asn His Asn 35 40 45 Ile Gly Ile Tyr Ser Ile Tyr
Trp Tyr Gln Gln Arg Pro Gly His Pro 50 55 60 Pro Thr Phe Leu Leu
Arg Phe Phe Ser His Ser Asp Lys Leu Gln Gly 65 70 75 80 Pro Lys Ile
Pro Pro Arg Phe Ser Gly Ser Lys Asp Thr Ala Arg Asn 85 90 95 Leu
Gly Tyr Leu Ser Ile Ser Asp Leu Gln Pro Glu Asp Glu Ala Val 100 105
110 Tyr Tyr Cys Ala Val Gly Leu Arg Ser Trp Glu Lys Glu Lys Arg Met
115 120 125 Glu Arg Glu Trp Glu Glu Glu Lys 130 135 11711DNARattus
norvegicus 11atggcctgga cgtctgccct gctcatactg ctggcccatc tcacaggtac
gggaactctt 60ggggcccaga gcctccttgc tcctcctctt gccttgctct gccgcagtga
tgggcacgct 120tctattttct caggttgtgg ccctcagccc gtgctgcatc
agccaccatc ggcctcttcc 180ttccttggaa cctccatccg cctcacctgt
gccctgagca gcaaccataa cattggcatt 240tacagcattt actggtacca
gcagaggccg ggccaccctc ccacgttcct gctgagattc 300ttctcacact
cagacaagct ccagggtccc aagatccccc ctcgcttctc cggatccaaa
360gatatagcca ggaacctggg gtacctgagc atctctgacc tgcagccaga
ggacgaggct 420gtgtattact gcgccgtggg gcttcggagc tgggaaaagg
agaagaggat ggagagggag 480tgggaagaag aaaagtagcg gacagattcg
ggatcttagg ctctggagac attcagacct 540agaaccgaag acggagtttg
ctttgctcgg ctaggctggt ttggggagga ggggtagaac 600accgggcttc
gcagagccag gaaggtggag ccagccgctt ttccttgtat tgcagtgttg
660ctatgcgccc catcggaggc tggattgtag aattaaagct gttttttact g
71112136PRTRattus norvegicus 12Met Ala Trp Thr Ser Ala Leu Leu Ile
Leu Leu Ala His Leu Thr Gly 1 5 10 15 Cys Gly Pro Gln Pro Val Leu
His Gln Pro Pro Ser Ala Ser Ser Phe 20 25 30 Leu Gly Thr Ser Ile
Arg Leu Thr Cys Ala Leu Ser Ser Asn His Asn 35 40 45 Ile Gly Ile
Tyr Ser Ile Tyr Trp Tyr Gln Gln Arg Pro Gly His Pro 50 55 60 Pro
Thr Phe Leu Leu Arg Phe Phe Ser His Ser Asp Lys Leu Gln Gly 65 70
75 80 Pro Lys Ile Pro Pro Arg Phe Ser Gly Ser Lys Asp Ile Ala Arg
Asn 85 90 95 Leu Gly Tyr Leu Ser Ile Ser Asp Leu Gln Pro Glu Asp
Glu Ala Val 100 105 110 Tyr Tyr Cys Ala Val Gly Leu Arg Ser Trp Glu
Lys Glu Lys Arg Met 115 120 125 Glu Arg Glu Trp Glu Glu Glu Lys 130
135 137184DNAHomo sapiens 13ggccacatgg actggggtgc aatgggacag
ctgctgccag cgagagggac cagggcacca 60ctctctaggg agcccacact gcaagtcagg
ccacaaggac ctctgaccct gagggccgat 120gaggccaggg acaggccagg
ggggccttga ggcccctggt gagccaggcc ccaacctcag 180gcagcgctgg
cccctgctgc tgctgggtct ggccgtggta acccatggcc tgctgcgccc
240aacagctgca tcgcagagca gggccctggg ccctggagcc cctggaggaa
gcagccggtc 300cagcctgagg agccggtggg gcaggtaagg ggtgagagat
tccaggggat gtgggggtct 360gggtggcaga ggcgggaaag gatgaccaag
gggagacgag ccagaggggt gaggaggaag 420gttaatccct ggaggggagc
cacagacact gactttaact aaagtgtcaa gattttgtcc 480atctttgaat
taatttttat tgcttaatgt catattaaaa tattatttat cttgattcct
540gagatttctt cccccactta catttggcac caaggccaat gtctccctca
cctcccccta 600gtccttgggg tagggcagga ctggaggcag gggcaggacg
tccacaggag tggtggccgc 660tatccctgaa ggatgcccag gcctctccct
cctcctcctc ccactcctcc tcccccccct 720cctcttttcc ccttggccta
tgtcacctgt ccactcccac cctcactggg caggggccac 780tccctggagc
tccagctaag gtgtgagggg cctttcctgg agtccctggg tcactagacc
840tcagccagca tcgcctcctg aaaccagccc ctaggagaca caagcttatc
cagggtgcaa 900gtgcctccaa agaagaagcc caggagaggc tctagggagg
ccacaactcc ctgtgtgacc 960tcagccattg ccaccactct gcgtgtggtg
ggaggtcccc agacaaagca ccaagcatcg 1020gggtccattt atgagcattt
gggacacaac agcctgttca ctggtgcatg ttatacccac 1080aggcgataat
catttcaggg gcagaacctc cctctcggtg gccccatagg caggtcctgc
1140tgtgatcccc tttgtgcaga cggggataga gcccggagag gtgaggtgac
ccgtccgagt 1200cactcagctc atgggcacag attctaaggc ccaagctatc
ccctctagct ctcccctgtc 1260ccatcctcta agctgatcga gcggacacgt
gcatctctgg gacctgagtt tccctttttc 1320tctctttttt ttctttttca
aataaagttt cacagagttt cactcttgtc gcccagtctg 1380gagtgcaatg
gcgagatctt ggctcattga aacctccgtc tcccaggttc aagacattct
1440cctgcctcag cttccggagt agctgggatt acaggcatct gccaccacac
ctggctaatt 1500ttgtgtattt ttttttagta aagacagagt ttcaccatgt
tggccaggct ggtctcaaac 1560tcctgacctc aggtgatcca cccacctcag
cctcccaaag tgctgggatt acaggcatga 1620gacaccacac cgggcctgag
tttccccttc tgcaatctga ggggccctga ctggtgaggg 1680ccttcagcgt
cccacccacc cagaggatgc tggggtggct gtggtgagag ctccagcagt
1740ggcagccgac ctgacccaca ccaggagccc ggccatggag gcggggtcag
catggtggca 1800ggccgggacc gggtgtcagt gtcctgcacg gacttctgag
caaggagtcc ccatcagggt 1860caggctctgt gctggggctg aggtcccaga
ggatctagat ttgccccaat tcaagtccac 1920aaggagcggg ggccgggtga
ggagacagcc acatgcaggg tgatgcctac agaacagaga 1980ctgggatggg
gaaggcccga ggggtctcca caagggacgg gtgacaggtg gagggagaca
2040cagataataa aaaatggtat tatgttgggg ggctattaat gtaagttttt
atattagaat 2100ctttagaaat cttatagaaa tactatgggc cgggtgctgt
gtctcatgcc tgtaatccca 2160gcactttagg acgccaagat gggcagatca
cgaggtcagg agattgagac catcctggcc 2220aacatggcaa aactccgtct
ctactaaaaa tacaaaaact agctgggcgt ggtggcgcga 2280gcctatagtc
ccagctactc gggaggggag gcaggagaat cgcttgaatc agggaggtgg
2340aggttgcagt gagctgagat tgcaccgctg cactccagcc tggacgacag
aacgagactc 2400ccactcaaaa aaaaaaaaag gtattatgct gggggggata
tgaatatgag tttttataat 2460ctttagaaat actatgggcc aggtgcagtg
gctcatgcct gtaatcccac aactttggga 2520ggctgaggcg ggattgtttg
agcccaggag tttgagatca gcctgagcaa catagcaaga 2580ccccatttct
acaaaacata taaaaactag ctagtcatgg tggcacttgc ctgtggtccc
2640agctacttag gaggctggtg agaggattgc ttaagcctcg gaggttgagg
atgcagtaag 2700ctgagatccc accactgcac tccagcctgg gtgacagaag
gagaccctgt ctcaaaaaaa 2760aaaaaaaaaa aaaaagactg attattcctg
tagaattctg gtaaatatct cctatcaaat 2820aaatgacttt tctattcata
gcttattaaa agatattttc attgttttta agaaataggt 2880tgtgtatcac
tttttatatt tagttgtaaa tttatttgtt ttatttattt ttttagagat
2940gggggtctca ctatgttgcc tgggctggcc tccaactgct gggctcaagc
aatatccctg 3000cctcagcgtc cccagtagct gggactacaa gcatgcgcta
ccacaccggc ataatttttt 3060gtagagatga ggtttcgcca tgttgcctgg
gctggtcttg aacccctggg ctcaagccat 3120ccacccgcct cggcctccta
aagtgctgag attacagacg tgagccaccc tacctagcct 3180gtactatttt
taataggtct taataggttt tgaatgttaa ttatttttaa attaatttca
3240aaaatcttct acaacatgga tgaaacctga agacattata cttagtgaaa
taagccagac 3300acaaaaggac aaatgtcatt tgaatccact tctatgaggt
acctagaata ggcaaattca 3360cttggacaaa aagtagattt gaggttagca
gggtgagggg gagggaagaa tgggggactg 3420tagttaacgg gtttagagtt
tctgtttggg aagatgaaag agttctggag atggatggtg 3480gtgaaggttg
cccaacggtg tgaatgtact tagtgccacg gagctgtacg tttaaaaata
3540gttaaagtgg aaatattgat gctatgtata aaaatggagc ggggtgtggt
ggctcacacc 3600tataatccca gcactttgag aggccaaggt gggcagatca
cctgaggtcg ggagttcgag 3660accagcctga caaacatgga gaaacaccgt
ctctactgaa aatacaaaaa attagccaag 3720tgtgctggca catgcctgta
atcccagcta ctcgggaggc tgaagcagga gaatcgcttg 3780aacccaggat
gtggaggttg cggtgagcca
aggtggcacc attgcactcc agcctgggcg 3840acaagggtga aattccattt
caaaaaaata aaaggaaatg ggactgtaca tagcaggaga 3900gagagggaga
gatcaatatg acacttcttt tttttttttt ttttttttgg gacagtcttg
3960ctctgttgcc aggctgcact ccagcctggg caacagagcg agactctgtc
tcaaaaaaaa 4020aaagaatgtc tagatgcagt agctaagttc gcagaagcca
tttcagtgtg ggaggcgagg 4080tgactgagtc cagggactcc aggtttctgg
ctgaggggtt gagaccgccc atggtcattg 4140tgatgagatg aagacagaaa
atgagctggg ctgggggaag gtggtcatct cctctggacg 4200tgattagttt
gaggctcctg ttgggtagcc cactgggcaa ggtcagtagg caattgagga
4260gctgagaggg tttggagctg ggatagactc cagcctcacc atgtgggcaa
tagtgggggt 4320cacagagtgt gaaaatggct aagaaagagg tctgggtggg
gtctggggag tcagcagcca 4380ggcatgggcc atggagaaac agatgccagg
ggaagaggaa aggggagtct cagaccccaa 4440ggggaaaaga gtcactggaa
agaggggcca gccctgtgtc gcatccagcg gagacaccag 4500gtacagcaga
aggaccttgg acatgaccat gaggagggcc ttgttgacca tggcctggga
4560gagatggggg tgagagcctg ggggaccaca ccatgtcccc agcacacagt
gcctggtaga 4620caggatggat ttatggatgg acggacaggt agatggatgg
acgaatggac agatgataga 4680tggatgcaaa gacagatgaa tagatggaca
gatgcataga tggacagatg gacagatgga 4740tggacggacg gatggaatga
atgatcagaa aaggcttcat gaacaaagtg agactgagct 4800gcatctccat
gggtagatat aaaagcagag gactctcctc ttgagtcagg aatgacccaa
4860tgtcctggtc cagggaggaa gtcagcctcc ttgactgggg acacttgtgg
cagatttcag 4920aggcccttaa aatgaggcca agtgaggtgg acaggtccga
gccagctgag gactcctcag 4980ccacacggca cagctgcctg aggggatgtg
tcactcaggg agttgctggg acctactggg 5040cccagcgttg ccatcagcac
caacagtttc agagaggggg acacacgctg gggcagcacc 5100tgcctcagag
aagggacagg cacagagaca ctactggggg acactactgg gacactggcc
5160acccccctac cctgtgcctg ggtcacagcc tacacactgc agccctgtgc
ccctcactcc 5220cagcaggttc ctgctccagc gcggctcctg gactggcccc
aggtgctggc cccgggggtt 5280tcaatccaag cataactcag tgacgcatgt
gtttggcagc gggacccagc tcaccgtttt 5340aagtaagtgg ctctaacttc
ccaggctgtc ccaccctctc ctgtctctgg aaaatgtgtt 5400ttctctctct
ggggcttctt cccctctgcc ctcccagcct taagcactga cccctacctt
5460tgtccatggg gcctggagga gatgtgttag tctcagggta atggcaggaa
gggcccccac 5520agtgggagca gccgccttca ggttccaaca gcaggacaca
gcctggtccc agggcctggg 5580ctgggattgg gcggggtcag ggctcctccc
ctctcccagg gcagatgtct gagtgaggga 5640cagaggctgg ttctgatgag
gggccctgca gtggccttag agacagtccc tgggacccca 5700ggttctaggc
tgagggctgg atgcccatcc agcctgggag ggccacacgg gggcctgggg
5760acacaggggt cacccccagg ggagaccaat ggagggcaca gagagggctc
tgggtctagg 5820ctgcagctct gtggcctctg ctgggtcttc agggcatggg
gacacagagg aacggatgag 5880gtcccagagc ccagccctcc caggacagtc
accagaaagg agagggtctc ttagtgcaga 5940gatgtgcctg tccctggagc
cctgtcatct ctggggcctg gtgtctctct gttcatgggt 6000cgacctccca
ccttcatttg aggaagggca ccttagactc agaaggtgac tagcggggag
6060taaacgggag tgcagagaac tccatggctg ccaggtgaag tccaggggca
tcagaggctg 6120ctggggtggg catgggggct gcggtgcccc aaagtctggg
ggagcagccc caagaaccca 6180gccgatgtga agggtcctgt ggtcgggctg
gtggggacag gggcgacggc agagccccag 6240ggtgtgtctg ggtggagccc
acgcttcacc aggagagctg agtgggccag gctggggcac 6300agcctggtgc
cccaggggat gggaagctcc aggccatgcc aggcttgggt ctccccacat
6360cctgccagta tagttttgtg tgctgtgagg gagaccccta gattccaaac
tcagactcca 6420gaaaccagga aggagggagc acagcctgcc ctgggtgcac
acggggaaac cgaggctgca 6480gaggaaaggg ctgggccagg acacctggga
aaggtgactt gggaagggct cctaggaagg 6540cacagggctg tctgctctcc
agagggctcc agtggaaagg agggaatgag gagggaagga 6600gaggccctgg
gtggaccagg cggccacacc atgaaccctc ccagagactt tagacagaga
6660gaggcgctcc acaacacccc acactccctc tgccatctct caccccctcc
tctgtccaca 6720caggtcagcc caaggccacc ccctcggtca ctctgttccc
gccgtcctct gaggagctcc 6780aagccaacaa ggctacactg gtgtgtctca
tgaatgactt ttatccggga atcttgacgg 6840tgacctggaa ggcagatggt
acccccatca cccagggcgt ggagatgacc acgccctcca 6900aacagagcaa
caacaagtac gcggccagca gctacctgag cctgacgccc gagcagtgga
6960ggtcccgcag aagctacagc tgccaggtca tgcacgaagg gagcaccgtg
gagaagacgg 7020tggcccctgc agaatgttca taggttccca gccccgaccc
cacccaaagg ggcctggagc 7080tgcaggatcc caggggaagg gtctctctct
gcatcccaag ccatccagcc cttctccctg 7140tacccagtaa accctaaata
aataccctct ttgtcaacca gaaa 718414213PRTHomo sapiens 14Met Arg Pro
Gly Thr Gly Gln Gly Gly Leu Glu Ala Pro Gly Glu Pro 1 5 10 15 Gly
Pro Asn Leu Arg Gln Arg Trp Pro Leu Leu Leu Leu Gly Leu Ala 20 25
30 Val Val Thr His Gly Leu Leu Arg Pro Thr Ala Ala Ser Gln Ser Arg
35 40 45 Ala Leu Gly Pro Gly Ala Pro Gly Gly Ser Ser Arg Ser Ser
Leu Arg 50 55 60 Ser Arg Trp Gly Arg Phe Leu Leu Gln Arg Gly Ser
Trp Thr Gly Pro 65 70 75 80 Arg Cys Trp Pro Arg Gly Phe Gln Ser Lys
His Asn Ser Val Thr His 85 90 95 Val Phe Gly Ser Gly Thr Gln Leu
Thr Val Leu Ser Gln Pro Lys Ala 100 105 110 Thr Pro Ser Val Thr Leu
Phe Pro Pro Ser Ser Glu Glu Leu Gln Ala 115 120 125 Asn Lys Ala Thr
Leu Val Cys Leu Met Asn Asp Phe Tyr Pro Gly Ile 130 135 140 Leu Thr
Val Thr Trp Lys Ala Asp Gly Thr Pro Ile Thr Gln Gly Val 145 150 155
160 Glu Met Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala Ala Ser
165 170 175 Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Arg Ser Arg Arg
Ser Tyr 180 185 190 Ser Cys Gln Val Met His Glu Gly Ser Thr Val Glu
Lys Thr Val Ala 195 200 205 Pro Ala Glu Cys Ser 210 153315DNAMus
musculus 15ctggaatagc ttttggccac cagaggagga acaatccttt tgccgggaga
tctacactgc 60aagtgaggct agagttgact ttggacttga gggtcaatga agctcagagt
aggacagact 120ctgggcacta tccccaggca gtgtgaagtt ctcctcctgc
tgctgctgtt gggtctagtg 180gatggtgtcc accacatact ttccccaagc
tcagcagaaa ggagcagagc tgtgggccct 240ggagcttcag tgggaagcaa
caggcctagc ctatgggccc ttcccggcag gtaagagact 300tgctttttgg
ggaaggtacg cgtgtaggtc cacggactag aggctagaat gagtgactgg
360gaaggaaggt ggctattgag gccatgggtg tgagaaggaa ggatctgcct
aagaggaggg 420ggctgtgcaa atgctagctt aaacttggta cctcgatcat
tgcaaggcca gtgttctacc 480aatgaaccac atccatagcc cacctccatt
ttccatttat tttgagaaga ggtcttgcta 540ggtttcccag gctgatctta
ctctctgtag cctatgcaag atttgaacgt cctatagctt 600tcctagatcc
ttcctccttc ctaagtcctc tttagtagct agaattaaga ctgtggtggc
660gcgtttgttt ttgttttttg ttttttgttt ttttgtgtgt gtgtgtgtgt
gtgtcatggt 720cctagttcat ttagaattaa atgtgtgtgt ttatcgtagt
caggtagttg cagttctaga 780agtttattct taggtaatta ttaaaacatc
cattaaatat tgtgagggtg tcttgggttg 840ggaggaggag acaccatggc
catggagatc acccagtcaa gaagaccttg cctgtaaagc 900atgaggactt
aattcagact ctcagcaacc attcatctac tatcaagatg tttttactca
960gataaataga aaaaaaaaaa aaaaaggttt ggtgtggtgg cacacctttt
atatcccagc 1020agttgggagg cagaggcagg cagatctttg tgagtttgag
gccagcctgg tctacatagt 1080agtctcatga tagaaataaa aacaaaagaa
tccttgcaat atagtgtgca tgggtcctgg 1140gaggaagcat agggccagta
ggaactgatg cacacacgca tgtatgcaca cacgcacaag 1200cacatatgca
cacacaaata ttcaccagag attcctggtt ccaccacacc caccagagaa
1260gatataccac ccaggaattt ctgagaatct gctgggcctg atattgccat
caacactgaa 1320aaaattcaga gatggaagta agagatggat agatggactt
gtcgggatac tggctgctca 1380tctattttct gccaaggaca tagtttattt
cctgaagttc tgtgtctgac tcacccaaca 1440ggctcctgtt ccagatcatc
ccacggggag caggtcccag gtgctcgccc cataggcttc 1500catctaagcc
ccagttttgg tatgtctttg gtggtgggac ccagctcaca atcctaggta
1560agtggttctc atggtctcat gatccagctg gctcagggaa gtccattttt
gctctgggga 1620attcttacta tctgcctttc ctagccttgc agtctgaact
gtaaaggcag tagtaattct 1680aaggtaaatc acagggaaag gccctaacag
cttcatctac tcttctgagg cagatgccca 1740aaaagagatc aaggaatgag
atttttcagg ccatagagac cactacacct cagcatctaa 1800accgaggccc
agatgcccat ccagactaag aagaccacat agtaggtgca gggacatggc
1860tggtgccatg aaccccacct tcaaagattc aggccaccct agatagaaaa
ccacagaggc 1920tgagagagaa atttggttca atttaatctt ctgctggccc
atgaggtcac agagacacac 1980aaaaggctca gagtgatcag gttactagaa
ccaggtcctc ccaggatgat tactagaaaa 2040gaaatgtaga ctgtctattg
ttcctgaggg ctggagcctg ttgtctaact tgtccatctt 2100cctcaaatat
ccttagactt agatgaggaa tgaaggagca aatggggcca agtgaaatca
2160ggagtaacca gagacttcct ggatggtcag gggtttgcta tccttcctag
tctgggagat 2220ggagcctcag gaacacagcc agtataggtc ttgtgattac
tgtggacaaa gcagtaggtc 2280cttggaggag ttggaggatt tttctggatg
gaatctaatc ctcggtgaga taactaaatg 2340gaatctggag cacaggcccc
gaagccctta tacagcaggc acacctcaag accaactctc 2400caggaccagt
cttgcagaat aaatgagcag caattctcag aggagtctct gagcactgga
2460gaagcaattc aggttgggga gctgccctct gcctcaccag aaggccaggg
tcagatccca 2520attcactacc aggaggcctg ggttagatcc caaatcaggt
tccagcttca aggggctaga 2580gaattcagct ggtcttagtc tcagcggggg
aactgagatt gcaagggtct gggtctgggt 2640cattttatct ggaagaggaa
catgttctaa tgggatgcta ggctgtctgc tctccagggg 2700actcaagtgg
tcagaggaga agaaggaagc atccctggat ggaagactga tgctgtagtg
2760aatggccaca gagctcctga taagagaagg acgcttcctt atcacgtggg
ctctcctatg 2820ctaactctta tctccttctc tatctgcgca ggtcagccca
agtctgaccc cttggtcact 2880ctgttcctgc cttccttaaa gaatcttcag
gccaacaagg ccacactagt gtgtttggtg 2940agcgaattct acccaggtac
tttggtggtg gactggaagg tagatggggt ccctgtcact 3000cagggtgtag
agacaaccca accctccaaa cagaccaaca acaaatacat ggtcagcagc
3060tacctgacac tgatatctga ccagtggatg cctcacagta gatacagctg
ccgggtcact 3120catgaaggaa acactgtgga gaagagtgtg tcacctgctg
agtgttctta gaccacaatc 3180ctccctgaag cctcaggggc ctggatctga
agtgccagaa aaagttgttt tttgttttgt 3240tttttgtttt ttttcccatt
aaccatctca ctgtctttcc tgtgcctaat actcaataaa 3300tatcttacca ccaac
331516209PRTMus musculus 16Met Lys Leu Arg Val Gly Gln Thr Leu Gly
Thr Ile Pro Arg Gln Cys 1 5 10 15 Glu Val Leu Leu Leu Leu Leu Leu
Leu Gly Leu Val Asp Gly Val His 20 25 30 His Ile Leu Ser Pro Ser
Ser Ala Glu Arg Ser Arg Ala Val Gly Pro 35 40 45 Gly Ala Ser Val
Gly Ser Asn Arg Pro Ser Leu Trp Ala Leu Pro Gly 50 55 60 Arg Leu
Leu Phe Gln Ile Ile Pro Arg Gly Ala Gly Pro Arg Cys Ser 65 70 75 80
Pro His Arg Leu Pro Ser Lys Pro Gln Phe Trp Tyr Val Phe Gly Gly 85
90 95 Gly Thr Gln Leu Thr Ile Leu Gly Gln Pro Lys Ser Asp Pro Leu
Val 100 105 110 Thr Leu Phe Leu Pro Ser Leu Lys Asn Leu Gln Ala Asn
Lys Ala Thr 115 120 125 Leu Val Cys Leu Val Ser Glu Phe Tyr Pro Gly
Thr Leu Val Val Asp 130 135 140 Trp Lys Val Asp Gly Val Pro Val Thr
Gln Gly Val Glu Thr Thr Gln 145 150 155 160 Pro Ser Lys Gln Thr Asn
Asn Lys Tyr Met Val Ser Ser Tyr Leu Thr 165 170 175 Leu Ile Ser Asp
Gln Trp Met Pro His Ser Arg Tyr Ser Cys Arg Val 180 185 190 Thr His
Glu Gly Asn Thr Val Glu Lys Ser Val Ser Pro Ala Glu Cys 195 200 205
Ser 172993DNARattus norvegicus 17atgaagctca gggcaggaca gacactgggc
actatcccca ggcaatgtga aattctcctt 60ctgttgctgc tgttgggcct ggtggatggt
gtccaccata tactttcccc aagctcagca 120caaaggggca gagctgtggg
ccctggagcc tcagtgggaa gcagcaggtc tagcctgtgg 180acccttccag
gcaggtaaga gactttctta taggggaatg tatgtgtgtg ggtccatgga
240ctggaggctg aaatgggtga ctgggaagga aggtaaccat tgaggccata
ggtgtgagaa 300ggaaggatct gcctaagagg agggggctgg gcaaatgcta
gcttaaactt agtacctaac 360tcatgcaagg ccagtattct atcaatgagc
catatccata gcccacctcc cttttccatt 420tatttagaga agagggcttg
cctgattgcc taggctgatc ttactttctg tagcctatgc 480aagatttgac
ctcctagatc cttcctcctt cctaagtcct ctttagtagc tggaattaag
540gctggtacca ggttatttta gtgtgtcatg gtcctagttc attcagaatt
gtgtgtgctc 600atcttagtca aatagttgca gttttagaag tttattctta
ggcaattatc aaaacatcca 660ttaaatattc taagagtgtc ttgggctggg
aagagtagac actggggaca tggagaccac 720ccagtgaaga agactttgac
tgtcaagcat gaggacctag ttcagactct cagcactcat 780gcatctgcta
tcaagataca atcacatgtt tttttactca gataaataga aaaaaattaa
840ggtttggtgt ggtggcacat cccttatatc ccagcagttg gcaggcagag
gcagatagac 900ctttgtgagt ttgaggccag tctggtttac atagtggcct
catgacagaa ataaaacaaa 960agaattctca caaaatatag tgtgcatggg
tcctgggatg aagcacagga ccaggaggaa 1020tacacacaca cacacacaca
cacacacaca cacacacaca cacacacaca aatacacatc 1080agagattcct
ggttccacca cactcaccag agaagatata ccacccagaa cttttctgag
1140aatcagttgg gcctggtgtt gccatcaact ggatggaaat aggagatgga
tagatggact 1200tattttctgc caaggacaca gttcatttcc tgaagtccgg
tgcctacctc acccaacagg 1260ttcctgttcc agatcatccc acggggagca
ggtcccaggt gctggcccca taggcttcca 1320tccaagtccc agttatggta
cgtctttggt agtgggaccc agctcacaat cctaggtaag 1380cgattcccat
ggtctcatga tccagctgtc ttagggaagt ccctttttcc tctggggagt
1440tcttctcacc tgcctttcct agtcttgtag tctgaatggt acctttttct
gtgagtgagg 1500ggaaggcaag tagttctaag gtaaaccaca ggaaaggtcc
caatagcttc agctactctt 1560ccgaggcaga tgtccaaaaa gggatcaggg
gctgaggttt tcaggctgta gagaccactg 1620cacttcagca tctaaactga
ggcccagatg cccatccaga ttaagaaggc cacatagtag 1680gtgcagggat
atgactggtg ccatgattcc tgcctttaaa gattcaggta accctagata
1740gaaaaccaca gaggctgaga gaagaatctg gcccagttta atcttctgct
ggccaatgag 1800gtcatagaga cacagaaaag gcttagagtg accaggtaac
tagaaccagc tcctcccagg 1860atgattacta gaaaaaaaat gtagactgtc
tattgttcct ggggtttctc aggcctggag 1920cctgttgtct aacttgtcca
tctccctcaa atgtccttag agttagatga ggaatgaggg 1980agcaaatggc
gccaagtgaa atcaggagtc accagagact tcctgggtgg tcaggggttt
2040gctatccttc ctagtctggg agacggagcc ccaggagcac agtcagagta
ggtcttgtga 2100ttactgtgga caaagcatca ggcccttgga ggagttccta
ggacttttca ggatggaatc 2160taatccttgg tgagataact aaatagaatc
tggagcacag gcccgggagc ccttatacag 2220caggcacacc tcaagaccaa
ctccccagga ccagtcttgc agaataaatg agcagtaatt 2280ctcagaggag
gctctgacac tggagaagca atgggggttg gggagctgct ccctgaactc
2340ccccaccccc ataggaggcc agcgtcagat cccaattcag attccagctc
ctagtggcta 2400gagagtacag atggccttgg tcttagtggg gaaactgaga
ttgcaagggg cagggtgtgg 2460gtcatttcac ctggaagagg aacacggtct
aatggggcac caggctgtct gctctccagg 2520ggactcaggt gggcagagga
aaagaaggaa gcatccttga tggaacactc tgagctgtag 2580tgaatggcta
cagggctcct gataagagga ggatgcttcc ctgtcatgtg ggctctccta
2640tgccaactct tatccccttc tctatctgca cagggcagcc caagtctgac
cccttggtca 2700ctctgttcct gccttcctta aagaatctcc aggttaagaa
ggcgacacta gtgtgtctgg 2760tgagcgaatt ctacccaggt actttggtgg
tggactggaa ggtagatggg atccctgtca 2820ctcagggtgt ggagacaacc
caaccctcca aacagaccaa caacaagtac gtggccagca 2880gctacctgac
actgatgtct gaccaatgga tgcctcacag tagatacacc tgccaggtca
2940ctcatgaagg aaacactgtg gagaagagtg tgtcacctgc tgaatgttct tag
299318209PRTRattus norvegicus 18Met Lys Leu Arg Ala Gly Gln Thr Leu
Gly Thr Ile Pro Arg Gln Cys 1 5 10 15 Glu Ile Leu Leu Leu Leu Leu
Leu Leu Gly Leu Val Asp Gly Val His 20 25 30 His Ile Leu Ser Pro
Ser Ser Ala Gln Arg Gly Arg Ala Val Gly Pro 35 40 45 Gly Ala Ser
Val Gly Ser Ser Arg Ser Ser Leu Trp Thr Leu Pro Gly 50 55 60 Arg
Phe Leu Phe Gln Ile Ile Pro Arg Gly Ala Gly Pro Arg Cys Trp 65 70
75 80 Pro His Arg Leu Pro Ser Lys Ser Gln Leu Trp Tyr Val Phe Gly
Ser 85 90 95 Gly Thr Gln Leu Thr Ile Leu Gly Gln Pro Lys Ser Asp
Pro Leu Val 100 105 110 Thr Leu Phe Leu Pro Ser Leu Lys Asn Leu Gln
Val Lys Lys Ala Thr 115 120 125 Leu Val Cys Leu Val Ser Glu Phe Tyr
Pro Gly Thr Leu Val Val Asp 130 135 140 Trp Lys Val Asp Gly Ile Pro
Val Thr Gln Gly Val Glu Thr Thr Gln 145 150 155 160 Pro Ser Lys Gln
Thr Asn Asn Lys Tyr Val Ala Ser Ser Tyr Leu Thr 165 170 175 Leu Met
Ser Asp Gln Trp Met Pro His Ser Arg Tyr Thr Cys Gln Val 180 185 190
Thr His Glu Gly Asn Thr Val Glu Lys Ser Val Ser Pro Ala Glu Cys 195
200 205 Ser 1980DNAArtificial Sequence5 homology arm 19acctggccaa
actgagcatg acctttgacc tagccagctc ttaaacttgt tctgagatca 60caaaccagcc
agaccaaatt 802080DNAArtificial Sequence3 homology arm 20tcctcccaga
atgcttccct gggtcaaacc cagagccaca aaggcttcca ttagaccatt 60ctggtaagtg
acagagtcac 8021348DNAArtificial Sequence5 homology arm 21aaaaaaaaaa
aagcccagct agcttagttg gtagagcatg agactcttaa tctcagagtc 60atgggttcag
gcctcatgtt tggcaccatc tatagtgtgc agttataaat caaacagttc
120acgatggctg gctaggcact ggcaactgca gtctcacctg ctcccatggt
tcccagttcc 180cacagctagt ttgctgccag gctgttcaca cttcccaggt
catctaccca ctgtggcaag 240cctgcagaaa gcctgctatt gctagctcag
ttcccttagc cctataaaat gataacacca 300cagactttta ctataccatc
cagatttata acagtaattc tccaaccc 34822389DNAArtificial Sequence3
homology arm 22caggagtaca ccaaaatgtc tagccaaaat ttttatatat
gatcacttaa ataagactcc 60ttaacataaa cctacatgat ataccaagtc ttttctgcca
aggctctgac actatagttt 120gtcctatctg gagttaggta agcaaagggc
tatttaggtg tggattgcaa agagagaata 180gcaagacaac ctgcccattc
tttgccacac ctcactaatc agtgtccctt ggaaagcact 240gtaaatatgg
aggtttcttt ttgtattatg tagtgtggat ttaacttgag gagccccaaa
300aggggtcagc aaagcatggg
aaatctaaga atttaacact tcagtgactt ttaatcacct 360acagatccag
gaaaataagc ctgtctctt 3892321RNAartificialRNA oligo 23agacgugugc
ucuuccgauc u 212421DNAartificialprimer 24gaagacattt gggaaggact g
212534DNAartificialprimer 25gtgactggag ttcagacgtg tgctcttccg atct
342655DNAartificialprimermisc_feature(34)..(35)n is a, c, g, or t
26acactctttc cctacacgac gctcttccga tctnngggaa ggactgactc tctga
55
* * * * *
References